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About the epidemic
History 
The Human Immunodeficiency Virus (HIV) has infected more than 70 million people worldwide 
and has killed a staggering 35 million since the start of  the epidemic [2]. In 1981, clinicians reported 
five homosexual men in 1981 presenting with pneumocystis jeroveci pneumonia, cytomegalovirus 
infection and mucosal candida [3]. Over the next years, a growing number of  individuals 
presented with a syndrome of  rare opportunistic infections, which was later named ‘Acquired 
Immunodeficiency Syndrome’ (AIDS). A fierce scientific race ended up in the discovery of  a 
retrovirus being the causative agent of  AIDS in 1983 [4,5]. The scientific community responded 
by searching for adequate treatment. Although the first active antiviral drugs were already available 
in the late 1980s, it took until 1996 before successful treatment was introduced. This treatment 
consisted of  a combination of  three antiretroviral drugs which suppress viral replication, abrogate 
immunological decline and prevent end-stage HIV disease, i.e. AIDS. To this date, combination 
antiretroviral therapy (cART) remains the cornerstone in HIV treatment. In the meantime, the 
epidemic continued with an estimated 36.7 million people around the world living with HIV at the 
end of  2015. Of  these people, approximately 46% (17 million) were on antiretroviral treatment [6]. 
Compared to 2010, global cART coverage has risen tremendously, with an increase from 24% to 
54% in eastern and southern Africa. In contrast, cART coverage in the the Middle East, Northern 
Africa and Eastern Europe has improved more modestly, with certain regions where still 7 out of  8 
people living with HIV are not receiving treatment, despite being  eligible [6,7]. 
Transmission 
The virus incontrovertibly has its roots in non-human species and surveys of  African apes 
identified the chimpanzee (Pan troglodytes troglodytis) as a prime suspect for the pandemic HIV-
1 strain M. However, it still remains elusive how, when and where the HIV pandemic started. 
Chimpanzees from southern Cameroon infected with the Simian Immunodeficiency Virus (SIV) 
exhibit broadly cross-reactive antibodies against HIV, indicating close resemblance of  both viruses 
in this region [8]. The oldest known proof  of  HIV infection dates back to 1959 and stems from 
a native inhabitant of  Kinshasa (Congo). Genotypic analysis of  this sample supports other large 
phylogeographic studies and places the spatial origin of  the pandemic strain of  HIV-1 to Kinshasa 
[9,10]. The most recent common ancestor is estimated to date back even further, around 1920. 
SIV likely crossed the species barrier at several occasions due to the consumption of  chimpanzee 
meat (also referred to as bushmeat) by indigenous clans. In the first decades of  the 20th century, 
the Sangha river (connecting Southern Cameroon with Kinshasa) provided an easy mode of  
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transportation for the export of  rubber and ivory. Colonial cities and trading posts along this route 
grew larger and as a result of  generalized social disruption in these area’s, commercial sex work 
and venereal diseases flourished [11]. The combination of  a high SIV prevalence in chimpanzees, 
bushmeat consumption intensity and accelerated urbanisation likely facilitated cross-species 
transmission of  the virus in Kinshasa. In Guinnea-Bissau, another HIV strain (HIV-2) emerged 
and grew to epidemic proportion around 1955-1970. Its zoonotic origin is the sooty mangabey 
(Cercocebus atys atys). HIV-2 is less pathogenic and results in lower infectivity compared to HIV-
1. Hence, the prevalence of  HIV-2 is now mainly restricted to the region of  Western Africa, its 
former colonial ruler (Portugal) and Portuguese migration destinations (e.g. Luxemburg) [12,13]. 
Recent advances 
The devastating consequences of  the HIV epidemic are unprecedented. The United Nations 
launched an ambitious campaign in 2014 to improve access to HIV testing and boost treatment 
coverage. Recent evidence suggests the need to treat people with HIV at a much earlier stage 
of  infection; the test and treat strategy. Early treatment can prevent future non-AIDS related 
complications [14].  While historically the CD4 count would guide clinicians when to start therapy, 
current guidelines advise to initiate cART regardless of  CD4 count. Early treatment is not only 
beneficial in terms of  prognosis, it also prevents new infections by reducing a person’s ability to 
transmit the disease, resulting in a societal benefit [15,16]. In analogy of  these benefits that test and 
treat provides, the UN adopted a ‘Fast Track strategy’. Its goal is to enable diagnosis in 90% of  all 
people living with HIV; to start treatment in 90% of  individuals with confirmed HIV diagnosis; 
and to induce viral suppression in 90% of  this population by the year 2020. Early treatment 
has already resulted in a dramatic effect in the number of  new HIV infections among children. 
As a result of  treating HIV-infected mothers, an estimated 1.6 million new HIV infections have 
been averted since 1995. However, the total number of  new infections per year on a global 
scale has not decreased since 2010 and remains around 2 million a year [17]. The inability to 
maintain linkage to care in low-income countries is likely a crucial factor in this observation. A 
promising breakthrough is the implementation of  pre-exposure prophylaxis. Several major studies 
demonstrated a protective effect of  antiretroviral chemoprophylaxis in high-risk seronegative 
individuals before potential exposure [18,19]. After studies indicating the cost-effectiveness of  this 
approach [20], National legislative authorities around the world are currently implementing this 
new approach, or are on the brink of  doing so.
About the virus
Structure 
Viruses are carriers of  genetic material and require a host organism to replicate. HIV 
taxonomically belongs to the family of  retroviridae and is placed in the genus of  lentiviridae. 
The highly structured genome of  HIV consists of  RNA and is organized in several open reading 
frames. Three regions (Gag, Pol and Env) encode large polyprotein precursors, which are 
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subsequently processed into mature proteins by viral or cellular proteases. These mature proteins 
are essential for virion structure (Matrix, Capsid and Nucleocapsid protein), enzymes (Protease, 
Reverse Transcriptase and Integrase) and surface proteins (gp120 and gp41). The remaining six 
regions (vif, vpr, vpu/vpx, tat, rev, nef) translate into regulatory and accessory proteins. Regulatory 
proteins are essential during replication, whereas the relevance of  accessory proteins remains 
uncertain. Accessory proteins have been shown to enhance replication efficacy and play a role in 
host-virus interaction [21]. After a virion fuses with a mammalian host cell, RNA is converted to 
DNA by Reverse Transcriptase and is subsequently integrated into the host genome by Integrase. 
This unique quality of  retroviruses is both a weakness and strength. Cells that contain integrated 
HIV DNA will harbor the virus until death, but the enzymes needed for this process can also be 
used as a target for specific classes of  antiviral drugs. After integration, the fate of  a replication 
competent virus is dictated by the activity of  the cell. Transcriptionally active cells are more likely 
to express HIV. Both host and viral factors regulate transcription of  HIV DNA. The process starts 
when host RNA polymerase II binds to the promoter region (Long Terminal Repeat), a region that 
flanks both sides of  the integrated HIV genome. Transcription of  the provirus (HIV DNA) initially 
starts out slowly but is amplified a hundredfold in the presence of  Tat. At first, short completely 
spliced mRNA’s are produced encoding mostly regulatory proteins, followed by larger incompletely 
spliced mRNA enabling the production of  larger proteins and later the full-length unspliced 
mRNA is produced that acts as the virion genomic RNA. After assembly and budding, the mature 
virion consists of  a combination of  proteins and two copies of  positive stranded RNA, protected 
from the outside environment by a cone-shaped cylindrical core and a lipid bilayer. 
Biology 
HIV is transmitted through unprotected sexual intercourse, mother to child transmission, 
intravenous drug use or blood transfusion. The major reservoir for HIV is CD4 T-cells, 
although cells of  the myeloid lineage can also become infected. HIV enters the cell through the 
CD4-receptor and a chemokine co-receptor, CCR5 or CXCR4. The R5-tropic HIV-1 strains 
predominate during acute infection and infect both T-cells as well as myeloid cells [22]. X4-tropic 
variants are well able to infect T-cells, but are less efficient in myeloid cells [23]. During the acute 
phase of  infection that typically lasts several weeks, a peak viremia of  106 to 107 RNA copies/mL 
is reached. CD4 T-cells are infected abundantly and a decrease in CD4 count is observed before 
equilibrium is obtained. A viral set point of  around 30,000 copies/mL is obtained within the first 
6-12 months. During this period of  clinical latency CD4 T-cell levels slowly decrease. 
Pathology 
When CD4 T-cell levels drop below 200 cells/m3, the host immune system is unable to mount 
an effective response to otherwise harmless bacteria, fungi and viruses. Pathogens such as 
Cryptococcus, Cytomegalovirus and Pneumocystis Jiroveci (formerly known as Pneumocystis 
carinii) can induce symptomatic disease and this results in AIDS. Another phenomenon associated 
with AIDS is HIV-associated dementia. This devastating illness was widespread during the pre-
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cART era with a prevalence rate of  approximately 30-50% in patients with AIDS. HIV-associated 
dementia (or AIDS dementia complex) is characterized by massive viral invasion and inflammation 
of  the CNS [24]. Although in vitro infection of  neurons has been established in the past, HIV is 
generally not considered a neurotropic virus. Neurons lack the CD4 receptor and do not support 
further replication. In vivo studies irrefutably demonstrated that other cell types are in fact the 
reservoir for HIV in the CNS. Under homeostatic conditions, the CNS is an immune privileged 
site deprived of  monocytes, T- and B-cells. Under abnormal conditions however, lymphocytes 
have been shown to pass the blood brain barrier [25]. Cells of  the mononuclear lineage have 
also repeatedly been found at inflammatory sites and perivascular lesions and are likely to play a 
more vital role than lymphocytes. Studies performed in non-human primates have demonstrated 
perivascular macrophages as a source of  HIV in the CNS [26]. Human post mortem studies have 
found HIV infected microglial cells in the CNS and compartmentalization of  so-called macrophage 
tropic variants of  HIV [27]. These observations support the notion of  the CNS being a reservoir 
for HIV and the mononuclear lineage as a culprit for viral persistence. It remains elusive what the 
origin of  these infected microglial cells are. However, these cells are associated with both nourishing 
and phagocytic characteristics. Viral invasion supposedly tips over the homeostatic balance that 
microglial cells maintain in the CNS. Irrespective of  the mechanism, untreated HIV-dementia 
is a serious complication and is associated with a high mortality rate. Treatment with cART can 
prevent AIDS and is able to suppress the viral load in the body to below the threshold of  detection. 
When treatment is interrupted, the viral load rebounds quickly and therefore cART should be 
administered life-long.
Beyond the virus
Non-AIDS related comorbidities 
With the introduction of  cART, HIV has been reverted to a chronic illness. However, in the 
last decade a multitude of  studies demonstrated that illnesses not associated with AIDS are 
found more frequently in people living with HIV as compared to uninfected controls. These 
include (but are not limited to) myocardial infarction, metabolic abnormalities, anal carcinoma, 
coagulation abnormalities and cognitive abnormalities [28–32]. The exact pathophysiology of  
this phenomenon remains unknown but causes like medication, risk behavior profile, smoking 
and HIV-related factors have been proposed as causative factors. A specific interest is taken in the 
role of  chronic immune activation, a condition characterized by elevated levels of  inflammatory 
biomarkers [33]. Several hypotheses exist that attempt to explain chronic immune activation, such 
as microbial translocation [34], pyroptosis [35] and co-infections [36], but the mechanism is most 
likely heterogeneous and complex. 
Neurocognitive disorders in HIV 
Viral invasion of  the central nervous system (CNS) is a well-known occurrence in HIV infection. 
The viral load in the cerebral spinal fluid (CSF) mirrors that in plasma, although it is generally 1 
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to 2 logarithmic scales lower in CSF. The CNS parenchyma of  HIV-infected individuals exhibits 
the formation of  multi-nucleated giant cells, and even though the viral load is undetectable, HIV 
can be detected in the central nervous system long after cART treatment has been initiated. For the 
treating physician, it remains the question whether these observations hold any clinical relevance. 
Mild cognitive changes are reported to be more prevalent in HIV compared to uninfected 
individuals [37] and can have a substantial impact on daily functioning. However, the methods for 
screening cognitive function applied in prior studies are being scrutinized in recent years [38]. The 
current gold standard to identify neurocognitive disorders in HIV is neuropsychological assessment. 
Neuroimaging studies have demonstrated increased white matter abnormalities in HIV-infected 
individuals. White matter abnormalities have been demonstrated in other neurologic disorders, 
but also have a strong association with increasing age and vascular co-morbidity. Although it seems 
tempting to link these abnormalities with cognitive disorders observed in HIV, to date no concrete 
evidence has been able to prove this statement.The presence of  pro-inflammatory biomarkers in 
plasma [39] and CSF has been used in the past to identify those at risk for neurocognitive disorders, 
but so far these markers have not been shown to be useful in clinical settings. The main reason is 
that progression to more severe cognitive disorders in HIV is unpredictable. Therefore, clinicians 
are hesitant to change therapy based solely on the presence of  neurocognitive abnormalities. 
However, when these abnormalities are present,European guidelines stress the need to monitor the 
viral load in the CSF to prevent viral failure. In the absence of  (substantial) plasma viremia, a high 
viral load in the CSF could point towards compartmentalization. However, intermittent viremia has 
also been observed in around 10% of  the HIV population without any major clinical complications 
[40]. In addition, considering the pro-thrombotic state during HIV and the increased prevalence 
of  vascular complications, it remains a question whether micro-infarctions could cause HIV related 
neurocognitive disease.
Coagulation abnormalities in HIV 
Infection and coagulation can be regarded as mutually influential. During severe septic shock 
and viral sepsis, consumptive coagulopathy occurs which can result in disseminated intravascular 
coagulation [41]. Vice versa, fibrinogen is an acute phase protein and has been linked to promote 
inflammatory processes [42]. Both coagulation and inflammation are strictly regulated biochemical 
processes with extensive enzymatic feedback loops. This homeostatic balance is compromised 
under pro-inflammatory conditions, as is the case during viral infection. Where some viruses can 
cause bleeding (e.g. dengue, Marburg and Ebola), other viruses are associated with pro-thrombotic 
complications, as is the case in HIV. Increased incidence of  venous and arterial thrombosis in HIV 
has been reported in retrospective studies. Patients with HIV seem to be more prone to develop 
stroke and myocardial infarction, but identifying those at risk has proven to be a difficult task. 
Coagulation abnormalities in HIV infected patients are reflected by change in a wide variety of  
plasma pro-coagulant and anti-coagulant biomarkers. Most of  these markers can be linked to a pro-
coagulant status. Treatment with cART normalizes these markers to some extent, but not completely. 
In the normal process of  aging, microvascular lesions can be seen in a large proportion of  adults. 
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Metabolic abnormalities 
Compared to the relationship that inflammation has with coagulation, the effect of  HIV on 
metabolic homeostasis is less well defined. The observation from large cohort studies that linked 
HIV to increased risk for myocardial infarction [28] have sparked researchers to investigate the 
vascular consequences of  HIV. A large tri-continental study linked the occurrence of  vascular 
events with the use of  protease inhibitors [43] and abnormal lipid profiles in general in patients 
receiving cART [44]. Treatment seems to play a large role in the occurrence of  metabolic 
abnormalities, but the influence of  pro-inflammatory monocytes in plaque formation is currently 
under investigation [45]. 
 
Outline of this thesis
HIV and neurologic complications Without treatment, end-stage HIV infection is accompanied 
by a high prevalence of  opportunistic infections. This prevalence has dropped dramatically after 
the introduction of  cART. During effective treatment the burden of  neurologic complications is 
also small, but not negligible. There is considerable debate about the prevalence, pathogenesis and 
clinical relevance of  certain neurological complications such as stroke, neurocognitive disease and 
the residual risk of  opportunistic infections. Chapter 2 focuses on the current body of  knowledge 
about neurocognitive disorders in HIV. The literature is reviewed on the prevalence, pathogenesis 
and implications of  cognitive disorders in HIV. In addition, clinically relevant topics such as stroke 
and pneumococcal meningitis in HIV infected individuals are discussed. Are people living with 
HIV prone to develop these co-morbidities? This question has been the subject of  many studies 
in the past. To understand the interplay between HIV and the CNS, we first reviewed current 
literature; chapter 2 is directed towards finding an answer to this question and forms a stepping-
stone towards the introduction of  the TREVI study. 
TREVI study 
To study the impact of  neurocognitive disorders in HIV, we designed a cross-sectional cohort study 
at the Erasmus MC. The goal was to assess the prevalence of  cognitive disorders in a chronically 
infected and well-treated HIV population. An appropriate screening strategy as advised by the 
European AIDS Clinical Society was applied and assessed for sensitivity and specificity using 
the Neuropsychological Assessment as a gold standard. During 2012 to 2013, we set up the 
TREVI study, which was intended to assess neurocognitive disorders in the HIV population of  
the Erasmus MC. From a clinical perspective, the consequence of  identifying cognitive deficits 
can be considerable. Patients diagnosed with cognitive disorders can be referred to a neurologist 
for further evaluation. Additional investigations include obtaining central spinal fluid to rule out 
compartmentalization of  viral replication as well as imaging studies. Depending on the results 
and clinical course, it can even result in initiating/switching therapy. Therefore, it is crucial to 
determine the benefit and consequences of  these screening strategies. In Chapter 3, we discuss 
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the results of  screening for cognitive disorders in the TREVI study. Chapter 4 focuses on socio-
economic characteristics of  the patients involved in the TREVI study. It describes various factors 
involved in the quality of  life and labor participation. 
Experimental TREVI studies 
Our understanding of  HIV is based on the work of  numerous researchers worldwide. Years of  
research have been invested in the development of  therapeutic approaches and the identification 
of  pathogenic mechanisms. These efforts have resulted in considerable progress, but many 
questions still remain unanswered. With the continuous introduction of  revolutionary laboratory 
techniques, the scientific community is moving forward in its quest to understand HIV. In the 
TREVI study, we attempted to contribute to the knowledge about HIV. We stipulated relevant 
research questions about inflammatory, coagulation- and metabolic abnormalities, and set up 
basic experiments to test our hypothesis. We collected blood specimens during the TREVI study 
and isolated plasma and peripheral blood mononuclear cells (PBMC’s). In Chapter 5 to 8 we 
describe the impact of  chronic infection in people living with HIV on coagulation and metabolic 
abnormalities as well as chronic immune activation. Chapter 5 describes the concept of  immune 
activation and the presence of  this phenomenon in a well-treated HIV-infected population at 
different treatment intervals. This experiment was designed to assess the effect of  long-term 
treatment on the expression of  pro-inflammatory cytokines in PBMC’s and plasma. In Chapter 6, 
we applied a novel tool to assess the risk for metabolic complications by measuring hair cortisol. 
Based on anthropomorphic and laboratory data, we identified patients with the metabolic 
syndrome and investigated whether this was correlated to cortisol levels. In contrast to uninfected 
individuals, people living with HIV at increased risk for the metabolic syndrome had low hair 
cortisol levels. This finding inspired us to initiate a follow up study. For this part, we tested the 
sensitivity of  PBMCs of  HIV infected individuals to corticosteroids. In Chapter 7 we zoom in on 
specific elements of  the coagulation cascade. Von Willebrand Factor (vWF), an important protein 
in the induction of  hemostasis, was measured in patients with and without a history of  thrombosis. 
Using vWF as a predictive marker, we assessed whether symptomatic disease is linked to the level 
of  this biomarker. For the last chapter of  part II, we recruited pediatric HIV-infected individuals. 
Contracting HIV during childhood, when the immune system is still developing, has potentially 
detrimental effects. When left untreated, 50% of  children develops AIDS and dies before the age 
of  two [46]. Although treatment is initiated at an increasingly earlier age, morbidity and mortality 
remains disproportionately high in children, even in developed countries [47,48]. Although clinical 
studies are still in progress, this manuscript already contains the first experimental study in this 
specific population. In chapter 8 we evaluate the levels of  circulating endothelial cells (CECs) 
in HIV-infected children. CECs represent the turnover rate and degradation of  the endothelial 
lining of  the vessel walls. Current literature already demonstrates an increase of  CECs under 
pathological conditions, particularly cancer and sickle cell anemia. Using CECs as a correlate of  
vascular damage, we investigated the impact of  chronic HIV infection on the endothelium.  
LONG TERM EFFECTS IN CHRONIC HIV INFECTION; CLINICAL AND  LABORATORY STUDIES - Final.indd   15 04/03/2018   09:58
Part I16
1
LONG TERM EFFECTS IN CHRONIC HIV INFECTION; CLINICAL AND  LABORATORY STUDIES - Final.indd   16 04/03/2018   09:58
2The Central Nervous System and Chronic HIV Infection 17
Chapter 2 The Central Nervous 
System and Chronic HIV Infection 
Lennert W.J. van den Dries.1, Kirsten S. Adriani,2, Eric C. M. van Gorp1
1. The Erasmus Medical Centre, Department of  Viroscience, Rotterdam, the Netherlands.
2. Onze Lieve Vrouwe Gasthuis/ZMC, Department of  Neurology, Amsterdam/Zaandam, the 
Netherlands.
(Submitted)
Abstract
The central nervous system (CNS) is important since it could act as a reservoir in chronic HIV 
infection, which has relevant implications in the perspective of  eradication strategies. In addition, 
the CNS is a target organ for developing late complications due to chronic HIV infection. HIV 
enters the CNS at an early stage of  infection but can still be detected even after a prolonged 
period of  effective treatment with combination antiretroviral therapy (cART). Much remains 
unknown about if  and how HIV infection affects CNS integrity and what the effect of  cART is. 
Clinicians are confronted with studies that report an increase in HIV-related complications such 
as cognitive disorders, stroke and the risk for infections of  the CNS. Current knowledge indicates 
a complex multifactorial pathogenesis. The literature is reviewed on current knowledge and 
insights from a clinical perspective.
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Introduction
The central nervous system (CNS) is one of  the “target organs” in chronic HIV infection and 
potentially acts as a reservoir. This is important in the context of  ongoing and future eradication 
approaches and clinical trials. However, even during adequate treatment, a certain degree of  
inflammation remains detectable in the CNS. The association of  chronic HIV and certain non-
AIDS associated co-morbidities (e.g. cardiovascular disease) are apparent, but to what extent 
chronic HIV affects the CNS remains elusive. The possibilities for measuring effects in the CNS 
as a vital organ are limited and often indirect, which poses a challenge for clinical research. 
Regardless of  the magnitude of  the reservoir or inflammatory conditions, in the end the health 
care practitioner needs to evaluate the risk of  specific CNS-related illnesses occurring in HIV-
infected individuals. In this review we focus on clinical neurological manifestations in well-treated 
chronic HIV infection, what is known about the pathogenesis of  HIV infection and the CNS, 
and possible implications for treatment. A specific interest is taken in the frequently reported 
but highly controversial subject of  HIV-associated cognitive disorders, as well as stroke and 
infections of  the CNS. Although the latter two subjects have been reported mainly in the context 
of  immunosuppression, recent studies in chronically infected individuals demonstrate an ongoing 
burden of  disease.
I. The CNS as a target organ for HIV
A. Infections of  the CNS 
From a historic perspective, HIV is closely related to opportunistic infections of  the CNS. 
These include bacterial, parasitic, fungal and viral infections that occur primarily during 
immunosuppression, as is the case in AIDS. During end-stage HIV, the failure to maintain 
immunologic control against commensals like JC virus and Cytomegalovirus results in overt 
pathology. The lack of  synergism between CD4 T-cells and other components of  the immune 
system, like the cytotoxic response, results in poor effector function against pathogens like 
Toxoplasma Gondii and Cryptococci. Late diagnosis of  HIV infected individuals is a crucial 
factor in the persistence of  these opportunistic complications of  the CNS in the post-cART era. 
Even in countries with advanced health care, today close to 60% of  patients have a CD4 below 
350 at the time of  HIV diagnosis [49]. 
Remarkably, some causes of  meningitis and encephalitis that are frequently encountered in 
immune competent patients are not commonly associated with AIDS. Herpes Simplex is often 
found in the cerebral spinal fluid (CSF) during encephalitis in immune competent individuals; 
however, this is not the case in AIDS patients, nor does literature support an increased prevalence 
in chronic HIV infection. However, invasive pneumococcal infections like bacterial meningitis 
do occur more often in HIV-infected individuals and these patients also have a higher chance 
on a worse outcome. Indeed, the susceptibility is most pronounced during immunosuppression, 
but individuals with normal CD4 counts under successful antiviral treatment seem to remain at 
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increased risk for bacterial meningitis [50]. The incidence of  bacterial meningitis is 8.3 times 
higher in HIV infected individuals compared to uninfected individuals [51]. S. pneumoniae is 
the most common causative organism of  bacterial meningitis in HIV-infected patients, just as 
in HIV-negative patients. Salmonella meningitis occurs more often in HIV-infected patients 
compared to HIV-negative patients [52]. 
There is not one unequivocal guideline for pneumococcal vaccination in HIV patients. Because 
of  a higher susceptibility to pneumococcal infections, national guidelines in the United States 
advise pneumococcal vaccinations in HIV infected individuals [53]. Dutch national guidelines 
only recommend pneumococcal vaccination when there is concomitant intravenous drug 
abuse [54]. Because side effects of  pneumococcal vaccinations are minimal, it seems justified 
to administer prophylactic vaccinations in this risk group [50], on the other hand, studies that 
evaluated efficacy of  pneumococcal vaccinations in HIV infected individuals have conflicting 
results. In patients with CD4+ T-lymphocyte counts less than 500 cells/μL, a lower response to 
pneumococcal vaccination is to be expected [53]. 
B. Stroke and vascular changes 
Only a limited amount of  studies have been published comparing stroke incidence between 
well-treated HIV-infected individuals and uninfected controls. Cohort studies frequently include 
patients with cancer and opportunistic infections, both of  which are known to independently 
increase the risk of  stroke. As a result, the actual incidence of  stroke is possibly overestimated. 
Overall, HIV is more commonly associated with an increase in ischemic strokes compared to 
hemorrhagic strokes.  A large retrospective study from the US reported a higher incidence rate 
of  ischemic stroke in HIV-positive versus HIV-negative individuals (5.27 vs 3.75 per 1000 person 
years of  observation) [55]. After excluding cancer and co-infections, a large European cohort 
study still found an increased 10 year cumulative incidence in HIV infected individuals compared 
to matched uninfected controls (2.68 vs 2.07) [56]. In contrast, a large prospective multicenter 
cohort study showed no difference in stroke incidence when comparing HIV-positive men who 
have sex with men (MSM) to HIV-negative MSM [57]. Furthermore, the incidence of  ischemic 
stroke and coexisting HIV-infection is increasing from 0.08% in 1997 to 0.18% in 2006, whereas 
the overall stroke hospitalization rate lessened by 7% [58]. 
Demographic characteristics and risk factors are known to influence stroke incidence. Traditional 
cardiovascular risk factors such as hypertension, old age and smoking remain significant 
predictors for stroke, also in HIV infected individuals. However, the increase in stroke risk in 
HIV infected individuals is most pronounced in a relatively young age group of  <50 years [55]. 
The reported median age of  stroke in HIV patients ranges from 42 to 48 years [58]. In lower-
income countries the median age is even lower; a median age of  33 years is reported in a large 
retrospective study in 2000-2006 in South-Africa [59], but this likely reflects a high portion of  
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patients with immunodeficiency and opportunistic neurological infections. Besides traditional 
risk factors, several ‘new’ risk factors exist in the HIV infected population. Large retrospective 
studies on stroke in HIV-infected patients identified higher odds of  stroke in non-Caucasians, 
and among individuals with liver and renal disease and cancer [60] compared to uninfected 
individuals with similar age and co-morbidity burden. In addition, a consistent association 
between stroke and HIV status persisted after adjusting for traditional ischemic stroke risk factors 
and co-morbidities, with the highest risk in patients with a baseline CD4 count below 200 cells/
μL [60]. 
Stroke is the result of  ischemia in the CNS due to thrombosis, hypoperfusion or hemorrhage. 
Vascular wall integrity is of  paramount importance in the occurrence of  stroke. Cerebral small 
vessel disease increases with age and vascular white matter changes can be detected in large 
population based studies [61]. In HIV, vascular changes to intracranial and extracranial vessels 
include the presence of  cerebral aneurysms, atherosclerosis and inflammatory changes [62]. 
Stroke is often preceded by additional co-morbidities promoting plaque formation such as 
hypertension, diabetes and dyslipidemia. HIV infection exacerbates these factors, but to which 
extent is of  current special interest. The prevalence of  carotid plaques is higher within the HIV 
infected population and is related to the increased risk on cerebrovascular events [63]. 
Diagnosing stroke can be challenging because a broad differential diagnosis in HIV-positive 
patients exists, especially in the case of  immunodeficiency. Mimics of  stroke, such as seizures 
or opportunistic CNS-infections, should be excluded. Studies on the safety of  thrombolysis in 
chronically infected individuals are lacking. Vasculopathy, aneurysms and other vessel wall-
changes occur more frequently in HIV infected individuals [59,64] and could precede stroke. 
However, it seems probable that a large proportion of  HIV-positive patients has a thrombo-
embolic or atherosclerotic cause of  stroke, similar to HIV-negative patients. In this case, 
thrombolysis is in accordance with current guidelines for treatment of  ischemic stroke and can be 
advantageous. Aneurysmal changes in HIV infected patients are in most cases asymptomatic and 
only associated with micro-infarctions. However, if  intracerebral hemorrhage is suspected, an 
aneurysmal bleeding has to be considered, similar to uninfected individuals [59]. 
The initiation of  cART decreases the incidence of  cardio- and cerebrovascular events. Statins 
have an additional beneficial effect in preventing cardiovascular events and stroke in HIV 
infected patients. This is also the case in the absence of  dyslipidemia, but the number needed 
to treat is relatively high [65]. After ischemic stroke, prophylactic therapy should be initiated, 
although statins and cART can have interactions. Protease inhibitors inhibit the enzyme 
CYP3A4 and the combination with simvastatin and atorvastatin results in a higher risk for 
rabdomyolysis, myopathy and kidney failure. Preferred therapy is rosuvastatin, pravastatin or 
fluvastatin. 
LONG TERM EFFECTS IN CHRONIC HIV INFECTION; CLINICAL AND  LABORATORY STUDIES - Final.indd   21 04/03/2018   09:58
Part I22
2
C. Cognitive disorders 
In the pre-cART era, HIV-associated dementia occurred in the late stages of  the disease in 
around 15% of  patients, but after the introduction of  cART in 1996 the incidence dramatically 
declined to around 2% [32]. Nevertheless, based on clinical observations there were indications 
that milder forms of  HIV-associated cognitive impairment remained common, affecting 
the quality of  life of  patients with chronic HIV infection. A classification was introduced to 
categorize cognitive impairment based on the severity of  the illness [66]. This classification, 
also referred to as the Frascati criteria, is predominantly used for research purposes. In 
this classification, HIV associated neurocognitive disorder (HAND) is used as an umbrella 
term covering HIV-associated dementia (HAD), minor neurocognitive disorder (MND) and 
asymptomatic neurocognitive impairment (ANI). The diagnosis of  MND in the 2007 Frascati 
criteria requires a 1SD lower performance compared to normative data in two out of  five 
domains, preferentially using the mean of  two or more neuropsychological tests. 
Studies in the post-cART era report different prevalence rates of  HIV associated cognitive 
impairment, which probably reflect various interpretations of  the Frascati algorithm, and 
different characteristics of  the cohorts. Overall, when compared to uninfected control groups, 
the HIV infected group performs worse on neuropsychological testing [32]. Recent studies 
have expressed the concern that the Frascati criteria exaggerate the prevalence of  impairment 
due to inadequate statistical interpretation and the use of  inappropriate reference data [38,67]. 
Moreover, the prevalence of  cognitive impairment greatly increases by considering asymptomatic 
impairment as abnormal, but in fact this entity holds unclear clinical relevance. This is illustrated 
by a large multicenter cohort study [32] which found no difference in prevalence of  HIV 
associated cognitive impairment after 35 months of  follow up. Over time, the study showed no 
unidirectional decline of  symptomatology [68]. Remarkably, imaging studies have demonstrated 
that even despite the ‘asymptomatic’ title, in vivo microglial activation remains present [69]. 
A great deal of  controversy exists about screening for HIV associated cognitive impairment. The 
2015 guidelines of  the European Aids Clinical Society (EACS) advise clinicians to screen for 
cognitive deficits, but so far, no tool has proven to be satisfactory.  For instance, the (international) 
HIV dementia scale (iHDS) has a sensitivity and specificity of  approximately 65%, which makes it 
at best a moderately useful screening tool [70].  
A vital argument in the discussion about cognitive impairment is the implication for treatment. 
The clinical consequences of  cognitive complaints involve additional diagnostic procedures as 
well as adjusting treatment. Additional procedures such as magnetic resonance imaging (MRI) 
of  the brain or a lumbar puncture to determine viral escape in the CSF are suggested in the 
2015 EACS guidelines. MRI studies of  the brain are primarily performed to exclude other 
neurologic disorders. A frequent finding in HIV infected patients is atrophy of  subcortical gray 
matter structures, as well as white matter abnormalities [71]. The clinical value of  these findings 
so far is unclear. Examination of  CSF viral load is aimed to rule out viral escape. Viral escape 
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defined as discordance between CSF and plasma viral load is considered a rare complication, 
and clinicians should consider optimizing therapy. Current guidelines call for active surveillance 
and modification of  cART strategy when applicable, i.e. to switch to a potentially more CNS-
active drug in case of  cognitive impairment or viral escape. The role of  the drug-specific CNS 
penetration effectiveness (CPE) remains a controversial topic. Switching to a regimen with a 
higher CPE score has been proven beneficial a number of  studies, but only when discordance 
exists between viral load in the CSF and plasma [72]. Switching therapy based on minor cognitive 
abnormalities has not been proven beneficial [73]. 
II. CNS as reservoir
A. Viral persistence
HIV can be detected in the CSF as early as 8 days after suspected infection (Fiebig stage 
I). From this acute phase onward, the viral load in the CSF continues to mirror the 
plasma viral load, although generally 1 to 2 logs lower [74]. The CNS is considered one 
of  the viral reservoirs in chronic HIV infection: a sanctuary where the virus can hide. 
The exact magnitude of  the reservoir in the CNS during effective treatment is difficult 
to assess because brain parenchymal tissue cannot easily be obtained. However, available 
studies in humans show that replication competent virus can be detected in the CNS 
during the chronic phase [75]. In the CSF, transient viremia is reported in up to 10% of  
successfully treated and neurologically asymptomatic patients [40]. So far, little is known 
about the impact and clinical relevance of  intermittent CSF viremia. However, the 
question rises as to what extent viral escape and intermittent CSF viremia overlap. 
Much is unknown about the mechanism behind migration of  HIV into the CNS, but increased 
transendothelial trafficking of  HIV-infected monocytes in response to chemotactic signals has 
repeatedly been demonstrated. Therefore monocytes, rather than T-cells, form a major mode 
of  transportation for HIV to the CNS and might support viral persistence [76]. These infected 
myeloid cells are found predominantly, but not exclusively, in perivascular regions [26]. Despite 
effective treatment with combination antiretroviral treatment (cART) and successful suppression 
of  plasma viral replication, HIV can still be detected in the CNS during the chronic phase of  
infection. Microglial cells are a cellular reservoir for HIV as well, although the origin of  these 
infected microglial cells remains under debate (i.e. monocyte derived versus residential). Astrocytes 
can harbor HIV, but for reasons unknown these cells do not support synthesis of  new virus. 
Neurons are not infected in vivo because they lack appropriate receptors for HIV. 
Viral suppression is seen rapidly upon treatment initiation and prevents AIDS related morbidity 
and mortality [14]. Early initiation of  treatment might reduce the extent of  reservoir formation, 
but more research is needed to answer this question. Another benefit of  early initiation of  
treatment is transient HIV remission, as was demonstrated in the Visconti study and the case of  
the Mississippi baby [77,78] .
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B. Chronic inflammation 
The association of  chronic HIV infection and the array of  CNS-related pathologic and clinical 
symptomatology has proven to be complex. The causes are most likely multifactorial and a 
number of  aspects potentially influence clinical outcome, such as lifestyle factors, the degree 
of  immunosuppresion, past opportunistic infections and direct viral cytotoxicity. However, in 
the recent decade it has become evident that a chronic inflammatory state seems to add to 
the burden of  disease in HIV. Patients exhibit chronic inflammation and diminished immune 
function which can be demonstrated by monocyte and T-cell activation, endothelial cell 
dysfunction, and increased coagulation [79,80]. In the CNS, a persistent pro-inflammatory 
phenotype and accumulation of  microglial cells and (perivascular) macrophages has repeatedly 
been demonstrated [24]. Several mechanisms have been identified to drive this process, for 
example microbial translocation and pyroptosis [34,35]. Certain co-infections that are more 
frequent in HIV-infected individuals, can contribute to this process, e.g. hepatitis C and 
cytomegalovirus [36]. Finally, even though the benefits of  cART far outweigh the possible 
risks, there are also potential side effects of  cART. Data from in vitro and animal models have 
demonstrated mitochondrial damage and subsequent oxidative stress [81]. Although CSF 
biomarkers of  neuronal damage and imaging studies in humans support the presence of  CNS 
injury in HIV infected patients, a possible additive role of  cART toxicity remains uncertain. 
Immune activation markers in plasma drop substantially within the first year of  treatment, 
although complete normalization is generally not achieved [80]. Early treatment will prevent a 
low CD4 nadir, might potentially diminish chronic immune activation and could also potentially 
lower the prevalence of  co-morbidities, also in the CNS. 
Discussion
HIV infects the CNS at an early stage and can be detected even after years of  successful 
treatment. Direct viral toxicity compromises the integrity of  brain parenchyma, but additional 
HIV-related risk factors, the presence of  a chronic illness and several other known and unknown 
factors contribute to this process. For physicians, the question whether chronic HIV infection will 
adversely affect the CNS is of  paramount importance. A great deal of  controversy exists whether 
clinical outcomes such as cognitive dysfunction, stroke and meningitis are directly or indirectly 
related to chronic HIV infection. Regardless of  this controversy, the incidence of  neurological 
diseases seems to be increased when compared to uninfected individuals. Medical care for these 
neurologic illnesses transcends medical disciplines; suggesting the need for a multidisciplinary 
approach. Therefore, specialists previously unacquainted with HIV will need to get familiar with 
this chronic disability, especially neurologists. 
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Conclusion and future perspectives
This review aims to summarize all relevant data and current insights on HIV and the CNS in 
relation to clinical decision-making. However, in an area where treatment options are rapidly 
improving, many questions remain unanswered and need further research. Although studies 
on opportunistic infections have taken a back seat with the introduction of  cART, a number 
of  CNS-related infections are still prevalent during chronic HIV infection, albeit at a much 
lower rate. With a favorable prognosis of  the HIV population in the Western world, the 
impact of  illnesses affected by increasing age will be accentuated, such as stroke and cognitive 
disorders. A number of  studies already investigated the benefit of  early treatment initiation 
on co-morbidities. For the clinician it will be important to know how this affects the incidence 
of  cognitive complaints, stroke and invasive pneumococcal infections. For stroke, the impact 
of  statins and antiplatelet medication as primary prevention in HIV infected individuals has 
only been investigated in a limited amount of  studies. The long-term benefit of  pneumococcal 
vaccination has been proven in certain (non-HIV) subgroups; similar trends have been observed 
in HIV patients, but definitive data from representative large cohort studies are lacking. Last 
but not least, the question of  fundamental importance is whether the CNS is a target organ for 
HIV and supports reservoir formation. The number of  study initiatives aimed to eradicate HIV 
is gradually increasing and the results can be carefully interpreted as promising. However, it will 
remain crucial in the development of  ‘cure research’ to address this potential sanctuary for HIV. 
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Abstract
Recent studies have indicated that the prevalence of  HIV associated neurocognitive disorder 
(HAND) as reported in the literature does not correspond with clinical observations. Current 
guidelines advise the use of  screening tools to detect patients eligible for Neuropsychological 
Assessment (NPA). We assessed the value of  screening for cognitive abnormalities in a well-
treated HIV population and investigated the association with clinical correlates. Patients with 
chronic HIV (N=388) were screened for cognitive complaints using the 3 Simioni questions 
and the international HIV dementia scale (iHDS). NPA was performed in a subset of  patients 
(N=69). The sensitivity and specificity of  current screening strategies were calculated; CD4, 
CD4 nadir, viral load, cART duration and the presence of  co-morbidities were evaluated for 
associations with NPA result. A total of  127 (33%) reported cognitive complaints. The sensitivity 
and specificity of  the Simioni questions was 82% and 24%, respectively. Adding the iHDS 
resulted in a sensitivity of  50% and a specificity of  73%. A CD4 nadir count <50 cells/m3 was 
associated with an abnormal NPA (p=0.01). Co-morbidities were more prevalent in patients with 
an abnormal NPA, although not statistically significant (p=0.276). Age, current CD4, viral load 
and cART duration were not associated with abnormal NPA. 
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Introduction
HIV associated neurocognitive disorders (HAND) are frequently reported in HIV infected 
individuals. The multicenter CHARTER study is one of  the largest studies of  HAND to 
date and reported a prevalence rate of  52%, which fluctuated depending on co-morbidity 
burden [32]. The large US Multicenter AIDS Cohort study reported a lower prevalence 
rate of  25-33% over a 5 year period [82]. The difference is likely a result of  different cohort 
characteristics, but this high reported prevalence raised the question whether this actually reflects 
clinical observations in daily practice. Neuropsychological Assessment (NPA) is considered the 
gold standard to detect cognitive abnormalities. HAND is diagnosed by a score of  at least 1 
standard deviation (SD) below the means of  normative scores in at least two out of  five tested 
cognitive domains and is divided in three different subtypes of  neurocognitive impairment. 
In asymptomatic neurocognitive impairment (ANI), there is no interference with everyday 
functioning. Patients meet the criteria for minor neurocognitive impairment (MND) when 
interference is present. The third entity, HIV associated dementia, is a rare complication 
estimated to strike 2% of  the HIV infected population and is defined as a score of  at least 2 SD 
below the means of  normative scores [66]. The introduction of  ANI was intended to identify 
a subgroup of  HIV-infected individuals who actually have neurocognitive impairment despite 
the absence of  functional decline in daily activities. However, major cohort studies did not show 
a clear unidirectional decline [68,82] so the question remains what the impact of  diagnosing 
ANI is on daily functioning and prognosis.  Recent studies have advocated for a more stringent 
definition of  HAND, incorporating more conservative statistical analysis, removing ANI as an 
entity within the HAND spectrum and introducing better normative data [38,67].  
The pathogenesis of  cognitive deficits in HIV has been subject to a myriad of  studies. It would 
be useful to characterize those patients at high risk for developing neurocognitive disorders. A 
high incidence of  cortical atrophy and white matter abnormalities have been demonstrated in 
imaging studies, but a causal relationship with cognitive complaints has not unequivocally been 
demonstrated [83]. Although the distinct contribution of  HIV in cognitive deficits is difficult to 
assess, the virus can be detected during acute infection, but also after years of  treatment with 
combination antiretroviral therapy (cART) [40]. Increased markers of  inflammation and central 
nervous system (CNS) injury have been demonstrated in a significant proportion of  HIV infected 
individuals, with monocyte-related markers being most prominently linked to cognitive outcome 
[24,84,85]. In addition, low CD4 counts as well as viral burden have been linked to cognitive 
disorders in the past [32,83]. 
Cognitive screening is part of  standard patient care, although not common practice. A 
number of  screening tools exist to assess cognitive functioning, such as the Mini Mental State 
Examination [86], the Montreal Cognitive Assessment, the HIV dementia scale [87] and the 
more widely used international HIV dementia scale [88]. All screening tools are aimed to 
identify cognitive abnormalities and assist the clinician in deciding to refer the HIV-infected 
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patient for further neurocognitive evaluation. A perfect screening tool should include all patients 
at risk with a 100% accuracy, has to be easy to perform and unambiguous in interpretation. This 
is unfortunately never the case in real life and the importance of  each factor has to be weighed. 
Co-morbidities in HIV infected individuals have gained a great deal of  attention in the recent 
decade. Although cART initiation greatly reduces AIDS related diseases, chronically infected 
individuals seem to remain at increased risk for other, non-AIDS associated illnesses such 
as cardiovascular disease, metabolic abnormalities and certain malignancies [14,43]. The 
exact etiology of  this phenomenon has not yet been elucidated and little is known about the 
relationship with cognitive deficits.
The present study was aimed to address the controversial impact that cognitive disorders have 
in HIV infected individuals. We investigated the prevalence of  cognitive deficits in a chronically, 
well suppressed cross-sectional cohort of  HIV patients. We hypothesized that the most widely 
used screening tool for cognitive disorders in HIV, the international HIV dementia scale (iHDS) 
is sensitive to detect cognitive deficits. We also investigated clinical correlates of  disease severity 
as predictors for HAND. Considering the potential impact of  non-neurological co-morbidities, 
we also determined the burden of  non-neurological co-morbidities in HIV infected patients with 
and without cognitive deficits. 
METHODS
The TREVI study was designed to investigate the prevalence of  cognitive disorders in a well-
treated HIV population. We recruited patients attending the outpatient clinic of  the Erasmus 
Medical Center in Rotterdam (the Netherlands) in consecutive order for a period of  1 year 
between December 2012 and December 2013. All patients had to master the Dutch or English 
language to appropriately compare the NPA. Patients with major neurologic co-morbidities 
that could affect the outcome of  NPA were excluded. Patients were asked to participate in 
neurocognitive screening and sign the informed consent. Patients were asked if  they had any 
cognitive complaints, based on the 3 Simioni questions as advised by the EACS guidelines [89]. 
This included any problems encompassing concentration, attention and/or memory that patients 
perceived in their daily lives. A trained research assistant screened patients using the iHDS. A 
cut-off score of  10 is currently applied to determine whether patients are indicated for further 
investigation [88]. Consecutive patients with a score of  10 or less and patients with a score of  
10,5 and higher and inquired for their willingness to participate in NPA were randomly selected. 
An experienced neuropsychologist supervised the tests used in the NPA.
The test battery was adapted to the CHARTER study as much as possible to increase 
international validity [32]. The duration of  the NPA is approximately two hours, and it contains 
13 validated and commonly used tests. In brief, the NPA included the following tests (in this 
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order): Mini Mental State Examination, 15-word task (an episodic memory task, which measures 
learning abilities and memory consolidation), Trail making task [90] (attention, executive 
functioning), Stroop colour-word task [91] (attention, executive functioning), Fluency (language 
and/or semantic memory), Wechsler Adult Intelligence Scale-III [92] (visual-motor coordination, 
motor and processing speed), Rey Complex Figure Test [93] (visuoconstructive abilities, visual 
memory), Boston Naming Test [94] (word retrieval and language), WAIS-III (working memory, 
attention and concentration), Wisconsin Card Sorting Test [95] (attention, executive functioning 
and cognitive flexibility), Grooved Pegboard [96] (constructional praxis), Similarities (WAIS-III; 
verbal comprehension and reasoning), Block Design (WAIS-III, visuoconstruction). The scores 
from all tests were converted to z-scores. All z-scores were weighed and converted to a global 
deficit score. A global deficit score above 0.5 was considered abnormal. 
The sensitivity of  the iHDS was assessed in a 2x2 table by the ability to accurately predict NPA 
outcome, as represented by a GDS above or below the cut-off. Medical history of  all participants 
was assessed for treatment duration and co-morbidities. Laboratory history was assessed for 
immunologic and viral parameters. CD4 (nadir) counts were grouped and GDS of  these groups 
were compared using a Mann Whitney test. The amount of  co-morbidities was scored and 
grouped based on dichotomous GDS (impaired vs normal). Co-morbidities that were non-
chronic (e.g. a thrombo-embolic event or myocardial infarction) were only included if  it occurred 
less than 6 months prior to inclusion. The proportion of  patients without co-morbidities was 
compared between GD categories using a Pearson chi-square test. 
Results
Patient characteristics 
Out of  a population of  1648 patients, we recruited a total of  400 patients for this study. 
Four patients were excluded during the study because the iHDS was not performed and 8 
patients withdrew from the study. Out of  388 patients, 127 (33%) reported to have problems 
in concentration, attention and/or memory (figure 1). The mean age was 48 years (± 11), the 
majority of  the patients were male (89%), the median CD count was 600 (IQR=450 – 780) and 
326 (84%) had a viral load below 200 copies per ml (table 1a). From this cohort, 74 participated 
in the NPA; 5 patients were excluded from the analysis due to incomplete data. A total of  69 
patients were used for analysis. Characteristics of  this group (table 1b) were comparable to the 
entire cohort, although patients were older (53 ± 11). Detailed characteristics comparing patients 
with and without complaints are listed in table 2. 
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iHDS<10
N=62
Figure 1. Flowchart of  the TREVI study on neurocognitive impairment. Complaints were 
assessed by applying the 3 Simioni questions. iHDS: international HIV dementia scale.
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Complaints no. (%) 127 (33)
Age at inclusion Mean (SD) 48 (11)
Male seks no. (%) 344 (89)
Caucasian ethnicity no. (%) 363 (94)
CD4 Median (IQR) 600 (450-780)
CD4 Nadir Median (IQR) 240 (130-340)
Viral Load <200 co/ml no. (%) 326 (84)
Table 1a. Participants of  the TREVI cohort (N=388)
General characteristics of  the TREVI cohort. All 388 patients underwent  neurocognitive 
screening. 
Age Mean (SD) 53 (11)
Males no (%) 57 (82,6)
Caucasian no (%) 63 (91,3)
iHDS < 10 no (%) 34 (49)
Complaints no (%) 54 (78,3)
CD4 count Median (IQR) 600 (430 - 740)
CD4 Nadir Median (IQR) 220 (60 - 355)
Table 1b. Participants in Neuropsychological Assessment (N=69)
General characteristics of  TREVI cohort that underwent neuropsychological evaluation. Patients 
with and without complaints were included, both with normal and abnormal cognitive screening.
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Predictive value of  screening
Of  the 69 patients that underwent NPA, 54 patients reported cognitive problems in daily 
functioning. When applying the Simioni questions, 23 out of  these 54 patients had an abnormal 
NPA. However, 5 out of  15 patients without complaints also had an abnormal NPA. This results 
in a reasonable sensitivity (82%), but a low specificity (24%). Adding the iHDS greatly improved 
the specificity (73%) but at the expense of  sensitivity (50%). The iHDS on its own correctly 
predicted an abnormal NPA result in 19 out of  34 patients, but 9 out of  35 patients with a 
normal iHDS still had an abnormal NPA (table 3). The sensitivity of  the iHDS alone was 68% 
and specificity 63%.
Clinical correlates
Patients with an abnormal NPA had a significantly lower iHDS score (p=0.009). Age, current 
CD4, viral load and cART duration were not associated with abnormal NPA outcome (table 4). 
The nadir CD4 counts of  patients were grouped based on clinically relevant cut-of  values (50, 
200, 350 and 500). Patients with a CD4 nadir count <50 cells/m3 had a statistically lower GDS 
compared to patients with a CD4 nadir >50 cells/m3 (0.55 vs 0.18; p=0.01). No significant 
difference in GDS was detected in the groups with CD4 nadir count below 200 (p=0.334;), 350 
(p=0.802) or 500 (p=0.780). In the group with abnormal NPA, a larger proportion had one 
or more co-morbidities (figure 2), although not statistically significant. In comparison, 70% of  
patients in the normal NPA group had no co-morbidities, versus 61 percent in the abnormal 
NPA group (p=0.276).
Table 2. Characteristics of  NPA participants per complaint group.
Complaints No (15) Yes (54) p-value
Age Mean (SD) 60 (10) 51 (10) 0,005
Males no (%) 12 (80) 45 (83,3) 0,763
Caucasian no (%) 15 (100) 48 (88,9) 0,401
iHDS Median (IQR) 10 (8,5 - 12) 10,8 (9 - 12) 0,544
<10 no (%) 9 (60) 25 (46,3) 0,348
CD4 count Median (IQR) 560 (370 - 710) 640 (450 - 743) 0,272
CD4 Nadir Median (IQR) 180 (50 - 230) 245 (65 - 373)
0,39
Viral load < 
200 co/ml
Median (IQR) 14 (93,3) 49 (90,7) 0,753
General characteristics based on complaints expressed by patients. Complaints were assessed by 
asking the 3 Simioni questions. 
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Legends
A contingency table assessing complaints and the results of  the iHDS compared to the gold standard, 
neuropsychological evaluation. A global deficit score (GDS) was calculated to determine which 
patients scored below average. 
Table 3. Contingency table of  complaints/iHDS vs NPA.
GDS > 0,5 GDS < 0,5 Total
Impairment No impairment
No Compaints iHDS < 10 
(Impairment)
5 4 9
iHDS > 10 (No 
impairment)
0 6 6
Complaints iHDS < 10 
(Impairment)
14 11 25
iHDS > 10 (No 
impairment)
9 20 29
Total 28 41 69
Figure 2. Distribution in number of  co-morbidities in patients with normal and abnormal NPA 
scores. 70% in the group with normal NPA results had no co-morbidities vs 61% in the group 
with abnormal NPA results.
LONG TERM EFFECTS IN CHRONIC HIV INFECTION; CLINICAL AND  LABORATORY STUDIES - Final.indd   37 04/03/2018   09:58
3Part II38
Discussion
This study was designed to evaluate the use of  the international HIV dementia scale in a clinical 
setting and clinical factors associated with neurocognitive disorders. Current European guidelines 
stress the need to regularly screen for cognitive deficits in HIV infected individuals [89]. The 3 
Simioni questions should guide clinicians in determining whether the patient should be referred 
for extensive neuropsychological evaluation. Considering that NPA is a laborious exercise it 
would be beneficial for both patient and clinician to have a screening test with a high specificity. 
Possible consequences of  reduced cognitive function include lower quality of  life and reduced 
drug adherence [97,98]. Therefore, penalty for missing cognitive dysfunction is considerable, and 
a sensitive test would be beneficial as well. We therefore investigated the use of  the international 
HIV dementia scale, one of  the most widely used HIV-specific screening tools. A third of  our 
study population noted to have difficulties in concentration, attention or memory. 
However, of  the patients with complaints that underwent full neuropsychological investigation, 
57% would prove to be unimpaired according to NPA results. Adding the iHDS filters out false 
positives, but also results in a disappointing low sensitivity (50%). We concluded that current 
clinical practice to detect neurocognitive disorders in HIV-infected individuals is unsatisfactory. 
Considering the impact that neurocognitive deficits can have on an individual, more sensitive 
and specific screening tools are needed. 
In our study, a low CD4 nadir seems to be associated with poorer neurocognitive functioning. 
Table 4. Characterisics of  NPA group per outcome.
NPA
Normal (N=41) Abnormal 
(N=28)
p-value
GDS Median (IQR) 0,14 (0,05 - 
0,25)
0,7 (0,59 - 0,82)  < 0,0001
Age Mean (SD) 51 (11,5) 55,8 (9,5) 0,07
iHDS Median (IQR) 11 (9,8 - 12) 9,8 (8,6 - 11) 0,009
Years on cART Median (IQR) 2,7 (0,6 - 7,9) 4,7 (1,5 - 11,8) 0,122
Years since 
diagnosis
Median (IQR) 4,2 (1,7 - 13,9) 6,1 (1,9 - 14) 0,449
CD4 count Median (IQR) 650 (485 - 815) 530 (403 - 720) 0,071
CD4 Nadir Median (IQR) 250 (100 - 355) 165 (35 - 393) 0,165
Viral load Median (IQR) 19 (19 - 28) 19 (19 - 19) 0,616
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In the CHARTER study, one of  the largest cohort studies on HAND to date, CD4 nadir 
was also associated with poorer neurocognitive functioning [32]. This is comparable with 
results from other large cohort studies investigating HAND [99]. In addition, the CHARTER 
cohort demonstrated that a low CD4 nadir was also associated with a higher level of  with 
white matter damage and variability in subcortical volumes [83]. This might be explained 
by irreversible damage caused by factors such as opportunistic infections, chronic immune 
activation, or a history of  HIV encephalitis [24]. We found no differences when applying higher 
(clinically relevant) cut-off scores, indicating that this effect occurs below a certain threshold. 
Preventing severe immunosuppression could protect HIV-infected individuals from cognitive 
deficits. Other mechanisms of  neurological damage could include vascular damage and 
other existing co-morbidities. We found a higher degree of  co-morbidities in the group with 
cognitive deficits, albeit non-significant. It is also possible that direct viral cytotoxicity induces 
parenchymal damage. In vivo studies already demonstrated high viral loads in the cerebral spinal 
compartment during the chronic phase of  infection [40]. There have even been studies linking 
viral burden in the CNS to ante-mortem cognitive functioning [100]. Although the plasma viral 
load was undetectable in the majority of  patients in our study, we can’t rule out the effect of  
cytotoxicity. We could not find any other clinical parameters that could help guide clinicians in 
determining which patients to screen.
The strength of  this study is a clinical set-up in a relatively uncontrolled environment, reflecting 
a realistic outpatient setting. Clinicians are often confronted with vague symptoms in chronically 
well-treated HIV infected individuals. We implemented the application of  current guidelines in 
a standardized way and identified the pitfalls in the evaluation of  cognitive deficits. However, 
our study does have some limitations. First of  all, it would have been optimal to perform NPA 
in all the included patients. However, we choose to perform NPA only in a subpopulation due to 
the extensiveness of  this examination. We only included Dutch and English-speaking individuals 
to minimize the effect that language can have during NPA. Cultural aspects can influence the 
perception of  cognitive complaints and might affect CD4 nadir because immigrants have shown 
to present relatively late in the course of  HIV infection [49]. In addition, we only measured 
cross-sectional and have no information on whether individuals with cognitive complaints 
progress in their symptoms. 
This study demonstrates the limitations of  brief  cognitive evaluation and rapid screening tests 
such as the international HIV dementia scale. Its intentional use is to identify those patients at 
risk for cognitive dysfunction. Based on our data, we would recommend caution when assessing a 
patient in a clinical setting. Ideally, all patients would have to be subjected to the gold standard of  
neurocognitive evaluation, i.e. NPA. However, the authors realize that this consequently causes a 
burden to both patient and neuropsychologist.    
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Conclusion
In a chronically well-treated HIV population, the amount of  patients expressing cognitive 
complaints when asked is exceptionally high (33%). We used the iHDS, an internationally valid 
screening tool, to screen for cognitive deficits. We found a sensitivity of  68% for the iHDS, which 
decreased to 50% when applying this as an addition to the Simioni questions. The sole presence 
of  complaints as indication of  cognitive deficits resulted in an unacceptably low specificity (24%). 
The presence of  a CD4 nadir below 50 cells/m3 was associated with a significantly lower GDS. 
We found no other clinical correlates associated with an abnormal NPA. We detected slightly 
more (non-confounding) co-morbidities in the group with an abnormal NPA but this was not 
significant. There is a need to improve neurocognitive screening and selection tools.  
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Abstract
Since HIV has become a manageable chronic disease, employment is of  increasing importance 
for people living with HIV (PLWH). This study aimed to investigate the level of  work 
participation among PLWH in the Netherlands, and the associated determinants of  employment. 
For this study the baseline measurements of  a longitudinal cohort study with a 2-year follow-up, 
the TREVI project, were used. The TREVI project aims to study cognitive function disorders 
among PLWH in relation to their employment, productivity, and social functioning. From 
December 2012 until December 2013, data on cognitive functioning, measured by the HIV 
Dementia Scale, and medical data derived from patient records were collected. Employment 
status and possible determinants of  employment were assessed by a digital survey. Chi square 
analysis and multivariate logistic regression analysis were conducted in order to investigate the 
level of  employment and associated determinants of  employment. This cross-sectional study 
revealed significant differences in the level of  employment compared with Dutch reference 
data: i.e. in the age group 40-54 years PLWH had a significantly lower employment rate than 
the general Dutch population. Multivariate analysis showed that employment was negatively 
associated with a lower or higher age (reference: 40-54 years), a longer period since diagnosis, 
problems with physical functioning, and a higher score on the HADS Depression. Having paid 
work at diagnosis was positively associated with employment. PLWH, particularly in the age of  
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40-54, in the Netherlands have a significant lower level of  employment compared to the general 
population. 
Counseling should address reduced psychological and physical functioning in order to improve 
the position of  PLWH on the labor market.
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Introduction
The life expectancy of  people living with HIV (PLWH) has increased substantially since the 
introduction of  combination antiretroviral therapy. In high-income countries, such as the 
Netherlands, HIV can nowadays be seen as a chronic disease. With reduced mortality and longer 
survival, the quality of  life of  PLWH has become increasingly important [1]. Participating 
in society and having a job is an important component of  the quality of  life and has proven 
beneficial for PLWH because it helps to structure life, leads to social contacts, provides identity 
and status, and helps to set targets and obtain resources [2]. Moreover, employment status is 
reported to be strongly related to better physical/mental health and quality of  life among PLWH 
[3]. 
Employment is negatively affected by chronic diseases [4, 5]. Previous research on employment 
showed that the level of  unemployment among PLWH is substantially higher than in the overall 
labor force with comparable demographic characteristics. PLWH contemplate returning to work 
but are still unable to be gainfully employed due to perceived barriers such as loss of  income 
disability benefits [6-9].  Therefore, the impact of  HIV on work participation appears to be 
substantial. In addition, PWLH often experience stigma and discrimination at work [10-12], or 
when returning to work after a period of  work disability.  
Moreover, various disease-related factors may influence a patient’s employability. First, 
neurocognitive functioning may play a significant role in occupational success and maintenance. 
For example, van Gorp et al. showed that an index of  learning and memory stood out as a robust 
predictor of  finding employment [13]. Secondly, another symptom of  HIV affecting a patient’s 
ability to work is fatigue, which has a prevalence of  about 20-60% in this patient population. 
Finally, depression and other psychosocial issues among PLWH are known to influence their 
ability to work [1, 3, 10]. 
In 2012, a multidisciplinary guideline on ‘HIV and Work’ was developed in the Netherlands [11, 
14]. In this context, background studies (including a literature review, a qualitative study on work 
experiences of  PLWH, and an expert panel) acknowledged the topicality and relevance of  the 
above-mentioned determinants, and also highlighted the lack of  studies addressing vocational 
outcomes among PLWH.
Therefore, this study investigates the level of  work participation and related determinants among 
PLWH in the Netherlands. Apart from aiming to confirm determinants already described, we 
also explore the relevance of  additional determinants emerging from the development of  related 
guidelines in the Netherlands. 
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Methods
Study design 
For this study the baseline measurements of  a longitudinal cohort study with a 2-year follow-up, 
the TREVI project, were used. The TREVI project aims to study cognitive function disorders 
among PLWH in relation to their employment, productivity, and social functioning. 
Study population
The population for the present study consists of  PLWH attending the outpatient clinic of  
the Erasmus Medical Center (EMC; Rotterdam, the Netherlands). Patients were eligible 
for enrolment if  they spoke adequate Dutch. Patients were excluded if  they had a current 
opportunistic central nervous system infection, had current schizophrenia, current severe 
affective disorder believed to account for the subject’s cognitive impairment, or a current 
neurological disorder such as epilepsy or multiple sclerosis. 
Procedures
From December 2012 until December 2013, all eligible patients visiting the outpatient clinic of  
EMC were invited to participate in the TREVI project by their HIV physician or HIV nurse. If  
they were interested, patients underwent cognitive screening by a trained research assistant, using 
the International HIV Dementia Scale [15]. This is a standardized and internationally validated 
cognitive screening tool, which takes ± 2-3 min to complete. Patients with a score of  10 points 
(out of  12) or less, were considered for further evaluation of  cognitive functioning. In addition, 
they received an informed consent document (with a random document number), information 
letter, and either an email with a web link to the questionnaire or a hardcopy questionnaire. 
After the informed consent document was returned, we linked the document number to patient 
data, using a key that was in the possession of  the principle investigator only. The questionnaire 
could be completed anonymously using a secured online survey system. Only the researchers had 
access to the survey responses. In case of  non-response, a reminder was sent after 2 and 4 weeks. 
The study was reviewed by the Medical Ethics Committee of  the EMC and approved as not 
falling under the scope of  the Medical Research Involving Human Subjects Act (WMO).
Outcome measures
Employment status was assessed by asking participants if  they had a paid job at the time of  
completing the questionnaire. 
Determinants of  employment
Possible determinants for employment status were derived from a systematic literature review, 
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a qualitative study [11] and recommendations from the expert panel that was involved in 
developing the multidisciplinary guideline on ‘HIV and Work’ [14]. The following determinants 
were included in the questionnaire. 
Background characteristics. 
Gender, age, educational level, presence of  children, sexual orientation, and marital status were 
assessed. Education level referred to the highest level of  education completed and was divided 
into three categories: low (no, primary or lower secondary, and lower vocational education), 
middle (intermediate secondary and intermediate vocational education), and high (higher 
vocational education and university). Marital status was dichotomized as: married/cohabiting 
versus single (including divorced or widowed). 
Medical status
Medical data (i.e., CD-4 count, CD-4 nadir, and viral load) were derived from patient records. 
Viral load measurements were divided into two groups: < 200 co/ml and ≥ 200 co/ml.
Work history
All respondents were asked about their work history over the past 12 months, e.g. if  they had 
applied for another job. Furthermore, they were asked to indicate whether they had stopped or 
changed work since their HIV diagnosis.
Psychological functioning
Psychological functioning was measured with the anxiety and depression dimensions of  the 
Hospital Anxiety and Depression Scale (HADS) [16]. The HADS contains 7 items relating to 
anxiety and 7 relating to depression. Items are answered on a 4-point Likert scale, resulting 
in a score of  0-21 on each construct (depression or anxiety). A score of  ≥ 8 points indicates a 
psychiatric problem. At the intake of  participants for the present study (at the outpatient clinic), 
scores on the International HIV Dementia Scale [15] were recorded.
General health and daily functioning
Health-related quality of  life (HRQL) was measured with the MOS-HIV, a HIV-specific 
instrument consisting of  35 items addressing 10 dimensions of  health (overall health, physical 
functioning, social and role functioning, cognitive functioning, pain, mental health, energy, 
distress, and quality of  life) [17]. The subscales of  the MOS-HIV were scored as summated 
rating scales on a 0-100 scale, with higher scores indicate better HRQL. From these 10 subscales, 
two summary scores were created: the Physical Health Summary score (PHS) and a Mental 
Health Summary score (MHS) [18].
Disclosure
The level of  disclosure was measured by asking who had been informed about the HIV infection. 
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This question was asked for 13 different situations (e.g. sexual partner, close family, friends, 
neighbors, colleagues, in contacts with the healthcare sector, etc.). The answer options varied 
from (1) not disclosed at all to (6) full disclosure. The 13 different situations were reclassified 
into 4 groups: 1) sexual partner and close family, 2) social network, 3) work, and 4) contacts with 
financial and health sector. Also, a total disclosure score was calculated by summarizing the 
scores on all 13 different situations. The mean score for every group, and for the total sample was 
calculated, ranging from 1-6.
Stigma
Stigma was measured by asking about experienced stigma in the same situations as described for 
disclosure. The answer options were: never, rarely, sometimes, and often. An overall score for the 
experienced stigma in various situations was calculated by summarizing the scores on all these 
items, resulting in a mean score ranging from 1 (never) to 4 (often). Stigma was also measured 
by a selection of  four items from the Berger Stigma Scale [19], of  which a mean score was 
calculated ranging from 1 (completely disagree) to 5 (completely agree).  
Lifestyle
Smoking, drinking, exercising and eating behavior were assessed by several questions, as in 
Rappange et al. [20]. Smoking was measured by asking ‘Do you smoke?’ (answer options: ‘yes’, 
‘no, not anymore’, ‘no, never smoked’). Drinking behavior was measured by asking about the 
number of  alcoholic consumptions per week. Participants were categorized as ‘no’, ‘moderate’ 
or ‘excessive drinker’, based on Dutch guidelines [21]. Exercising was measured by the number 
of  days per week with at least 30 min of  exercise/day [22]. Eating behavior was measured by the 
number of  days a week that balanced meals (a varied diet, rich in vegetables, fruit and whole-
grain cereal products) were eaten [21].
Volunteer work and informal care
Respondents were asked to indicate whether they performed volunteer work or informal care at 
the time of  the survey. 
Statistical analyses
Statistical analyses were restricted to the participants who gave informed consent and had 
completed the full questionnaire. For all statistical analyses SPSS software (Version 22.0 for 
Windows) was used. Descriptive statistics were used to describe the characteristics of  the study 
population. These descriptive data were analyzed for between-group differences with bivariate 
analyses (ANOVA) for numeric and continuous variables and Chi-square analyses for ordinal 
variables. A p-value < 0.05 was regarded as statistically significant.
Chi-square statistics were applied to compare the level of  work participation among the 
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participants of  this study with the general Dutch population [23]. These analyses were 
conducted for various subgroups (gender, age, educational level). A p-value <0.05 was regarded 
as statistically significant.
Logistic regression analyses were used to explore associations, expressed as odds ratios (OR) 
with corresponding 95% confidence intervals (CI), between the dependent variable employment 
status (having paid work for at least 1 h/week) and the possible determinants. Bivariate logistic 
regression was used to determine the single effects of  all determinants of  interest. Variables 
with a p-value < 0.1 were included in the multivariate analysis. Multicollinearity between 
constructs was measured by assessing the Variance Inflation Factor. A backward logistic 
regression technique was performed to determine the multivariate model with the best overall 
fit. In this analysis, independent variables with a p-value < 0.05 were retained in the final model. 
Variables were considered in blocks of  related determinants (i.e., background characteristics, 
medical status, work history, cognitive functioning, general health, disclosure and stigma, 
lifestyle, volunteer work and informal care). The order of  the blocks was determined based on 
the expected influence of  the determinants, as observed in previous research. ORs, the 95% CI, 
and the change in the percentage of  explained variance (incremental R square), are reported as 
results of  the multivariate logistic regression analysis.
Results
Baseline characteristics
Of  the estimated eligible patients (n=600) visiting the outpatient clinic of  EMC [24], 400 were 
interested to participate in this study. Of  these, 315 (79%) completed the survey. Informed 
consent was obtained from all individual participants included in the study. Table 1 presents the 
baseline characteristics of  the study sample. The group consisted of  87% men/13% women, 
with a mean age of  48 years. Overall, the participants had a relatively high education level. 
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Employed versus unemployed participants
Almost two out of  three participants (65.3%) had a paid job at the time of  the survey. 
Compared with participants without employment, the 207 employed participants had a higher 
educational level (47% versus 37%). At the time of  the diagnosis, 80% of  the participants had 
a paid job. The work situation of  15% of  the participants had changed because of  HIV (e.g. 
reducing hours, changing hours, and another function). Overall, the scores on medical data were 
comparable between both groups, although those without employment had been diagnosed with 
HIV for a longer period of  time (119 months versus 82 months).
Level of  employment compared to the general Dutch population
The employment level for the total group of  men and women was not significantly lower than 
that of  the general Dutch population. Figure 1 shows the level of  employment for the three 
age groups in the TREVI cohort compared to the general Dutch population. The level of  
employment for the group aged 40-54 years was significantly lower than that in the general 
Dutch population (75% versus 81%). 
Figure 1 Level of  employment in the different age groups (working at least 1 hour/week) p<0.05
Among men, the level of  employment was significantly lower in the age groups 20-39 years 
(71% versus 82%) and 40-54 years (80% versus 87%) (Figure 2). No significant differences in 
employment were found between the TREVI cohort and the general Dutch population based on 
the level of  education. 
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Figure 2 Level of  employment among men in the different age groups (working at least 1 hour/
week) *p<0.05
The employed participants had a lower score on the HADS Anxiety scale, 6% was indicated as 
probably having an anxiety disorder (versus 31% of  the unemployed participants). In addition, 
their score on the HADS Depression scale was significantly lower, 4% was indicated as probably 
having a depression (versus 21% of  unemployed participants). Participants with employment 
reported a significantly lower level of  experienced stigma on the items of  the Berger Stigma 
Scale than unemployed participants (1.9 versus 2.6 on a scale from 1-5). 
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Characteristics related to employment status 
Table 2 presents the results of  the bivariate analysis.
Table 2 Bivariate logistic regression models for characteristics associated 
with employment (n=315)
Characteristics OR 95% C.I.
Background 
Male (ref. female) 1.57 .81 - 3.06
Age .94* .91 - .96
Age in years (ref. 40-54 years)
20-39
55+
.90
.23*
.47 – 1.74
.13 - .40
Marital status
Married or living together
(ref. Single, divorced or widowed)
2.06* 1.27 - 3.34
Has children (ref. no) .56* .32 - .97
Educational level (ref. low)
Middle
High
1.95*
2.21*
1.01 - 3.61
1.23 - 3.98
Sexual orientation (ref. mainly men)
Both men and women
Mainly women
.58
.68
.19 - 1.78
.32 - 1.41
Medical status
Months since diagnosis .99* .99 - 1.00
CD-4 1.33 .380 - 1.51
CD4 Nadir 1.36 .21 - 8.72
Viral load (ref. <200 co/ml) 1,03 .62 - 1.71
Work history
Working at diagnosis (ref. not working) 8.03* 4.32 - 
15.09
General Health
MOS-HIV: Physical Health Summary Score 1.10* 1.05 - 1.15
MOSHIV: Mental Health Summary Score 1.05* 1.01 - 1.09
Psychological factors
HADS: Anxiety .93 .85 - 1.02
HADS: Depression .87* .80 - .95
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The following characteristics were significantly associated with employment: age, marital status, 
having children, educational level, months since diagnosis, work status at diagnosis, score on 
the MOS HIV Physical and Mental Health Summary, HADS Depression, International HIV 
Dementia Scale, total level of  disclosure, disclosure at work, experienced stigma (using the 
Berger stigma scale), smoking, conducting informal care, and volunteering. For example, lower 
employment status was observed in PLWH who had a higher score on the HADS Depression 
scales (OR 0.87, 95% CI 0.80-0.95) and a lower score on the HIV Dementia Scale (OR 1.40, 
95% CI 1.15-1.70). 
Participants who had a paid job at the time of  diagnosis (OR 8.03. 95% CI 4.32-15.09) were 
significantly more likely to have a paid job at the time of  the survey.
Characteristics OR 95% C.I.
International HIV Dementia Scale 1.40* 1.15 - 1.70
Disclosure
Total .11* .01 - 1.15
Work 1.77* .97 - 3.22
Stigma
Experienced general .66 .38 - 1.14
Experienced items Berger Stigma Scale .70* .52 - .95
Life style 
Smoking (ref. non smoking)
Yes
Not anymore    
.35*
.46*
.20 - .63
.25 - .84
Drinking (ref. yes)
No    .72 .43 - 1.22
Eating healthy .96 .81 - 1.14
Exercise .95 .86 - 1.06
Informal care
Conducting informal care family or roommate (ref. no) .49* .24 - .98
Conducting informal care other people (ref. no) .28* .09 - .85
Volunteering
Volunteering (ref. no) .20* .11 - .39
OR=odds ratio, *p<0.1, CI=95% confidence interval
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All variables included in the model together explained 47% of  the variance. Work status at 
diagnosis had the greatest influence on the R-square. In the final model, the variables age, 
months since diagnosis, score on the MOS HIV Physical Health Summary, work status at 
diagnosis, and the score on the HADS Depression were significant characteristics related to 
employment. 
Discussion
This study contributes to a small but growing body of  literature on PLWH and employment. 
The results show that PLWH in the Netherlands clearly have problems regarding their work 
participation and work situation. 
In this study, at first glance the overall level of  employment among PLWH in the Netherlands 
seems similar to the general Dutch population. However, on closer analysis, among an important 
part of  the labor force (the age group 40-54 years), the level of  employment of  the TREVI 
cohort was significantly lower compared to the general Dutch population (relative reduction of  
6%). Especially men in this age group (but also in the age group 20-39 years) had a significantly 
lower level of  work participation (in the age group 20-39 years a relative reduction of  11%, and 
in the age group 40-54 years of  7%). Due to a lack of  power it was not possible to provide more 
insight into the employment of  women. 
In contrast to earlier reports on PLWH [6, 8, 25], the overall level of  employment in the Dutch 
sample was relatively high (65% in this study versus 40-55% in other studies); however, in those 
latter studies no distinction was made between subgroups. Compared to a previous Dutch study 
[26] the employment level in the TREVI cohort was low, especially in the youngest group (20-40 
years; 73% versus 86%) and in the oldest group (55-75 years; 40% versus 48%). This may be 
related to the composition of  the sample (e.g. distribution in education level) or to the status of  
the labor market/ economic situation, which may have been less favorable at the time of  the 
survey. 
Subsequently, we examined factors that could explain differences in employment among PLWH. 
It was found that age, months since diagnosis, work status at diagnosis, the MOS HIV Physical 
Health Summary score, and the HADS Depression score were factors significantly related to 
employment. 
In the present study, being younger or older than the reference group was negatively related to 
employment. Previous studies also described that older people have less chance of  getting a paid 
job [6-9, 27-33], which does not differ from the general population. The lower employment rate 
in our  younger age group might be explained by the fact that younger PLWH do not yet have a 
stable working position and may still experience many changes in their personal life. There are 
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indications that fluctuations in the disease and uncertainty about the prognosis are negatively 
associated with employment [6, 9, 34]. Therefore, being HIV positive makes it harder to find and 
keep a paid job and start a career.
In our multivariate analysis a lower MOS HIV Physical Health Summary score and a higher 
HADS Depression score were significantly associated with unemployment. The role of  the MOS 
HIV Physical Health Summary score confirms results from other studies, that physical limitations 
in PLWH are associated with decreased employment [2, 6, 8-10, 27, 29, 33, 35, 36]. With regard 
to depression the evidence remains contradictory; for example, Rabkin et al., Ezzy et al. and the 
present study support a negative association, whereas Lem et al. do not [8, 37, 33].
The relation between work history and actual level of  employment among PLWH is not 
extensively studied. Only one qualitative study concluded that a gap in the resume of  PLWH 
was a barrier for return to work [30]. In our study, having a paid job at the time of  diagnosis was 
the strongest factor related to employment at the time of  the survey. However, this result should 
be interpreted with caution because there could be other reasons why participants had no job 
at the time of  diagnosis and of  the survey. Nevertheless, because being employed at the time of  
diagnosis is an advantage for staying employed, it is important to make every effort to maintain 
work.  
The results of  our multivariate analysis do not confirm the role of  some determinants described 
in other studies, such as impaired cognitive functioning, stigma and disclosure. Impaired 
cognitive functioning has been associated with problems at work and as a barrier for return 
to work [2, 9, 33, 38]. In our study a higher score on the International HIV Dementia Scale 
was not significantly related to unemployment. This may be explained by a limited variation 
in cognitive impairment in our HIV population. In future studies, comparison with the 
general population is also needed. In order to further investigate the relation between cognitive 
functioning and employment among PLWH, we will investigate the association between the 
results of  neuropsychological evaluation and employment.  
Stigma and disclosure are reported to be work-related issues affecting employment among 
PLWH [2, 6, 10, 29, 39-42]. However, in our study neither stigma nor disclosure remained in our 
multivariate model; additional studies are required for further insight into these determinants.
The present study has some limitations. First, since our data were cross-sectional, the observed 
relations cannot be interpreted as causal. However, many of  our results are in line with other 
studies, indicating that these associations should be further explored in longitudinal research. 
Second, some selection bias may have occurred as our sample included only Dutch-speaking 
patients from one outpatient clinic. For example, non-Dutch speaking migrants were not 
included in the study and this subgroup of  the population may experience additional or 
different problems related to employment, such as stigma because of  their ethnicity. On the 
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other hand, this selection can also be regarded as a strength of  our study because it avoids other 
influencing factors, such as language difficulties. The present study had insufficient power to 
draw conclusions regarding female PLWH, who might have different experiences related to the 
keeping or finding a paid job. Therefore, because our results cannot be generalized to all PLWH 
in the Netherlands, additional studies are needed on HIV and work among other ethnic groups 
and women with HIV. Furthermore, because the majority of  our participants were homosexual, 
they may have to deal with a double stigma related to their HIV status and their homosexuality. 
In many countries loss of  social services is an issue among PLWH [2, 10, 30, 35, 41]. In the 
Netherlands this is not necessary because in case of  unemployment PLWH can apply for an 
unemployment benefit. However, in future research in other countries this possible determinant 
of  employment, depending on the local insurance system, might be taken to account.
Furthermore, data on non-participation and non-response were not registered. Also, as 
employment was the main topic of  this study, it is possible that mainly people with work (or 
interested in work) responded to the survey. If  we have missed those individuals who function less 
well in the work situation, this may imply that the problem of  employment among PLWH has 
been underestimated. 
Finally, most data in this study were self-reported and (even though participation was 
anonymous), the responses may be subject to social desirability and/or recall bias. 
In conclusion, by providing insight into the employment level and several factors associated with 
employment, this study highlights possible issues to be addressed in the vocational guidance of  
PLWH, and emphasizes the importance of  surveillance of  the work status and work-related 
problems of  PLWH. Such information is important to provide proper counseling and may also 
be used for policy development, in work organizations, and even at the national level. Finally, 
the study underlines the need for longitudinal research to clarify the causality in the relationship 
between determinants and employment. 
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Abstract
Sustained immune activation during chronic HIV infection is considered to augment co-
morbidity and mortality. Effective combination antiretroviral therapy (cART) has shown to 
dampen immune activation especially during the first year cART, but the effects of  long-term 
cART in patients without major comorbidities remains under-investigated. We performed a 
comprehensive analysis including cellular, intracellular and plasma biomarkers to study the 
effect of  cART on immune parameters in 50 HIV patients. All patients were without major 
co-morbidities and grouped based on cART duration (0, 1, 3, 5, and 10 years). We included 
10 matched healthy controls for comparison. The frequency of  activated HLA-DR+CD38+ 
CD4 and CD8 T cells declined to levels observed in healthy controls after 1 to 3 years of  
cART initiation. The phenotype and ex vivo cytokine production of  monocytes and NK cells 
were generally similar in HIV patients and healthy controls and remained unaffected by the 
duration of  cART. Plasma IP-10 and TNF-RII were increased in untreated HIV patients, which 
normalized to levels comparable to healthy control levels in patients on cART. Plasma sIL-2R, 
D-dimer and CRP was not significantly different between groups. After the first year of  cART, 
no additional effect on the level of  inflammatory markers is observed in HIV infected patients 
without major co-morbidities. Residual immune activation status in well-treated HIV-infection is 
similar to levels observed in healthy controls. 
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Introduction
With the introduction of  combination anti-retroviral therapy (cART), HIV-related mortality 
and morbidity has decreased dramatically. As a result, studies investigating AIDS-related 
complications are substituted with studies focusing on long-term health consequences of  HIV 
infection in patients with cART induced viral suppression [33,101]. These studies draw the 
picture that successful therapy does not completely reverse/normalize the inflammatory status 
induced by HIV infection since sustained activation of  the immune system is observed which in 
turn leads to non-AIDS-related morbidity such as cardiovascular disease and non-AIDS related 
cancers.
Studies comparing immune parameters in HIV patients and healthy individuals have shown 
enhanced levels of  the plasma cytokines IL-6 [102–105] and sCD14 [80,104,106,107], increased 
inflammatory profiles of  monocytes [108–110] and enhanced frequencies of  activated CD8+ 
T cells as determined by CD38 and HLA-DR expression [111–113] which is most pronounced 
during viremia and in case of  poor immunologic recovery. However, not all studies were able 
to reproduce these findings and conflicting data or only subtle effects of  HIV infection on 
monocytes and plasma cytokines were observed [80,107,114–117]. 
Several theories have been suggested to cause the sustained immune activation in HIV infection, 
which include microbial translocation, continued viral replication and pyroptosis [35,118]. 
cART-induced reduction of  viral load is likely to diminish the degree of  immune activation. 
Indeed, it has been shown that early after cART is initiated, markers of  immune activation 
drop dramatically [80,119]. However, the long-term effects of  cART treatment have been less 
well studied. One study showed that markers of  immune activation fluctuate substantially over 
the course of  chronic treatment [120], while another study demonstrated that T cell activation 
markers can reach levels comparable to uninfected controls as early as 6 months after treatment 
initiation [121].
The effect of  long-term cART on immune activation after initial viral suppression remains 
under-investigated. The question whether immune activation persists in well-suppressed patients 
with good immunological recovery is of  paramount importance, especially considering the 
suspected risks on increased mortality and morbidity. In the current study, we investigated 
the effect of  long-term cART treatment on a comprehensive panel of  biomarkers of  immune 
activation in HIV patients. We investigated the temporal effect of  cART in cross-sectional 
matched groups of  well-treated HIV infected individuals. We found that after the first year of  
therapy-induced HIV suppression no additional effect on inflammation markers is observed 
in HIV-infected patients without any major co-morbidities. Importantly, the residual immune 
activation status in this population with well-treated HIV-infection is comparable to levels 
observed in healthy individuals.
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Methods
Subjects Fifty individuals infected with HIV were recruited between 2012 and 2013 from the 
outpatient clinic of  the Erasmus MC and participated in the cross-sectional TREVI cohort, a 
Dutch study focusing on neurocognitive disorders in patients living with HIV [30]. A selection of  
10 individuals per group was performed based on the duration of  cART treatment. The groups 
consisted of  patients not receiving treatment, patients during the early phase of  treatment (1 
year on cART), patients during an intermediate phase of  treatment (3 and 5 years on cART) 
and patients on long-term treatment (10 years of  cART). A group of  10 uninfected otherwise 
healthy individuals was used as control (HC). Groups were matched on age, sex and (with the 
exception of  the control group) smoking. Patient history was assessed and individuals with major 
co-morbidities, such as active hepatitis B or C and malignancies, were excluded. The presence of  
age related non-communicable diseases were reduced to a minimum in al groups. All participants 
provided written informed consent and the study was approved by the ethical committee of  the 
Erasmus MC, the Netherlands.
Assessment of  the frequency of  leukocyte subpopulations Blood was collected in heparin BD 
Vacutainer® CPTTM tubes, and PBMC were isolated within 24 hours and cryopreserved in 
RPMI-1640 medium and DMSO (20%) for later use. Plasma was collected in 3.2% Citrated 
Vacutainer® tubes, spun twice and cryopreserved for later use. Viable PBMC were stained with 
the following antibodies: CD3-FITC/PE-Cy-7, CD45RO-PE, HLA-DR-PerCP-Cy5.5, CD8-
APC-H7/FITC, CD4-PE-Cy7/APC-H7, CD38-eFluor450, CD14-PE/eFluor450, CD56-
APC, CD19-APC-eFluor780, and CD16-eFluor450 (Biolegend/eBioscience/BD Biosciences). 
Flowcytometry was performed using the MACSQuant® (Miltenyi Biotec) and analyzed using 
Flowjo software (Treestar). The frequency of  lymphocytes and monocytes was determined on the 
basis of  their forward/sideward scatter (FSC-SSC) profile. 
Intracellular cytokine staining Cytokine production by monocytes was determined as described 
before [122]. Briefly, PBMC were seeded at 0.25x106/250μl with serum free X-vivo media 
(Lonza) alone, or in combination with 2 ng/ml LPS Minnesota (TLR4 agonist, Sigma), or 1 μg/
ml R848 (TLR7/8 agonist, Enzo Lifesciences). Cells were incubated for 2 hours and treated 
with 10 μg/ml brefeldin A (Sigma) to block protein secretion. After 7 hours of  incubation, cells 
were fixed with 2% formaldehyde and stained for CD14. Cells were then permeabilized with 
0.5% saponin and then stained with antibodies against MIP-1β-PE, TNF-PE-Cy7; MCP-1-
APC; Tissue Factor (CD142)-PE, IL-6-FITC, IL-8-FITC. For the intracellular staining of  NK 
and T cells, 0.5 x106 PBMC were incubated in a 96 wells plate for 1 hour in 200 μl RPMI-1640 
medium with 5% FCS and subsequently fixed with 2% formaldehyde. Cells were then washed 
once with PBS, permeabilized with 0.5% saponin and stained with antibodies against TRAIL-
FITC, granzyme B-PE, perforin-PerCp-Cy5.5, CD56-APC and CD3-eFluor450.  0.5 x106 
PBMC were incubated in a 24 wells plate for 21 hours in 250 μl RPMI-1640 medium with 5% 
FCS in the presence or absence of  IL-12 (0.25 ng/ml, Miltenyi) and IL-18 (50 ng/ml, R&D 
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systems). Cells were fixed, stained for CD3 and CD56, permeabilized and stained with antibodies 
against IFNγ-FITC [123]. Flowcytometry and analysis was performed as described earlier. All 
antibodies were purchased from Biolegend, eBioscience or BD Biosciences.
Assessment of  plasma cytokines using multiplex immunoassays The ProcartaPlex human 
multiplex assay was used to detect cytokines in plasma (Affymetrix eBioscience). Targets included 
sIL-2R, interferon-gamma-inducible protein (IP)10, sTNFRII, IL-10, D-dimer, and CRP. The 
assays were analysed on the Ap54 microsphere based multiplex LUMINEX 100 FIDIS v3 using 
ProcartaPlex Analyst 1.0 Software.
 
Statistical analysis Statistical analysis was performed using SPSS software (IBM, v21.0). Cell 
populations of  each sample were measured as percentage within the parent population and 
compared between subgroups. Continuous variables were assessed for normality and significance 
between groups was detected using a one-way ANOVA. A post-hoc correction for multiple 
comparisons was applied using Tukey HSD test when equal variances were assumed. For analysis 
of  data with clear heterogeneity of  variances, a Games-Howel test was applied. 
Results
Table 1 displays the characteristics of  the study population. All HIV patients and HC were 
male, and almost exclusively Caucasian. The mean age of  patients combined was 45 years and 
did not significantly differ between the HIV groups and HC (p=0.848). The CD4 nadir count 
and viral load were highest at baseline (both p<0.0001). The CD4 counts were comparable 
across HIV groups (p=0.978). To minimize the effect of  smoking as a potential confounder, 
we choose to balance this risk factor across the HIV groups. All patients were free from 
malignancies and active hepatitis co-infection. Only three patients had been previously diagnosed 
with comorbidities with a possible effect on inflammation. Two patients had well-controlled 
diabetes and one patient had minor myocardial ischemia 5 years before sampling for which he 
received adequate treatment. One diabetes patient was on cART for 3 years; the other diabetes 
patient and the myocardial ischemia patient were on cART for 10 years. None of  the patients 
demonstrated significantly stronger inflammatory responses compared to other subjects.
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Proportions of  lymphocyte subsets not affected by prolonged HIV 
suppression by cART
Phenotypic characterization was performed to assess the impact of  prolonged HIV suppression 
by cART on the percentage of  blood lymphocyte populations. Figure 1 shows the proportion 
of  CD4+ and CD8+ T cells, CD19+ B cells, NK cells, and NKT cells within the lymphocyte 
population. All HIV positive patients showed significantly lower CD4+ and higher CD8+ T cell 
percentages in comparison to healthy control subjects and these percentages did not normalize 
in patients with prolonged cART. Our patient population consists of  chronically HIV-infected 
patients in which treatment was initiated when CD4 counts dropped below 350x10e6 CD4+ T 
cells/ml following previous guidelines [124]. The proportions of  CD19+ B cells, NK cells, and 
NKT cells did not differ between untreated patients and those treated with cART for 1, 3, 5 or 
10 years, and were comparable to those observed for healthy individuals.
Activation of  CD4+ and CD8+ T cells reduced during cART induced HIV 
suppression
Next, we investigated the impact of  duration of  cART on the activation status of  lymphocyte 
subpopulations. While no differences in CD45RO expression was observed in CD4+ and CD8+ 
T cells before and during cART (data not shown), the fraction of  CD4+ and CD8+ T cells being 
HLA-DR+CD38+ were reduced in patients on cART and seemed to normalize to the low levels 
observed in healthy controls after 3 to 5 years (figure 1). Also in patients treated with cART for 1 
year only, this effect was observed, albeit not significant (p=0.069). 
Groups
HC 0 1 3 5 10
Years on cART M (±SD) 0 (0) 0 (0) 1,1 (0,5) 3 (0,3) 5,2 (0,6) 10,8 (2,3)
Age M (±SD) 44 (4) 45 (4) 42 (8) 44 (2) 45 (8) 45 (5)
Males (%) 100 100 100 100 100 100
Caucasian (%) 90 100 100 100 100 100
CD4 Nadir M (±SD) n.a 511 (209) 296 (151) 257 (131) 200 (77) 200 (99)
CD4 M (±SD) n.a 629 (222) 601 (271) 630 (172) 624 (276) 667 (160)
VL below 200 co/ml (%) n.a 0 80 100 100 100
Years since diagnosis M (±SD) 0 (0) 4,4 (2,8) 2,3 (1,2) 4,5 (1,8) 6,9 (2,4) 12,3 (2,4)
Smoking (%) (%) 0 40 50 40 50 50
Table 1. Basic characteristics of HIV infected cases and uninfected controls. Each group 
consisted of 10 individuals. N.a.= not applicable. HC= Healthy Controls. 0, 1, 3, 5, 10 = 
HIV groups with corresponding cART treatment duration (in years).
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Fig. 1. Distribution of  CD4, CD8, CD19, NK and NKT cells within lymphocyte populations. 
HC had more CD4 cells and less CD8 cells compared to all HIV+ groups. Below: the proportion 
of  HLA DR positivity of  corresponding CD4 and CD8 population. A significantly higher 
percentage of  HLA DR+ CD38+ cells in the CD4 population of  untreated HIV+ patients was 
found compared to patients more than 5 years on treatment and HC. The percentage of  HLA+ 
DR+ cells in CD8 population was higher in untreated HIV+ patients compared to patients 
longer than 3 years on treatment. 
0, 1, 3, 5, 10 = HIV infected patients in ascending order of  antiretroviral treatment duration (0, 
1, 3, 5 or 10 years of  therapy). HC = Healthy Controls.
* p≤0.05
** p≤0.01
*** p≤0.001
LONG TERM EFFECTS IN CHRONIC HIV INFECTION; CLINICAL AND  LABORATORY STUDIES - Final.indd   73 04/03/2018   09:58
5Part III74
Monocytes seem unaffected by HIV infection and subsequent cART 
initiation
Circulating monocytes can be subdivided on the basis of  expression of  CD14 and CD16 into 
inflammatory (CD14++CD16+), patrolling (CD14+CD16+) and traditional (CD14+CD16-) 
monocytes. The proportions of  inflammatory, patrolling and traditional monocytes seem 
unchanged by HIV infection, and cART initiation has no significant impact on their relative 
distribution (figure 2a). Also, the proportions of  monocytes producing the pro-inflammatory 
cytokines TNF, IL-6, MIP-1β and MCP-1 (figure 2B) as well as the anti-inflammatory cytokine 
IL-10 (data not shown) were similar between healthy subjects and HIV patients, irrespective of  
treatment duration. Only when all HIV patients were pooled, significantly higher proportions 
of  monocytes producing MCP-1 (p=0.003), IL-8 (p=0.008; data not shown) and Tissue Factor 
(p=0.011; data not shown) were observed as compared to healthy control subjects. However, it 
is important to note that the levels of  induction of  pro-inflammatory cytokines by monocytes of  
HIV-infected patients are variable. 
Fig 2a. Proportion of  traditional (CD14+CD16-), inflammatory (CD14+CD16+) and patrolling 
(CD14dimCD16+) monocytes in otherwise healthy uninfected controls (HC) and patients with 
HIV infection in ascending order of  cART treatment duration (0, 1, 3, 5 or 10 years of  therapy). 
The variation of  CD16 expression within groups was considerable but no statistically significant 
differences were observed between groups.
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NK cells seem unaffected by HIV infection and subsequent cART initiation
Under pro-inflammatory conditions, NK cells are able to mount a potent antiviral response, 
primarily mediated by IL-12 and IL-18. This results in the production of  IFNγ, a cytokine 
crucial in controlling viral infections [125]. NK cells are able to induce killing of  virus-infected 
host cells by self-recognition and subsequent production of  enzymes, like perforin, granzyme B 
and membrane expression of  TRAIL. Figure 3 illustrates the frequency of  NK cells expressing 
TRAIL, granzyme B and perforin, and demonstrates no significant differences between 
expression of  these markers in NK cells of  patients compared to HC, albeit that the expression 
of  granzyme B appeared higher in patients than controls. Also, no clear association with 
treatment duration was observed. The range of  perforin expressing cells was high, probably 
reflecting a large intra-individual spread of  this marker. To evaluate the function of  NK cells, 
IFNγ production was induced with IL-12 and IL-18. The frequencies of  IFNγ-producing NK 
cells were comparable in all HIV groups, and did not statistically differ from HC. 
Fig 2b. Expression of  inflammatory markers in monocytes of  otherwise healthy uninfected 
controls (HC) and patients with HIV infection in ascending order of  cART treatment duration 
(0, 1, 3, 5 or 10 years of  therapy). No significant difference was found across groups in baseline 
intracellular levels of  TNF, IL-6, MIP1β and MCP1.
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Fig 3. Intracellular markers associated with immune activation in NK cells. Intracellular 
expression of  TRAIL, Granzyme, IFNγ and Perforin in NK cells. For the IFNγ assay, prior 
stimulation with IL-12 and IL-18 was performed. No uniderectional trend of  immune activation 
level was observed with treatment duration. 
TRAIL: TNF-related apoptosis-inducing ligand. IFN: interferon
* p<0.05
** p<0.01
*** p<0.001
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Except for IP-10, the levels of  inflammatory markers in plasma were not 
significantly elevated during untreated or cART suppressed HIV-infection.
Finally, plasma levels of  various pro-inflammatory biomarkers were determined. As shown 
in Figure 4, plasma IP-10 levels were higher in untreated HIV patients compared to early, 
intermediate and long-term cART treated patients. sTNF-RII was higher in untreated HIV 
patients compared to HC. The plasma levels of  sIL-2R and CRP showed a trend towards higher 
levels in the untreated group as compared to HC, but the levels did not significantly decline 
during the course of  cART. Plasma D-dimer levels were not increased and displayed no change 
during the course of  cART.
Fig 4. Plasma biomarkers measured in plasma of  HIV infected patients in ascending order of  
treatment duration and healthy controls. The untreated group had significantly higher levels 
compared to patients on 1, 3, 5 and 10 years on treatment (IP10) and healthy controls (TNF-
RII). Although sIL2R was generally higher in the HIV infected groups, no significance was 
achieved after multiple comparisons. D-dimer and CRP showed no clear association with 
treatment duration or HIV status. Results are in pg/ml.
sIL2R= soluble IL2 receptor. IP10=Interferon gamma-induced protein 10. TNF-RII= TNF 
receptor II. CRP= C-reactive protein. 
* p<0.05
** p<0.01
*** p<0.001
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Discussion
A number of  studies have demonstrated that effective cART treatment of  chronic HIV patients 
results in reduced activation of  components of  the patient’s immune system. Most studies 
evaluated the immune effects during the first year after start of  therapy. We now show the 
immune effects of  HIV suppression up to 10 years after start of  cART in a well-defined cross-
sectional study cohort. Importantly, the selected patients are without any major co-morbidities, 
including hepatitis and malignancies, and reduced the number of  individuals with age related 
diseases to an absolute minimum. Our findings show that after the first year of  therapy-induced 
HIV suppression no additional effect on inflammation markers is observed in HIV-infected 
patients without major co-morbidities. Our observation of  no or mild immune activation in 
suppressed HIV-infection questions the impact of  ongoing inflammation on co-morbidity and 
mortality observed in HIV-infected patients without any previous major co-morbidities.
In line with previous studies, we observed that untreated HIV infection is associated with an 
increased expression of  the activation markers HLA-DR and CD38 on CD4+ and CD8+ 
T cells, indicating occurrence of  the persistent immune activation in untreated HIV-infected 
individuals [33,36,126]. Importantly, the T cell activation is not permanent, since the frequencies 
of  HLA-DR+CD38+ T cells drop during the early stage (1 year) after treatment initiation and 
plateau during the intermediate (3 and 5 years) and long-term (10 years) phase of  treatment. 
We did not detect a significant difference in this marker when comparing intermediate and 
long-term treatment to healthy controls. This is in line with a number of  studies, although 
conflicting data exists. Some studies investigating the level of  activated T cells in well treated 
HIV infected individuals report levels comparable to uninfected controls [111,112,121], others 
find a modest but significant increase [113,127]. These contradictory findings point towards 
additional confounding factors that influence the activation status of  T cells in the absence of  
viremia. Behavioral and socio-demographic risk factors might play a role, as well as the timing of  
treatment initiation [128].
Different from the effect of  chronic HIV infection on T cells, we were unable to find modulation 
of  monocyte and NK cell frequencies, phenotype or function as a consequence of  the ongoing 
infection, and as a result the additional effect of  cART could not be assessed. 
Little information is available in literature on the effect of  long-term cART on NK cells, but a 
number of  studies in monocytes have been performed. Our results are in line with studies these 
studies and show that monocytes do not exhibit an inflammatory profile [116,129–131]. In 
studies where increased CD16+ monocyte subsets are identified, these observations are often in 
the context of  viremia [108,109,131]. 
We observed a large variation on the production of  intracellular cytokines in monocytes 
between individuals. These outliers could represent patients that are at increased risk for illnesses 
associated with an activated myeloid phenotype. The presence of  patrolling and inflammatory 
monocytes is strongly associated with cardiovascular disease in the setting of  HIV infection 
LONG TERM EFFECTS IN CHRONIC HIV INFECTION; CLINICAL AND  LABORATORY STUDIES - Final.indd   78 04/03/2018   09:58
5Immune activation in prolonged cART-suppressed HIV+ patients is comparable to that of  healthy controls 79
[45]. However, our patients show similar percentages of  patrolling and inflammatory monocytes 
and only a minority of  HIV-infected patients shows elevated production by monocytes of  pro-
inflammatory cytokines. Considering the absence of  inflammatory profile in other subjects, we 
expect this phenomenon not to be HIV-related. It is tempting to speculate that HIV infection 
does not increase the risk of  cardiovascular disease in patients in the absence of  prior risk factors. 
Longitudinal studies are needed to formally address this issue.
In line with the effects of  cART on T cell activation, we also observed that serum IP-10 and 
serum sTNFRII levels significantly declined during the first year after start of  treatment, 
and normalized during continued treatment as compared to the levels observed in healthy 
individuals. Our results corroborate with a previous study where no additional effect of  treatment 
was observed after one year of  treatment [80]. However, others showed that the same plasma 
biomarkers have shown to correlate with morbidity and mortality [132–134]. In this context, 
IL-6 has been studied most extensively for its predictive value [132,135,136]. However, Borges et 
al. elegantly demonstrated using the data from these 3 major clinical trials representing close to 
10,000 patients that plasma IL-6 can be influenced by a variety of  other, non-HIV related factors 
like age, smoking and co-morbidities [105]. The aim of  our study was to investigate the specific 
effect of  cART on the level of  immune activation. We therefor matched all patients on age and 
smoking status and excluded individuals with potentially confounding co-morbidities. 
In conclusion, our findings suggest that in a HIV patient population devoid of  clinically apparent 
co-morbidities, the modulation of  immune parameters as a consequence of  persistent HIV 
infection is relatively weak, with the majority of  monocyte and NK cell markers as well as the 
serum biomarkers tested, resemble those in healthy individuals. cART reduced normalization 
of  the T cell activation status and serum IP-10 and sTNFRII was observed early following 
treatment initiation, and no additional immune effects were observed upon continued treatment 
for up to 10 years. The data therefore questions the concept of  chronic inflammation in HIV as 
the driving mechanism in the development of  long-term co-morbidities in HIV as suggested by 
others [113,116,137], and leave room for alternative explanations. 
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Abstract
Patients infected with the human immunodeficiency virus (HIV), have an increased risk of  
metabolic complications such as dyslipidemia, insulin resistance and hypertension; symptoms 
that are also associated with an excess of  the hormone cortisol. We studied the relationship 
between long-term cortisol levels and metabolic syndrome (MetS) in HIV-infected patients. 
Cross-sectional study, performed in the outpatient clinic of  infectious diseases of  the Erasmus 
MC, University Medical Center Rotterdam, The Netherlands. Fasting blood samples and 
anthropometric data were collected in 126 HIV-infected patients. An ELISA-based technique 
was used to determine long-term cortisol levels in scalp hair. Cortisol levels were compared 
to 191 healthy controls. A higher risk of  MetS was observed in HIV patients with a low hair 
cortisol (odds ratio lower vs. upper tertile 4.23, p = .04). Hair cortisol levels were not significantly 
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different between HIV patients and healthy controls (16.4 pg/mg vs. 13.5 pg/mg; p = .14).  The 
risk of  MetS was significantly higher in HIV infected patients in the lowest hair cortisol group 
compared with patients in the highest hair cortisol group. This finding contrasts with results from 
studies in uninfected individuals where a high cortisol level in hair is associated with metabolic 
syndrome. The results of  this study suggest that these metabolic complications might be related 
to relative cortisol hypersensitivity in HIV patients. We therefor developed a novel simple and 
fast method to assess glucocorticoid sensitivity using only a few milliliters of  blood. This assay 
confirmed our hypothesis.
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Introduction
Since the introduction of  combination antiretroviral therapy (cART) in 1996, the survival 
of  patients suffering from HIV has increased dramatically. However, a higher incidence 
of  metabolic complications has been observed in patients infected with the human 
immunodeficiency virus (HIV) as compared to the uninfected population (1-3). These 
complications include dyslipidemia, abnormal fat distribution (e.g. abdominal fat accumulation), 
hypertension, insulin resistance and type 2 diabetes mellitus (4,5). 
Subsequently, metabolic derangements can result in the metabolic syndrome (MetS) and the 
HIV lipodystrophy syndrome (4,6). Although the exact mechanism of  MetS in HIV has not been 
identified, a large tri-continental study demonstrated the additive effect of  cART in developing 
cardiovascular complications. In this study, a 26 percent relative increased risk of  myocardial 
infarction was observed per year of  cART exposure (7). Many of  the metabolic side effects that 
can occur in HIV patients are similar to symptoms caused by excessive glucocorticoid exposition, 
as seen in Cushing’s Syndrome (CS). Patient with CS have excessive cortisol levels and frequently 
exhibit signs of  dyslipidemia, insulin resistance, diabetes mellitus, hypertension, osteoporosis and 
abnormal fat distribution (e.g. buffalo hump and abdominal fat accumulation) (8,9). Because of  
the similarities between side effects of  cART and CS, several studies have been performed to 
examine whether cortisol levels are elevated in HIV-infected patients. The results are conflicting; 
some studies find elevated levels of  cortisol (10,11) whereas others contradict these findings 
(12,13).
Earlier studies used short-term cortisol measurements in serum, saliva or urine. These reflect 
cortisol levels of  that specific moment in time varying from minutes up to a maximum of  24 
hours. Cortisol is released in a circadian rhythm, with high cortisol levels in the morning and 
low levels in the evening (14). Furthermore, there is a daily variation in cortisol production due 
to stress, illness and physical activity (14). In comparison to serum, saliva or urine tests, cortisol 
measurement in scalp hair provides a better estimation of  long-term cortisol levels. With this 
relatively novel method it is possible to measure long-term cortisol levels during one or several 
months, as the growth rate of  scalp hair is one centimeter per month (15,16). This study is the 
first study that uses cortisol in scalp hair for a cortisol assessment in HIV patients.
The aim of  this cross-sectional study was to investigate the relation between the hair cortisol 
levels and the presence and severity of  the metabolic complications in HIV-infected patients. In 
addition, we aimed to investigate whether hair cortisol levels in HIV-infected patients differ from 
those in a healthy control group. 
Methods
We included 126 HIV-infected patients who participated in the longitudinal TREVI cohort 
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study at the Erasmus University Medical Center in Rotterdam, The Netherlands. A control 
group consisting of  191 healthy subjects was used for comparison of  the hair cortisol levels 
(16). Participants that used systemic corticosteroids or topical corticosteroids on the scalp 
were excluded from this study. All participants included in this study signed informed consent. 
Approval was obtained from the local ethical committee. 
Body height, weight, waist circumference and blood pressure were obtained from the patients 
at the time of  inclusion. Hair samples of  approximately 150 hairs were collected from all 
participants, cut off as close as possible to the scalp at the posterior vertex. Fasting blood samples 
from 91 of  the 126 HIV patients were obtained in a period of  two weeks prior to four weeks after 
the hair sample collection. General risk factors such as alcohol and nicotine use were assessed 
with a questionnaire. Patient files were accessed to review medical history and medication use. 
Fasting blood glucose, insulin, total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-
density lipoprotein (HDL)-cholesterol and triglycerides were measured as well as CD4+ cell 
count and HIV RNA load. The degree of  insulin resistance was estimated with the use of  the 
homeostasis model assessment of  insulin resistance (HOMA-IR) (17).
The diagnosis MetS was applied following the NCEP ATP III criteria (18). A diagnosis of  
MetS was established when three or more of  the five following conditions were met: waist 
circumference >102 cm in men and >88 cm in women, blood pressure ≥135 (systolic) or ≥85 
(diastolic) mmHg, triglycerides >1.70 mmol/l, HDL-cholesterol <1.03 mmol/l in men and <1.29 
mmol/l in women and plasma glucose levels ≥6.1 mmol/l. In addition, blood pressure and blood 
glucose were also considered elevated in patients who used antihypertensive medication and/ 
or glucose lowering medication, respectively. In patients who were on lipid-lowering therapy, 
triglycerides levels were considered too high (>1.70 mmol/l) and HDL-cholesterol levels were 
considered too low (<1.03 mmol/l in men and <1.29 mmol/l in women). 
Analyses of  glucose and lipids were performed according to standard laboratory procedures. 
Fasting serum insulin levels were determined by chemiluminescent immunoassays (Immulite® 
2000 Automated Immunoassay Analyzer), HIV RNA concentrations were determined with 
CAP-CTM HIV-1 v2 (Roche diagnostics, Almere, NL).
 
Cortisol measurement was performed using the proximal three centimeters of  the hair strands, 
corresponding with long-term cortisol levels during the preceding three months. The hairs 
were processed as described previously (16). Cortisol levels were measured with a commercially 
available ELISA kit for salivary cortisol (DRG Instruments GmbH, Marburg, Germany). A 
correction factor was used on all hair samples to correct for background signal caused by the hair 
matrix (19). 
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Mean hair cortisol levels between the patient group and the control group were compared using 
ANCOVA adjusting for gender and age. Correlations between hair cortisol and anthropometric 
and cardiometabolic parameters in the HIV patients were analyzed using bivariate and 
partial Pearson correlation analysis, controlling for gender and age. Continuous variables were 
logarithmically transformed where appropriate. Spearman correlation analysis was used to 
investigate the role between HIV RNA concentrations and hair cortisol levels. To assess the 
risk of  MetS in HIV patients, hair cortisol levels were divided in tertiles (low, intermediate and 
high hair cortisol levels). Logistic regression was used to examine the relationship between hair 
cortisol and the risk of  MetS. These analyses were adjusted for gender and age. All analyses were 
performed with the use of  IBM SPSS for Windows, version 21 (SPSS Inc., Chicago, Illinois.) A 
p-value < 0.05 was considered as a statistically significant difference. 
For the glucocorticoid (GC) sensitivity assay, we adapted a well known assay based on gene 
expression profiles in peripheral blood mononuclear cells (PBMC’s). Because this strategy is 
time consuming and requires a high blood volume, we optimized an evealuated a novel simple 
and fast method to assess GC sensitivity requiring only a few milliliters of  blood. A total of  31 
patients with known hair cortisol levels were selected. Whole PBMCs were stimulated for 4 hours 
with 10-7, 10-8, 10-9, 10-10 or 10-11 M dexamethasone (DEX). GR function was assessed by 
intracellular staining of  Glucocorticoid Induced Leucine Zipper (GILZ) and interleukin 2 (IL-2) 
followed by subsequent flowcytometric analysis. For IL-2 expression, cells were initially primed 
with 10ug/ml phytohaemagglutinin (PHA). Patients with MetS and low hair cortisol (group 1, 
N=7) were compared to all others (group 2, N=34).
Results
Patients’ characteristics are shown in Table 1. Gender and age were significantly different in the 
patient group compared to the control group. Three patients with hair cortisol levels exceeding 
four times SD were excluded from this study. Although not reported at the first visit, one patient 
appeared in retrospect to have used topical corticosteroids on the scalp. The cause of  increased 
hair cortisol levels in the other two patients remains unknown.
Of  the 91 patients from whom fasting blood samples were obtained, 23 (25.3%) met three 
or more ATP III criteria and were thus diagnosed with the MetS. The most frequent MetS 
criterion in the HIV group was elevated systolic blood pressure (52.7%), followed by reduced 
HDL-cholesterol (43.9%) and hypertriglyceridemia (42.9%). The presence of  enlarged waist 
circumference (14.3%) and elevated blood glucose levels (13.2%) were both less frequent (Table 
2). 
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med: median, IQR: interquartile range, cART: combined antiretroviral therapy, NRTI: 
nucleoside reverse transcriptase inhibitor, MetS: metabolic syndrome, NNRTI: non-nucleoside 
reverse transcriptase inhibitor,  PI: protease inhibitor.
Table 1. HIV patients and control group characteristics 
HIV patients Controls p
n 123 191
Male, n (%) 102 (82.9) 88 (46.1) < .001
Age , mean (SD), years 47.3 (11.5) 36.4 (12.3) < .001
BMI, mean (SD), kg/m2
Hair cortisol, mean (SD), pg/mg 
MetS, n (%)
23.8 (3.9)
16.4 (16.8)
23 (25.2)
24.4 (3.9)
13.5 (13.5)
.26
.14
Time since HIV diagnosis, mean (SD), 
years
7.4 (6.6)
Receiving cART, n (%) 113 (91.9)
Time since start cART, mean (SD), 
years
5.4 (5.7)
CD4+ cell count x106/l, med (IQR) 550 (400 - 740)
HIV RNA load < 200 co/ml, n (%)
Ethnicity
Caucasian, n (%)
Other, n (%)
Unknown, n (%)
101 (82.1)
115 (93.5)
6 (4.9)
2 (1.6)
170 (89.0)
18 (9.4)
3 (1.6)
Antiretroviral therapy
2 NRTI’sa + 1 NNRTIb, n (%) 86 (70)
Receiving PIc, n (%)
Other, n (%)
18 (14.6)
19 (15.4)
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The mean hair cortisol levels in the patient group were not significantly different from the 
control group (p = .14), also after correction for gender and age (p = .20). However, there was a 
significant difference in the mean hair cortisol levels of  HIV patients without MetS compared to 
the control group (17.3 pg/mg vs. 13.5 pg/mg, p = .03).
Hair cortisol levels were not correlated with age or gender in both the patient group and the 
control group. In the HIV group, there was a significant positive relation between hair cortisol 
levels and body mass index (BMI) (r = .180, p = .05). In the control group, no significant relation 
between hair cortisol and BMI was present (p = .18). There were no significant differences 
in gender, CD4+ cell count or HIV RNA load between the HIV-infected patients with MetS 
compared to the non-MetS patients. After correction for age there were no significant differences 
in time since first HIV diagnosis and duration of  cART use between MetS and non-MetS 
patients (10.2 years vs. 6.4 years, p = .30 and 8.0 years vs. 4.6 years, p = .18 respectively). In both 
the HIV and control group no relation was found between hair cortisol levels, smoking status or 
alcohol use (p > .05). 
Table 2 Anthropometric and (fasting) metabolic parameters of  the HIV 
patients (n=91).
Waist circumference males, cm 87.9 (±9.8)
Waist circumference females, cm
Systolic blood pressure, mmHg
89 (±15.1)
130 (94 – 187)
Diastolic blood pressure, mmHg 81 (±12)
Triglycerides, mmol/l 1.34 (.40 – 5.74)
HDL-cholesterol, mmol/l 1.22  (.53 – 2.24)
LDL-cholesterol, mmol/
Total cholesterol, mmol/l
Glucose, mmol/l
3.34 (±1.00)
5.05 (2.3 – 8.1)
5.20 (4.0 – 9.7)
Insulin, pmol/l 75 (7.0 – 385)
HOMA-IR 2.83 (.20 – 11.6)
MetS, n (%) 23 (25.2)
Normally distributed data are presented as mean (±SD), non-normally distributed data as 
median (range).
HDL: high-density lipoprotein, HOMA-IR: homeostatic model  assessment insulin resistance, 
LDL: low-density lipoprotein, MetS: metabolic syndrome.
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We found no significant correlation between hair cortisol levels and LDL-cholesterol, total 
cholesterol, waist circumference, CD4+ cell count, insulin, glucose or HOMA-IR in the HIV 
patients. A positive correlation between hair cortisol and HDL-cholesterol was found in both 
the bivariate correlation (r = .381, p < .001) and in the adjusted correlation (r = .341, p = .001) 
(Table 3). In the HIV patients with a MetS diagnosis, the correlation between hair cortisol and 
HDL-cholesterol was stronger than in the total HIV group (r = .751 p < .001 in the non-adjusted 
model and r = .769, p < .001 in the model corrected for gender and age) (Figure 1). 
Table 3. Bivariate and adjusted Pearson and Spearman correlations between 
hair cortisol levels and anthropometric and cardiometabolic parameters in 
HIV-infected patients.
r r (adjusted)b
BMI .180* .040
Waist circumference .074 .029
Systolic bp −.052 −.087
Diastolic bp .067 .034
Glucose .130 -.049
Insulin .033 -.002
HOMA-IR .032 0.00
Triglycerides −.097 −.085
HDL-cholesterol .381*** .341**
LDL-cholesterol .007 −.107
Total cholesterol .110 .054
CD4+ cell count
HIV RNAa
.103
−.105
.049
a Spearman correlation analysis was used because of  a non-normal distribution, b Adjusted for 
gender and age, bp: blood pressure, HOMA-IR: homeostatic model assessment insulin resistance, 
HDL: high-density lipoprotein, LDL: low-density lipoprotein.
* p < .05, ** p < .01, ***p < .001.
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Figure 1. Correlation of  hair cortisol with HDL-cholesterol in (a) the total HIV patients group 
(n=90, r = .381, p < .001) and (b) in the MetS diagnosed group (n = 22 r = .751, p < .001). The 
best-fit line and its 95% confidence interval (CI) are shown.
Hair cortisol levels were divided in tertiles (low-, intermediate- and high hair cortisol levels) and 
the odds ratio (OR) for MetS was calculated for each tertile. The highest hair cortisol tertile 
was considered the reference tertile. Cut off points were 8.33 and 19.35 pg/mg hair. In the 
unadjusted model, the OR for MetS was 2.9 (p= .09, 95% CI: 0.86 – 9.75) in the lowest hair 
cortisol tertile compared to the highest hair cortisol tertile and 1.5 (p= .56, 95% CI: 0.41 – 5.23) 
for the intermediate hair cortisol tertile compared to the high hair cortisol tertile. After correction 
for gender and age, the OR for the lowest hair cortisol group was 4.23 (p = .04, 95% CI: 1.09 
– 16.47) and for the intermediate hair cortisol group was 1.65 (p = .48, 95% CI: .42 – 6.55) 
compared with the highest hair cortisol group (Figure 2).
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For the expression of  GILZ and IL-2, stimulation with high dose (10-7)M DEX resulted in a 14,6 
fold increase in GILZ positive and a 1,3 fold mean decrease in IL-2 positive CD8 T-cells (data 
not shown). GILZ frequencies were significantly higher in HIV patients with both MetS and low 
hair cortisol (group 1) compared to others (group 2) after stimulation with 10-7, 10-8, 10-9 M 
DEX (p<0,05). There was no difference in the frequency of  IL-2 producing cells between the 
two groups.
Discussion 
This study has been the first to study long-term cortisol levels using hair analysis in relation to 
MetS in HIV-infected patients. Interestingly and in contrast to our hypothesis, we found that the 
odds for the MetS are 4.2 times higher in the patients group with the lower hair cortisol levels 
compared to the patients group with the higher hair cortisol levels. This result differs from the 
results from recent published studies in non-HIV infected subjects in which the risk of  MetS 
was significantly higher in the highest hair cortisol quartile compared to the lowest hair cortisol 
quartile (20,21). Taken the literature into account, the results of  this study could point toward 
a modulatory effect of  cortisol in de development of  metabolic complications in HIV-infected 
patients. 
Figure 2. Odds ratios with 95% confidence interval for metabolic syndrome (MetS) diagnosis 
according to hair cortisol tertiles. Both in the unadjusted model, as well as after correction for 
gender and age (shown in figure) the risk of  MetS was highest in HIV patients with the lowest 
long-term cortisol, as measured in scalp hair.
Ref: reference tertile, * p < .05.
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In addition, we found that hair cortisol levels in HIV-infected patients on average are not 
different from healthy persons. Interestingly, there is a positive correlation between hair cortisol 
and HDL-cholesterol that became even stronger when stratified for patients with MetS. These 
results are in contrast with previous observations in the (non HIV-infected) general population in 
which cortisol levels are negatively correlated with HDL-cholesterol (20,22).
The low hair cortisol in HIV patients with increased risk of  MetS could hypothetically 
be explained by a hypersensitivity to cortisol. The effects of  cortisol are mediated by the 
glucocorticoid receptor (GR), which is an important factor in determining cortisol sensitivity 
at a cellular level. Under physiological stress, including during HIV infection, GR function at 
tissue level is disturbed (23). Cortisol hypersensitivity is characterized by low systemic cortisol 
levels due to increased negative feedback action. Cortisol hypersensitivity could explain the signs 
of  hypercortisolism in our cohort (23). Intracellular detection of  GILZ and IL-2 as a correlate 
of  GR sensitivity seems a promising tool and valuable alternative to the currently used gene 
expression assays. Using our novel flowcytometry based method; we demonstrated increased GR 
sensitivity in HIV infected individuals with MetS and low hair cortisol. 
Several mechanisms have been described which could explain an increased cortisol exposure 
at the tissue level or cortisol hypersensitivity in HIV patients. The first possibility is that some 
HIV patients may have enhanced activity of  the enzyme 11β- hydroxysteroid dehydrogenase 
type 1 (11β-HSD1). This enzyme converts the inactive metabolite cortisone in the active 
cortisol, resulting in increased cortisol activity at tissue level (24). Multiple pro-inflammatory 
cytokines such as TNF-alpha (TNF-α) and interleukine-1 beta (IL-1β) can increase the activity 
of  11β-HSD1 in vitro (25,26). A study concerning 30 HIV-infected participants showed that 
11β-HSD1 mRNA concentrations in adipose tissue were three times as high in HIV-infected 
patients with lipodystrophy compared to HIV patients without lipodystrophy (12). Another 
possibility is the presence of  the viral protein R (Vpr) in these patients. Vpr is a 96-amino acid 
virion associated accessory HIV protein that is required for replication of  HIV in non-dividing 
cells (27). Vpr is a co-activator of  the GR (28) and it is therefore plausible that it causes cortisol 
hypersensitivity.
We also looked if  altered cortisol clearance can play a role in the results that are found in this 
study. Cortisol is partly metabolized in the liver by CYP3A4 enzymes. Many antiretroviral drugs 
can alter CYP3A4 activity. Protease inhibitors (PI’s) can inhibit CYP3A4 enzymes, whereas almost 
all non-nucleoside reverse transcriptase inhibitors (NNRTI’s) can induce CYP3A4 enzymes (31). 
In this study 18 patients were on a medication regime that consisted of  a PI without a NNRTI (PI 
group) and 86 patients received one or more NNRTI’s without receiving a PI (NNRTI group). We 
found no statistically significant difference in hair cortisol levels between the PI group and NNRTI 
group (18.0 pg/mg vs. 17.2 pg/mg, p = .58). Therefore, it seems unlikely that altered cortisol 
clearance mediated by cART influences the results found in this study.
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The strength of  our study includes a well monitored and representable chronically HIV infected 
cohort. All samples were collected after overnight fasting. In contrast to previous studies using 
single time point (saliva, serum) or short-term (24h urine) cortisol measurements, we used a 
relatively novel but well validated, method to determine long-term systemic cortisol levels in 
scalp hair (32). This method has been investigated within the context of  a wide variety of  clinical 
conditions such as (cyclic) Cushing’s syndrome, cardiovascular disease and obesity (33-35).
Our study does have some limitations. The cross-sectional design does not allow us to assess 
whether a person with MetS has a propensity to remain in the lower tertile of  cortisol over 
time. In addition, the observed associations do not determine whether the lower mean hair 
cortisol levels in HIV patients with MetS are cause or result of  the metabolic complications in 
these patients.  In the control group, no in depth phenotyping with respect to the metabolic 
syndrome was performed. The definition of  MetS using the NCEP ATP III criteria is useful in 
clinical practice and is closely related to the Framingham risk score, a tool that has gained great 
interest in HIV care. However, some elements in these tools are based on snapshots of  patient 
characteristics, such as systolic blood pressure, plasma cholesterol and glucose. Therefore, results 
should be interpreted in the context of  patient care. 
In conclusion, we found that relatively low long-term cortisol levels, measured in hair, are 
associated with an increased risk of  MetS in HIV-infected patients. These results suggest that 
HIV patients with MetS and low hair cortisol levels may be cortisol hypersensitive. We performed 
further research by indirect ex vivo measurement of  GR expression and bio-activity in HIV 
infected patients with MetS and low hair cortisol levels (36). We showed that MetS in HIV may 
be partially related to GC hypersensitivity, potentially leading to new treatment opportunities 
for these metabolic abnormalities. It would be interesting to elucidate the mechanism of  cortisol 
metabolism and the exact role cortisol plays in the development of  metabolic derangements in 
HIV-infected patients.
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Abstract
Arterial and venous thrombotic events are more prevalent in HIV infected individuals compared 
to the general population, even in the era of  combination antiretroviral therapy. Although 
the mechanism is not fully understood, recent evidence suggests a role for chronic immune 
activation. We reviewed the Dutch National HIV registry database for HIV infected patients 
in Rotterdam with a history of  arterial or venous thrombosis and calculated the incidence. We 
collected samples from patients with and without thrombosis and compared plasma levels of  
lipopolysaccharide (LPS), LPS binding protein (LBP), soluble CD14 (sCD14), and von Willebrand 
Factor antigen level (vWF). During a 10-year period, a total of  60 documented events in 14,026 
person years of  observation (PYO) occurred, resulting in an incidence rate of  2.50, 2.21 and 4.28 
for arterial, venous and combined thrombotic events per 1000 PYO, respectively. The vWF was 
elevated in the majority of  study subjects (mean 2,36 SD±0.88 IU/ml); we found a significant 
difference when comparing venous cases to controls (mean 2.68 SD±0.82 IU/ml vs 2.20 
SD±0.77 IU/ml; p=0.024). This difference remained significant for recurrent events (mean 2.78 
SD±0.75p=0,043).). sCD14 was positively correlated with LPS (r=0.255; p=0.003). The incidence 
of  venous thrombosis was twofold higher in HIV infected patients compared to age-adjusted data 
from general population cohort studies. We couldn't find a clear association between immune 
activation markers to either arterial or venous thrombotic events. We observed a marked increase 
in vWF levels as well as a correlation of  vWF to first and recurrent venous thrombo-embolic 
events.
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These findings suggest that HIV infection is an independent risk factor for coagulation 
abnormalities and could contribute to the observed high incidence in venous thrombosis. This 
could be a reason to prolong anti-thrombotic treatment in HIV patients with a history of  
thrombosis.
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Introduction
The delicate interaction between inflammation and coagulation has long been recognized 
and persists to play a pivotal role in numerous infections such as sepsis and viral hemorrhagic 
diseases. In chronic HIV infection, the hemostatic balance is tipped towards a more pro-
coagulant status, resulting in thrombosis [138]. This is supported by both epidemiological and 
experimental data.
The annual risk on venous thrombosis in a representable European population below the age 
of  60 is slightly over 1 per 1000 person years of  observation (PYO) [139] [140]. For arterial 
thrombosis, the annual risk is higher with incidence rates between 2-3 per 1000 PYO for 
myocardial infarction and around 0.65 per 1000 PYO for stroke [141] [142]. It is likely that HIV 
infection independently adds to this risk [143]. A nationwide study comprising of  4,333 HIV 
infected individuals reported an incidence of  venous thrombosis in 3.2 per 1000 PYO [144]. 
In addition, events occur at a significantly younger age compared to the control population 
[145] [146]. Similar trends have been observed in myocardial infarction [147], stroke [148] and 
peripheral atherosclerosis [149]. A large tri-continental study determined an incidence of  5.7 
per 1000 PYO for first cardio- or cerebrovascular event in a relatively young cohort [150] with 
cumulative exposure to cART as a major contributor [151] [43].
The exact pathophysiology of  increased thrombotic activity in HIV remains unknown but recent 
publications advocate a role for chronic immune activation. In this hypothesis, HIV infection 
causes a loss of  mucosal integrity in the gut together with CD4 T-cell depletion in local lymphoid 
tissue. This results in translocation of  microbial products from the lumen to the circulation [34]. 
Bacterial endotoxins such as LPS are subsequently bound to pattern recognition receptors and 
trigger a potent inflammatory response in monocytes and macrophages [152] [153].  LPS, LBP 
and soluble CD14 levels have been found to correlate with a hypercoagulable state in chronic 
HIV, with or without combined cART [154] [134] [101] [155]. Although it is conceivable that 
immune activation accelerates clot formation, the exact mechanism remains to be elucidated. 
In this study we addressed HIV as a common risk factor for both arterial and venous thrombosis 
and investigated chronic immune activation as the proposed driving mechanism. To test this 
hypothesis, we assessed the incidence of  venous and arterial thrombotic events in a chronically 
infected HIV population. We compared coagulation (vWF), microbial translocation (LPS and 
LBP) and inflammatory parameters (sCD14) of  patients with a past thrombotic event to patients 
without an event. We hypothesized that HIV infected individuals with a past thrombotic event 
have a higher exposure to microbial-driven immune activation.
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Materials and Methods
Patients and study design
On February 25th 2013, we retrieved information from the Stichting HIV Monitoring (SHM) 
database, described elsewhere, which includes anonymized data obtained from treated and 
untreated HIV-infected patients, who have been followed in or after 1996 in our hospital [156].  
Cases were defined as patients with a thrombotic event and a presumed or definite preceding 
HIV diagnosis. A preceding HIV diagnosis was presumed when the CD4 cell count was <200/
mm3 within one year of  the HIV diagnosis. Venous thrombo-embolic events included deep 
venous thrombosis (DVT), diagnosed by compression ultrasonography; or pulmonary embolism 
(PE), diagnosed by Computer Tomography (CT) pulmonary angiography. Arterial thrombo-
embolic events included myocardial infarction (MI), diagnosed by electrocardiogram and cardiac 
biomarkers; cerebrovascular incident (CVA) or ischemic attack (TIA), diagnosed by neurological 
examination in combination with CT scan results; and claudication intermittens (CI) diagnosed 
by the ankle-brachial index. Cases were compared to randomly selected controls i.e. patients 
with HIV infection but no thrombo-embolic event in their history. This control population was 
comparable to the general HIV population in Rotterdam with respect to age and sex. All cases 
and controls were offered a questionnaire concerning classical risk factors. This research was 
approved by the local ehtics committee, patients had to sign an informed consent document to 
participate. 
 
LPS, LBP, sCD14 and vWF measurements
We collected plasma from 65 cases and 65 control patients for analysis of  LPS, LBP, sCD14 and 
vWF. The patient blood samples were collected in Ethylene diamine tetra acetic acid (EDTA). 
These were initially intended for viral load analysis and stored at -80° Celsius. The mean time 
from thrombotic event to blood sample collection was 6.2 years (SD±4.7). Samples were thawed 
only once to prevent protein degradation. LPS levels were measured using the Pyros Kinetix 
Flex® chromogenic endotoxin detection system (Associates of  Cape Cod). Plasma samples were 
heat inactivated at 60°C and subsequently diluted with LPS free LAL H2O at concentrations 
varying from 1:20 to up to 1:400. Exact LPS quantities were derived from a standard curve of  
known control endotoxin concentrations. LBP was measured using a LBP ELISA kit® (Hycult 
biotech); soluble CD14 was measured using the Human sCD14 Quantikine ELISA Kit® (R&D 
systems); vWF antigen levels were measured with an in-house ELISA using DAKOPATTS 
antibodies and compared to the vWF antigen levels to commercially available pooled plasma 
from 20 or more otherwise healthy donors (CRYOcheck™). 
Data analysis
For the calculation of  incidence, we used available SHM data on all HIV patients in care at the 
Erasmus MC from February 25th 2003 to February 25th 2013. The incidence rate of  an event 
was calculated as the number of  documented cases occurring in a 10 year time period, divided 
by the total amount of  unique person-years contributed to the cohort. Data was censored when 
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an event occurred, when the patient died or on the index date, whichever came first. Cases with 
both arterial and venous events were censored on whichever date came first, but were included in 
both calculations.
Normality of  data was assessed by a Shapiro Wilk test and inspection of  Q-Q Plots. 
Homogeneity of  variance was assessed by Levene's Test for Equality of  Variances. An 
independent T-test or Man-Whitney was performed for continuous variables when appropriate. 
vWF was normally distributed, and sCD14, LBP and LPS showed a non-parametric distribution. 
For categorical variables, a Chi-Square test was applied. Correlation analysis was performed 
using the Spearman’s Rank-order test. A significance level of  0.05 was applied. All statistical 
analysis was performed using SPSS software, version 21 (IBM corp ©). Graphs were constructed 
using GraphPad Prism software, version 6.
Results
From February 25th 2003 to February 25th 2013, a total of  2,731 unique patients were registered 
in the Rotterdam SHM database, representing 14,026 person years. A total of  60 thrombotic 
events occurred during this 10-year period. The overall incidence of  both arterial and venous 
thrombotic events combined was 4.28 per 1000 PYO. These rates were 2.50 and 2.21 for arterial 
events and venous thrombotic events, respectively. The incidence of  patients with a recurrent 
event was 0.93 in the arterial group and 0.57 in the venous group per 1000 PYO when divided 
by the total amount of  person years. When divided by the corresponding amount of  person 
years in the specific event group only, the incidence increased to 95 in the arterial group and 73 
in the venous group per 1000 PYO.  In the group that had experienced a venous thrombosis, the 
incidence of  patients that had a recurrence of  a venous event was 30% after a period of  3 years. 
At the time of  inclusion on February 25th 2013, a total of  1679 HIV-infected patients were 
still in care out of  which 79 were reported with a thrombotic event (see figure 1). Of  these 
79 patients, 10 patients were excluded based on a negative HIV test at the time of  event 
and 4 patients refused participation, resulting in 65 available cases. In addition, we searched 
the database for patients that died between April 1st 2002 and November 22nd 20012 and 
had a history of  thrombosis In total, 223 patients died during this period of  which 20 had a 
documented thrombotic event in the past. Of  these 85 patients, 37 were diagnosed with a PE of  
DVT; 41 with a MI, CVA or CI; and 7 had endured both a venous and arterial event. 
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A random selection of  the patients registered in the Rotterdam SHM database (as described 
earlier) was applied to select a control group of  198 HIV-infected patients. This group was 
comparable to the whole HIV population at the Erasmus Medical Center in respect to age and 
sex. When compared to the 198 controls at the time of  observation, cases with arterial and 
venous events were significantly older (46.85 SD±11.10 vs 57.83 SD±11.01 years p<0.001 
(arterial) vs 52.80 SD±11.21 p=0.007 (venous)), more likely to be of  Caucasian descent (46.5% 
vs 70.7% p=0.005 (arterial) vs 67.6% p=0.018 (venous)) and were more likely to have history 
of  hypertension (8.1% vs 39% p<0.001 (arterial) vs 21.6%  p=0.013 (venous)) and malignancy 
(6.1% vs 19.5 % p=0.005 (arterial) vs 21.6% p=0.002 (venous)). Compared to controls, an 
arterial event was specifically associated with male sex (71.2% vs 90.2% p=0.011), a positive 
family history for cardiovascular events (17.7% vs 39.0% p=0.002) and diabetes mellitus (4.5% vs 
22.0% p<0.001). There was no difference between cases and controls for traditional risk factors 
such as a high body mass index, smoking or immobilization. No difference was found for HIV 
related risk factors such as a low CD4 nadir count or protease inhibitor (PI) use (table 1). 
Figure 1. Flow chart depicting the selection of  patients for this study.
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Table 1. Patient Characteristics.
For patient characteristics of  patients that underwent analysis of  sCD14, LPS, LBP and vWF 
please see supplementary table 1. Patients with a thrombotic event in the past had a higher mean 
vWF antigen level when compared to controls (venous: 2.68 SD±0.82 IU/ml; arterial: 2.31 
SD±1.10 IU/ml; both: 2.74 SD±0.90 IU/ml; controls: 2.20 SD±0.77 IU/ml). The difference 
in vWF antigen levels was significant in patients with a past venous event compared to controls 
(p=0.024, Independent samples T-test) (figure 2), which remained significant when comparing 
only recurrent events to controls (2.78 SD±0.75; p=0.043 Independent Samples T-test, figure 
3). The significance of  difference in vWF antigen level between cases combined versus controls 
varied upon the applied statistical test (p=0.047, Mann Whitney; p=0.071 Independent samples 
T-test). There was no clear connection between time since thrombotic event and the level of  
vWF antigen (see figure 4). There was no significant difference between cases and controls 
in sCD14 (median: 2.45 IQR±2.08 vs 2.31 IQR±1.36; p=0.341) and LBP (median: 20.19 
IQR±17.56 vs 16.63 IQR±15.05 μ/ml; p=0.264) as well as LPS (median: 12.19 IQR±24.70 vs 
10.76 IQR±23.58) although values tended to be higher in cases (figure 2). 
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Figure 2. Plasma levels of  LPS (N=101), LBP (N=130), sCD14 (N=130), and vWF antigen 
(N=93) in chronic HIV infected individuals with or without a history of  arterial or venous 
thrombotic disease. Horizontal bar represents median for LPS, LBP and sCD14; and mean in 
vWF. Cases had a significantly higher vWF antigen level as compared to controls. Grey: controls 
Figure 3. vWF antigen in individuals with HIV without thrombosis compared to HIV infected 
individuals with a recurrent venous or arterial trombotic event. Patients with a recurrent venous 
thrombotic event had a statistically significant higher vWF (p=0.043). vWF: von Willebrand 
Factor antigen level.
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Figure 4. Time from event to blood sample collection plotted against vWF antigen level in HIV 
infected individuals with an arterial or venous event. The level of  vWF antigen is considerably 
higher than the reference value. vWF= von Willebrand Factor antigen. Red: arterial events; blue: 
venous events; green: both arterial and venous events. Light blue area: reference value for vWF 
antigen level. 
The only association detected was a positive correlation between levels of  soluble CD14 and 
log 10 levels of  LPS (p=0.003; r=0.255, fig 5A). There was also a weak trend toward positive 
correlation between plasma levels of  vWF and sCD14 (p=0.078; r=0.184, fig 5D). The four 
other combinations of  markers (vWF versus LBP; vWF versus log 10 LPS; sCD14 versus LBP; 
LBP versus log 10 LPS) were not correlated (all p values > 0.1). 
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Figure 5. Correlation analysis of  sCD14, LBP, LPS (log-transformed) and vWF. A Spearman’s 
Rank-order test was used for analysis. Only sCD14 and LPS (log-transformed) had a statistically 
significant correlation (A). There was a weak trend toward positive correlation between vWF and 
sCD14 (D). LPS: Lipopolysaccharide; LBP: LPS binding protein; sCD14: soluble CD14; vWF: 
von Willebrand factor antigen level.
Discussion
Our results confirm previous observations of  thrombosis being a prevalent co-morbidity in the 
HIV population, even in a cohort with prolonged c-ART treatment. Comparable to uninfected 
individuals, traditional risk factors such as diabetes, malignancy, hypertension and a positive 
family history continue to contribute to the development of  an event, but additional factors 
play a role. This study was aimed to investigate the incidence of  arterial and venous thrombosis 
in patients living with chronic HIV infection. In addition, we wanted to address what factors 
predispose HIV patients for the occurrence of  a thrombotic event and by which mechanism. 
To answer the first question, we performed a retrospective analysis. The incidence of  arterial 
and thrombotic events combined was 4.28 per 1000 PYO. We found an incidence of  2.21 per 
1000 PYO of  venous thrombotic events, which is more than twofold higher compared to healthy 
controls from large cohort studies [140]. This result corroborates with literature where the risk 
on venous thrombotic disease is reported to be 2 to10-fold increased [157,158]. The variation 
in observed incidences between studies is probably related to the nature of  these studies, mostly 
retrospective, the difference in diagnostic criteria and cohort characteristics such as immune 
status of  patients. An increasing amount of  evidence in the literature supports the notion that 
HIV status is associated with increased risk on myocardial infarction, stroke and venous thrombo-
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embolism [159]. With the aging of  HIV cohorts and related increased exposure to cART, it 
remains important to re-evaluate this incidence rate. The incidence rate for arterial events in our 
study was lower than previously found. Compared to the Data Collection on Adverse Events of  
Anti-HIV Drugs (DAD) Study Group, the incidence in our study is twofold lower [150]. The 
prevalence of  risk factors such as smoking, diabetes and hypertension, were comparable in both 
studies. One difference is a high use of  PI’s in the DAD study cohort.  PI’s are known to cause 
metabolic abnormalities and could add in disease severity, although a direct causal relationship 
with arterial disease remains controversial [160].  
In HIV infection, several well-defined coagulation abnormalities exist, such as Activated Protein 
C resistance, Protein S deficiency, increased D-dimer, Tissue Factor expression on monocytes 
and increased levels of  vWF. In this study, we choose to examine vWF as a prognostic marker 
to investigate the predisposition to a thrombotic event. This protein is crucial in both primary 
and secondary hemostasis. It is produced almost exclusively in the endothelium and is stored 
as large multimers in vesicles called Weibel Palade bodies. The vWF antigen level in HIV 
patients was two-fold higher compared to the reference material (i.e. healthy donors), which 
implies an increased coagulation potential in all HIV infected patients. Several mechanisms 
could potentially result in a high level of  vWF antigen. A delayed clearance of  vWF, as is 
seen in conditions such as thrombotic thrombocytopenic purpura (TTP) and hemolytic 
uremic syndrome (HUS), is unlikely the cause of  high vWF antigen in HIV. The activity of  
ADAMTS13, the metalloproteinase responsible for clearing vWF, can be lower in HIV, but does 
not reach the levels needed for overt pathology (Jong et al, unpublished data) [161]. In addition, 
antibodies against ADAMTS13 are incidental in HIV related TTP [162]. It seems more 
logical to attribute the high vWF to increased transcriptional activity in endothelial cells due to 
chronic immune activation [163]. The production, storage and exocytosis of  vWF are regulated 
through intrinsic and extrinsic factors such as, but not limited to nitric oxide, hypoxia, histamine, 
thrombin and other secretagogues. LPS, for instance, could be a potent stimulator of  endothelial 
cells. Therefore, we explored the possibility of  immune activation as a driving factor behind 
arterial and venous thrombosis. It is likely that monocytes rather than T-cells are responsible 
for the initial immunologic response to LPS translocation, considering these cells express CD14 
and TLR4, the receptors for LPS. Although markers of  coagulation and immune activation are 
partially restored upon initiation of  cART, a complete normalization fails to appear [101] [79]. 
In the SMART study, a study aimed to investigate the benefit of  a CD4 guided approach on 
treatment [164], markers of  inflammation and coagulation such as IL-6, D-dimer and sCD14 
were shown to be excellent predictors of  atherosclerosis and mortality [165] [166] [134]. If  
immune activation is chronic and predisposes patients for morbidity, we expected to find higher 
baseline levels of  these markers in patients with a thrombotic event in the past. Although levels of  
immune activation tended to be at the high end in all patients, we could not detect a significant 
difference between cases and controls. Correlation analysis revealed only a significant correlation 
between sCD14 and LPS (fig 5A). This could represent the increased inflammatory response of  
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monocytes on microbial products. It is reasonable to assume that immunologic and hemostatic 
factors can mutually influence each other. However, all the other associations we describe in this 
manuscript were non-significant. 
 
Taken together, these data support the hypothesis of  an increased activity in coagulation, 
although the exact mechanism remains to be elucidated. The presence of  endothelial cell 
activation, increased fibrin formation and decreased anticoagulation, as observed in HIV infected 
patients, is compatible with a pro-thrombotic state [154] [167] and mirror markers of  immune 
activation [168]. Additive pro-coagulant mechanisms such as increased tissue factor activity 
on monocytes as proposed by Funderburg et al [169] could be involved alongside endothelial 
cell activation. In the end, the model of  chronic immune activation as proposed by Brenchley 
et al. [34], has given rise to new insights in the pro-thrombotic state in HIV. In the meanwhile, 
we should consider HIV as an independent risk factor for thrombosis. Possible strategies to 
further investigate immune activation as a causative mechanism could include the use of  anti-
inflammatory agents or early initiation of  therapy. Further research on the specific interaction 
between endothelial cells and monocytes during HIV infection would be especially interesting. 
Caution has to be made in conferring primary prevention of  thrombosis in HIV patients, since 
anti-coagulation has potentially serious side effects. It may be worth considering extending 
secondary prophylaxis in HIV patients with a history of  venous thrombosis, since the recurrence 
rate is relatively high. Although we found a significant difference in vWF between venous 
recurrences and controls, the wide distribution of  values prevents an accurate discrimination 
between these two, limiting vWF as a predictor for venous thrombosis.
The strength of  our study is the detailed baseline demographic and clinical data recorded from a 
well-characterized population in the SHM cohort. Our study does have several limitations. The 
study is retrospective, relying largely on the quality of  existing data. We are aware of  the fact 
that our data reflect only documented thrombotic events, so the incidence calculated in our study 
probably underestimates the real number. The ideal study would be a prospective study with 
comparable person years of  inclusion and blood samples before and after an event. We realize 
this is a laborious task considering practical issues. In addition, HIV-positive patients were mostly 
on cART, so the individual contribution of  HIV infection and cART to immune activation 
biomarkers could not be distinguished. Our experiments could not establish a relationship 
between LPS, LBP, sCD14 and event status. A possible explanation could be the large interval 
between occurrence of  the event and measurement of  the parameters (mean = 6.2 years later). 
We would expect a higher level of  immune activation markers around the time of  the event. 
Although microbial translocation has gained much attention as a potential driver for immune 
activation, it should be stated other mechanisms have not been addressed in this study. We cannot 
exclude other potential mechanisms such as residual viral replication, CMV seropositivity and 
pyroptosis [35] as a driver for coagulation abnormalities.
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In conclusion, our study confirms previous findings that HIV-infection results in a pro-
thrombotic state, reflected by a high incidence in venous thrombotic events and a high 
percentage that experiences a recurrence. Although we did not see a clear association between 
markers of  immune activation to event status, we did encounter a significant difference in vWF 
levels between patients with a past venous thrombo-embolism and those without. These data 
support the rationale to extend anticoagulant therapy once venous thrombosis has occurred. 
However, further investigation on e.g. fVIII and other pro-coagulants is needed. The wide 
distribution of  vWF in our patient groups does not support the use of  this marker as a clinical 
predictor for recurrent thrombosis in HIV patients.
Supplementary table 1. Patient characteristics of  the 130 patients of  whom samples were 
obtained. Cases and controls were age- and sex matched as a group.
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Abstract
Circulating endothelial cells (CECs) are mature endothelial cells discarded from the endothelium 
during normal homeostasis. An increased number of  CECs is found in response to vascular 
damage, which has been demonstrated during chronic HIV infection in adults. Vascular damage 
might lead to vascular complications such as myocardial infarction and cerebrovascular events 
that are more prevalent in HIV infected adults. We hypothesized that CECs are also increased 
in HIV infected children. In addition, we investigated the potential correlation of  CECs with 
metabolic parameters associated with increased risk on vascular damage. Peripheral blood was 
obtained from 40 HIV-infected children (age 5-20 years) at the ErasmusMC-Sophia children's 
hospital in Rotterdam, the Netherlands. Blood from 30 uninfected adults was used as control, as 
well as blood from 31 age-matched pediatric controls undergoing elective surgery. CECs were 
examined for associations with immunologic and metabolic parameters. The median CEC 
count per 4 mL was significantly higher in HIV infected children compared to uninfected adults 
(p=0,0001) but not compared to uninfected children (p=0.261). There was a significant but weak 
association between CECs and duration of  antiretroviral therapy (r= -0,330; p=0,038). CECs 
are increased in treated HIV infected children compared to healthy adults, but not compared 
to children undergoing elective surgery in this study. We found a significant but weak inverse 
correlation with the duration of  antiretroviral therapy. 
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Background
Vascular complications such as myocardial infarction and cerebrovascular events are more 
prevalent in the HIV population [28,144]. Although classical risk factors such as smoking, obesity 
and hypertension remain prominent predictors, other contributing factors seem to play a role in 
HIV. Increased tendencies of  metabolic abnormalities like dyslipidemia have been demonstrated 
previously and a strong correlation has been established with the use of  Protease Inhibitors 
[151]. In addition to antiretroviral therapy, chronic immune activation has been suggested 
as a potential driving mechanism in the occurrence of  co-morbidities, but studies so far have 
not been able to prove this hypothesis [170]. Several small studies support the hypothesis that 
endothelial dysfunction associated with HIV viremia is an important contributor to the elevated 
cardiovascular disease risk in patients with HIV infection. [11]
The inner lining of  the vasculature is composed of  a continuous layer of  endothelial cells. The 
function of  the endothelium is complex and diverse. It acts as a barrier to separate the intravascular 
blood flow from the interstitium and regulates coagulation by the production von Willebrand 
factor. In addition, the endothelium promotes diapedesis of  leucocytes during inflammation. Under 
normal conditions, vessel formation is established by sprouting of  existing vessels (angiogenesis); 
through proliferation of  resident or bone marrow derived EPCs (vasculogenesis); and splitting of  
vessels called intussusception. The exact embryonic origin of  endothelial cells remains elusive, but 
studies have shown a close relationship to the hematopoietic lineage [171]. Several studies have 
investigated the correlation of  endothelial subpopulations and cardiovascular outcome. Lopez et al 
[172] found a decreased number of  Endothelial Progenitor Cells (EPCs) and an increased number 
of  circulating endothelial cells (CECs)in HIV-infected adult patients. They suggest a model where 
damage of  the endothelium in HIV infection is increased and repair diminished [173]. EPCs are 
regarded as endothelial cells with proliferative capacities but are difficult to distinguish from the 
hematopoietic lineage because both cell types share similar cellular markers. In contrast to Lopez 
et al, Costinuk et al [174] reported no difference in the number of  EPCs between HIV infected 
and uninfected. At the other end of  the spectrum, CECs are mature endothelial cells discarded 
from the endothelium during normal homeostasis. The degree of  turnover of  the vascular bed is 
relatively limited, represented by a low number of  CECs. Therefor, enumeration of  CECs relies 
upon sensitive techniques and accurate sample preparation. Flowcytometry has proven the best 
tool so far. Markers used to identify CECs include DAPI, CD105, CD146 and CD45, as well as 
morphological criteria such as size and whole intact cells [175]. 
An increased number of  CECs is found in response to tumor related angiogenesis. Increased 
numbers of  CECs have been used in studies to predict clinical outcome and treatment response. 
Low CEC numbers have been associated with a better clinical outcome in coloncancer [176–
178] and prostate cancer [179]. In contrast, increased CECs have been associated with a clinical 
benefit in renal cancer and breast cancer [180–182]. CECs have also been measured in chronic 
HIV infection in adults. Three studies have been published so far. In addition to Lopez et al, 
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Falasca et al investigated the number of  EPCs in two HIV patients before and after initiation 
of  cART. They found a low level of  EPCs in acute HIV and demonstrated a restoration after 6 
months of  therapy [183]. Guaraldi et al investigated the effect of  switching from standard triple 
therapy to Ritonavir boosted Darunavir monotherapy (DRV/r) versus DRV/r and 2 nucleoside 
reverse transcriptase inhibitors (NRTIs). They randomized 30 patients and measured changes in 
EPCs and CECs and found no difference in levels after 24 an 48 weeks [184].
The clinical relevance of  high CECs in HIV infection remains uncertain, but in light of  the 
findings in adults, it is interesting to study the level of  CECs in HIV infected children versus 
healthy controls since in children the confounding classical risk factors for vascular complications 
such as smoking, obesity and hypertension are present less frequently compared to adults. 
Methods
We included 40 HIV infected children (age 5-20 years) that visited the outpatient department 
of  the ErasmusMC-Sophia children's hospital in Rotterdam, the Netherlands between April 
2014 and April 2015. The investigation was part of  a larger study investigating neurocognitive 
function in children, and adults. Patients with an age younger than 4 years and older than 20 
years were excluded, as well as patients exhibiting cognitive dysfunction. An adult control group 
of  30 healthy adults was recruited at the Erasmus MC, department of  Internal Oncology.  
The pediatric control group consisted of  31 age-matched children at the Erasmus MC-Sophia 
Children’s Hospital undergoing elective (relatively small) surgery. Patients were excluded in 
case of  traumatic injury, apparent infections, fever, overt organ disease (chronic lung-, gastro-
intestinal-, kidney- and liver disease), auto immune disease, immune deficiency, cancer as well as 
metabolic-, hematologic and endocrinological disorders and psychomotor impairment. Blood 
was sampled through venipuncture in the HIV- and adult group and through prior insertion of  a 
venous catheter before surgery in the age-matched control group. 
All patients and/or guardians as well as controls provided written informed consent. The local 
ethics committee approved the study. A 10ml EDTA collection tube was collected after at least 
one other collection tube was discarded. Patients had fasted for at least 4 hours before sample 
collection. For the control groups, we performed CEC enumeration only and fasting was 
not obligatory. Samples were stored at room temperature and processed within 8 hours after 
venipuncture. Blood peripheral mononuclear cells were isolated as described previously [185]. 
Briefly, the procedure included incubation with ammonium chloride to induce red cell lysis. 
After centrifuging, the supernatant was removed and the pellet was carefully re-suspended in 
PBS containing bovine serum albumin. Subsequently, cells were stained using a combination of  
monoclonal antibodies. Flowcytometric analysis was performed by selection on size, viability and 
expression of  markers specific for CECs. We defined CECs as CD34pos, CD45neg, CD146pos 
and CD105pos. 
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For the HIV infected population, we reviewed medical history for cART duration, use of  
Protease Inhibitors (PI), CD4 count at the time of  blood donation and metabolic laboratory 
markers (insulin, triglycerides, LDL, HDL). CECs were examined for associations with 
immunologic and metabolic parameters. 
Statistical analysis was performed using GraphPad (GraphPad Software Inc. v6) and SPSS 
software (IBM, v21.0). Data was assessed for normality and a Shapiro-Wilk test when 
appropriate; a Mann Whitney test was applied to assess a significant difference between groups. 
For correlation analysis, a Spearman Rho test was applied.
Results
A total of  40 pediatric patients were included in the HIV group; 30 adult patients were included 
in the group of  otherwise healthy adults and 31 pediatric patients were included in the group of  
children undergoing elective surgery. The median age in the HIV group was 10.1 years (IQR= 
6.6 – 13.9); 19 out of  40 patients were male (47.5%); 36 patients (90%) had a viral load < 40 
copies/ml at the moment of  the blood sampling for this study, and 28 patients (70%) had a viral 
load <40 copies/ml at all 3 monthly outpatient department visits during the last year with a 
mean CD4 count of  1011 (±338) cells/m3 (table 1). A total of  28 children (70%) were on a PI 
containing regimen. In the pediatric patients undergoing elective surgery, the median age was 
9.9 (IQR= 6.9 – 12.7) and 14 out of  31 were male (45%). The most common indications were 
internal and external ear surgery, (n=7) orchidopexia (n=4) and corrective skin surgery (n=3).
Table 1: General characteristics of  the HIV infected children.
General characteristics
Age Median (IQR) 10.1 (6.6-13.9)
Males No. (1%) 19 (47.5)
CEC Median (IQR) 53 (21-135)
CD4 Mean (SD) 1011 (338)
>500 No. (%) 39 (977.5)
Viral Load <40co/ml No. (%) 36 (90)
<40co/ml for 1 year No. (%) 28 (70)
Years on cART Median (IQR) 6.6 (4.8-11.4)
PI regimen No. (%) 28 (70)
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The median CEC count per 4 mL in the HIV infected group was 54 cells (IQR 21 - 135), which 
was significantly higher compared to adult controls (18 cells; IQR 8 – 40; p=0.0001, figure 1) 
but not compared to uninfected children undergoing elective surgery (80 cells; IQR 37-175). 
There was a significant difference between healthy adults and children undergoing elective 
surgery (p<0.0001). There was a significant but weak association between CECs and duration of  
antiretroviral therapy (r= -0.330; p=0.038). We found no correlation between number of  CECs 
and the viral load at the moment of  blood sampling for the study. We found no correlation of  
CECs with insulin, LDL, HDL, viral load, and CD4 T-cell count (table 2). Patients with a high 
CEC count (upper quartile) were more likely to have triglyceride levels above the appropriate age 
dependent cut-off compared to patients with a low CEC count (60% versus 18%; p=0.012). The 
use of  protease inhibitors was less common in the group with a high CEC count (i.e. the upper 
quartile versus the rest; 50% versus 77%), although not statistically significant (p=0.111). 
Figure 1. Enumeration of  Circulating Endothelial Cells (CECs) in otherwise healthy uninfected 
adult individuals compared to HIV- infected children. ***p=0,0001
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Table  2: Correlation of  HIV associated factors and CEC levels.
Discussion
We hypothesized that CECs, a biomarker for vascular damage, associated with endothelial 
dysfunction in HIV infection, would be increased in HIV infected children as has been found in 
HIV-infected adults on a PI containing regimen. We found an increased number of  CECs in HIV 
infected children when compared to healthy adults, but not compared to age matched children 
undergoing elective surgery. CECs are mature endothelial cells and represent increased vascular 
turnover or vascular damage, which could be associated with elevated cardiovascular disease risk, 
which has frequently been demonstrated in HIV. CECs have shown to be increased in HIV infected 
adults in other studies, but this phenomenon has not been studied in children, who relatively 
devoid of  classical risk factors and potential underlying co-morbidities like cancer. We expected a 
lower enumeration of  CECs in the group of  children undergoing elective surgery. Although this 
population can’t be considered as a healthy control, the co-morbidities for which these children 
underwent an operation were relatively insignificant and increased vascular turnover prior to 
surgery would be unexpected. The insertion of  a venous catheter for blood donation could be a 
potential bias. It is conceivable that this causes disruption of  the endothelial layer. Alternatively, 
another explanation for our observations could be that vascular turnover is actually increased 
during adolescence, perhaps representing normal vascular homeostasis during growth. A decreased 
number of  CECs in context of  these physiological processes would represent deterred vascular 
turnover. 
In addition, we investigated the confounding effect of  the use of  Protease Inhibitors, agents 
associated with metabolic perturbations. Interestingly, we found an inverse correlation of  cART 
duration and CEC enumeration, suggesting that the use of  antiviral drugs is not likely the cause 
Correlations to CECs Spearman Sig.
Age -0.272 0.089
CD4 -0.011 0.947
Viral Load 0.028 0.866
Time on cART -0.330 0.038
Triglycerides 0.146 0.382
Cholesterol 0.046 0.78
HDL 0.07 0.676
Chol/HDL -3.03 0.081
LDL -0.254 0.123
Insulin 0.049 0.768
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of  increased CECs. The specific effect of  cART regimens could not be determined in this study 
due to insufficient power, but considering 70% of  patients in this study were on PI’s, it would be 
unlikely that PI’s are responsible for the observed increase in CECs. Alternatively, this correlation 
might reflect the normalization of  CEC numbers after acute HIV. This would support the 
hypothesis of  Falasca et al where EPCs normalize after 6 months of  antiretroviral therapy. 
We found no correlation of  CECs with HIV related- and metabolic markers (insulin, LDL, 
HDL, viral load, and CD4 T-cell count), although high CEC numbers were associated with high 
Triglyceride levels. Although this finding might suggest an association of  CECs with metabolic 
abnormalities, more research is needed to confirm this observation and determine the underlying 
mechanism.
The strength of  our study lies in a robust, high throughput assay to enumerate CECs and the 
application of  this test in a population underrepresented in current literature, i.e. children and 
adolescents. Our study has a limitation however. The validity of  our observation would be 
increased if  we compared it to uninfected healthy age-matched controls in stead of  children 
undergoing elective surgery. 
In conclusion, CECs are increased in treated HIV infected children compared to healthy adults, 
but not compared to age-matched children undergoing elective surgery. We found a significant 
but weak inverse correlation with the duration of  antiretroviral therapy, which might reflect 
the normalization of  CECs after acute HIV infection. Patients with a high CEC count had an 
increased triglyceride level, which could at best be considered a surrogate end point for metabolic 
abnormalities. 
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Chapter 9   
Summarizing discussion
New scientific discoveries are made on a daily basis and help increase our understanding of  
complex issues. These discoveries can change our point of  view and are referred to in philosophy 
as breaking a paradigm. Paradigms are scientific concepts and are by definition related to the 
observer. For example, we know that microbes can cause disease, but this insight could not have 
evolved without the revolutionary discovery of  the microscope. As mentioned in the introduction, 
HIV has probably existed much longer than we realized. The first patients died from AIDS 
long before we even knew the virus existed. Sufficient support from the (scientific) community 
is a prerequisite to break a paradigm. This in turn is facilitated by the availability of  convincing 
evidence. Scientists need to challenge known concepts by delivering evidence to either support 
or break a certain paradigm. This thesis, like many others, was written to challenge our current 
view on certain scientific topic. It is divided in three parts: part I of  this thesis (Chapter 1 and 2) 
provides a general introduction to HIV and the central nervous system (CNS). Part II (Chapter 
3 and 4) focuses on clinical studies performed at the Erasmus Medical Center. Part III (Chapter 
5 to 8) describes the basic laboratory studies performed with biological samples from HIV 
infected individuals.
Chapter 1 provides a general introduction to HIV pathophysiology, epidemiology and discusses 
the outline of  this thesis. In Chapter 2, we discuss the proposed route of  infection of  HIV 
in the CNS and how it causes pathology, based on the results of  a systematic review. A great 
deal of  evidence points towards early infection of  the CNS and subsequent persistence. It is 
uncertain whether increased longevity of  infection causes complications in the long run. In 
addition, histopathological changes in the CNS also occur. Post mortem studies show that 
cells of  the mononuclear lineage within the CNS can be infected with HIV and are fused 
together to form multinucleated giant cells. Also, HIV infected monocytes have been found in 
perivascular regions within the CNS. This might be interpreted as adverse, but the actual clinical 
relevance remains uncertain. Both patients and healthcare workers were confronted with HIV-
related dementia during the pre-cART era. After implementation of  effective treatment, overt 
neurologic complications became scarce. Although HIV can still be detected in the CNS after 
years of  treatment, there seem to be few clinical consequences at the individual level. However, 
at the population level, an increased prevalence of  stroke and pneumococcal meningitis is 
demonstrated compared to the general population. Considering the preventative measures that 
are available for these illnesses (i.e. vaccination and specific drugs), these subjects could prove 
interesting for future research initiatives. Neuropsychological disorders, albeit mild, have also 
been reported as being disproportionately more present in the HIV population. Although we 
have put this finding into a larger context by discussing potentially confounding factors, this 
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subject remains a topic that deserves more research. In Chapter 3, we focused on neurological 
complications by assessing the prevalence, related factors and impact of  neurocognitive disorders 
in HIV-infected individuals. We evaluated the benefit of  screening for neurocognitive disorders in 
400 patients with HIV in a clinical setting. In addition, we investigated whether immunological 
and viral factors have an influence on neurocognitive outcome. Our study demonstrates the 
limitations of  rapid screening in a clinical setting. One of  our main findings was that a high 
number of  patients expressed cognitive complaints (33%). Although roughly a third of  our study 
population had difficulties with concentration, attention or memory, only 57% would prove to be 
unimpaired according to extensive neuropsychological testing. The international HIV dementia 
scale, an internationally well-validated screening instrument, proved ineffective in helping the 
clinician decide which patient to refer for neuropsychological testing. The most sensitive clinical 
correlate associated with poorer cognitive function was a low CD4 nadir, a marker that reflects a 
person’s poorest (reported) immunological status. This is in line with several large cohort studies 
performed earlier in the United States. Therefore, preventing severe immunosuppression would 
seem knowledgeable. Although we found a higher degree of  co-morbidities in the group with 
cognitive deficits, we cannot prove causality because of  a lack of  significance. This could be 
due to the relatively low number of  patients (400) in our study. However, this finding might be 
interesting for future scientific endeavors. Cognitive disorders can play a vital role in the lives 
of  HIV infected individuals. Social and work participation can be negatively influenced and in 
some cases, reduced compliance can be seen. In Chapter 4 we investigated the vocational and 
socio-economic characteristics of  our cohort. We specifically wanted to assess the effect of  HIV 
on employment status. Although the employment status of  HIV infected individuals generally 
corresponded well with Dutch socio-economic data, we found a remarkably lower employment 
rate among young seropositive males. A total of  15% of  our cohort reported a need to change 
work hours or function after HIV diagnosis, from which we concluded that HIV definitively 
affects vocational status. These findings could assist counselors and policy developers for 
organizations where HIV-infected individuals work. 
As illustrated in Chapter 3 and 4, the clinical outcome of  patients is decided in large part 
through the efforts of  patient and physician. Adequate treatment is available for our cohort 
and reduces the occurrence of  complications, specifically neurologic disorders. However, the 
prevalence of  non-AIDS related co-morbidities remains disproportionately high. Several 
theories exist as how this phenomenon is driven, ranging from personal attributable risk factors 
(e.g. smoking) to complex long-term direct- (e.g. pyropotosis) and indirect HIV-related effects 
(e.g. microbial translocation). One key similarity in all theories is the observation of  a state of  
chronic immune activation. A persistent pro-inflammatory state seems to be present in HIV-
infected individuals. In this final part of  the thesis, we focus on the mechanisms behind certain 
physiological abnormalities. We collected biological samples from patients that participated in 
our clinical studies and were able to perform basic clinical laboratory studies. In Chapter 5 
we investigated the effect of  long-term cART and the inflammatory phenotype. Most studies 
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evaluate immune activation during the first year of  therapy. We measured immune activity in 
patients that were on cART for up to 10 years. Importantly, the selected patients are without 
any major co-morbidities. Biomarkers were measured in peripheral blood mononuclear cells 
(PBMC’s) and plasma from patients participating in the TREVI cohort on 0, 1, 3, 5 and 10 years 
of  treatment. Our observation of  no or mild immune activation in suppressed HIV-infection 
questions the impact of  ongoing inflammation. One of  the major strengths in this study was 
the extensive panel of  markers. We observed notable up-regulation in some pro-inflammatory 
markers (e.g. IP-10 and HLA-DR) but not all. Adequate selection of  markers for scientific 
studies when investigating inflammation is therefore crucial. In Chapter 6 we assessed the 
prevalence of  metabolic syndrome and its relationship with long-term cortisol as measured in 
hair. Cortisol is popularly termed the ‘stress’ hormone and this reference holds true in many 
ways. High cortisol levels are associated with an increased risk of  metabolic complications such 
as dyslipidemia, insulin resistance and hypertension, referred to as the metabolic syndrome. 
As chronic inflammation in HIV can be perceived as a state of  chronic immunological stress, 
we hypothesized that cortisol would be increased in these patients as well. The mean levels of  
hair cortisol were similar in 91 HIV infected patients compared to a large group of  controls. In 
contrast to our hypothesis, the relationship of  cortisol and the metabolic syndrome (as defined by 
the international standard) was inverse. In non-HIV infected subjects, the risk of  the metabolic 
syndrome is higher in patients with high cortisol. In our study, patients with low hair cortisol had 
a higher chance on the metabolic syndrome. This pattern corresponds best to the presence of  
glucocorticoid receptor (GR) hypersensitivity, which could be triggered by the (in)direct effects 
of  HIV. We put this theory to the test by assessing the PBMC’s of  all the available patients on 
their capacity to respond to steroids in vitro. We used intracellular markers that are upregulated 
(GILZ) and downregulated (IL-2) upon dexamethasone stimulation. As hypothesized, we found 
higher levels of  GILZ and lower levels of  IL2 in patients with low hair cortisol upon exposure of  
dexamethasone, even at low concentrations. Although it seems tempting to conclude an increased 
GR sensitivity in all HIV patients, further validation is still necessary. Another interesting area 
that is linked to inflammation is coagulation. We adopted the hypothesis that depletion of  
CD4 T-cells in the gut-associated lymphoid tissue results in microbial translocation. Microbial 
products like lipopolysaccharide (LPS) are potent stimulators of  the coagulation cascade. 
Considering the observation that venous and arterial thrombosis are more prevalent in HIV 
infected individuals, we investigated the role of  von Willebrand Factor (an important coagulation 
factor), LPS and HIV in Chapter 7. We confirmed the increased prevalence of  thrombosis 
in more than 14,000 HIV patient years by retrospective analysis. In addition, we aimed to 
provide a potential mechanism by evaluating the level of  pro-coagulant markers and microbial 
translocation. Therefore we performed a case control study to investigate whether vWF or LPS 
would be increased in HIV patients with a thrombotic event, compared to HIV patients without 
an event. We measured vWF in plasma of  HIV-infected individuals and found an elevation in 
patients with a history of  thrombosis, especially in those with a recurrent event. Our experiments 
could not establish a relationship between LPS or LPS-related factors (LPS Binding Protein and 
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soluble CD14) with event status. vWF is produced in the endothelium, and increased production 
of  this protein might represent activation of  this cellular compartment. Taken together, this study 
supports the hypothesis of  an increased activity in coagulation, although the exact mechanism 
remains to be elucidated. Chapter 8 describes another aspect of  vascular abnormalities in 
HIV, namely the role of  circulating endothelial cells (CECs). The process of  neovascularization 
and how to prevent this is currently under investigation in the oncologic research area because 
it offers potential targets for therapy. CECs can be considered the aged endothelial cell that is 
discarded in the circulation. Within the field of  HIV, neovascularization as an entity holds little 
relevance, but measuring CECs in these patients might give insight why vascular complications 
are more prevalent in HIV. We analyzed the level of  CECs in HIV-infected children because this 
population is relatively deprived of  certain traditional risk factors (e.g. smoking). We found levels 
of  CECs to be increased compared to healthy adults, but not compared to age-matched children 
undergoing elective surgery. This observation supports our previous statement that homeostasis 
in endothelial cells is disturbed, but to what extent remains uncertain. More studies are necessary 
to put our observation of  increased CECs in patients with HIV into perspective, especially in 
relation to the development of  adverse outcomes (e.g. cardiovascular incidents or stroke).
The initial focus of  the research that is presented in this manuscript was to investigate the impact 
of  neurocognitive complications in HIV infected individuals in the TREVI study. During the 
course of  this research, several questions and opportunities to investigate indirect effects of  HIV 
came along. Through the efforts of  many researchers and clinicians, it was made possible to 
describe additional relevant topics that all hold relevance for chronic HIV infection. This thesis 
touches upon the presence and magnitude of  coagulation abnormalities, metabolic perturbations 
and immune activation. We applied novel and innovative techniques and selected highly 
representative groups of  patients.
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Chapter 10   
Nederlandse samenvatting
Binnen de wetenschap worden continu nieuwe ontdekkingen gedaan. Een nieuwe doorbraak kan 
betekenen dat we op een andere manier het vraagstuk behandelen. Dit wordt vanuit de filosofie 
ook wel eens het doorbreken van een paradigma genoemd. Paradigma’s zijn wetenschappelijke 
concepten die per definitie worden gevormd door de observator. Het concept dat bacteriën 
ziektes veroorzaken werd pas erkend na de revolutionaire ontdekking van de microscoop.  
Zoals reeds is aangegeven in de introductie bestond HIV al ruim voor de officiële ontdekking. 
Er stierven al mensen aan de gevolgen van AIDS voordat het virus werd geïsoleerd. Met de 
ontdekking van het Humaan Immunodeficiency Virus als veroorzaker van dit ziektebeeld 
werd een nieuw medisch en wetenschappelijk inzicht verworven. Eén van de voorwaarden 
om een paradigma te doorbreken is voldoende steun vanuit de wetenschap en maatschappij. 
Overtuigend bewijs is hiervoor onmisbaar. Een kritische blik is hiervoor onmisbaar en het is 
de taak van wetenschappers om bewijs te leveren om een paradigma te ondersteunen of  te 
doorbreken. Het doel van dit manuscript is om wetenschappelijke concepten te toetsen en waar 
mogelijk een paradigma te ondersteunen of  te doorbreken. Het boek is opgedeeld in 3 delen: 
deel I van dit manuscript (Hoofdstuk 1 en 2) is geschreven als algemene introductie en heeft tot 
doel de lezer te informeren over HIV en de gevolgen voor het centraal zenuwstelsel. Deel II 
(Hoofdstuk 3 en 4) richt zich op de klinische studies die verricht zijn in het Erasmus MC. Deel 
III (Hoofdstuk 5 tot en met 8) beschrijft de basale experimenten die verricht zijn met biologische 
materialen verkregen van HIV geïnfecteerde mensen. 
Hoofdstuk 1 is bedoeld ter introductie en geeft de lezer inzicht over de pathofysiologie en 
epidemiologie inzake HIV en sluit af  met een overzicht van dit manuscript. In Hoofdstuk 
2 bespreken we in een systematische review hoe HIV het zenuwstelsel infecteert en schade 
veroorzaakt. Uit recente onderzoeken blijkt dat HIV het zenuwstelsel in een vroege fase 
infecteert en in deze ruimte persisteert. Er bestaat nog onduidelijkheid hoe lang het virus 
aanwezig blijft onder adequate therapie en of  er klinische nadelige effecten optreden. 
Histopathologische studies hebben aangetoond dat er op cellulair niveau veranderingen optreden 
na infectie. Uit post mortem studies in mensen en apen blijkt dat met name verandering 
optreedt in monocyten. Deze cellen fuseren dan tot zogenaamde multinucleaire reuscellen. 
Geïnfecteerde monocyten worden ook gevonden in bloedvaten die door het zenuwstelsel lopen. 
Hoewel dit als pathologisch beschouwd kan worden, is de werkelijke klinische relevantie nog 
onduidelijk. Zowel patiënt als clinicus werden voor de introductie van adequate therapie vaak 
geconfronteerd met het optreden van HIV-gerelateerde dementie. Dit fenomeen werd tot een 
zeldzaamheid gereduceerd toen patiënten met combinatie antiretrovirale therapie (cART) 
werden behandeld. Hoewel het virus nog jaren na adequate therapie kan worden gemeten, 
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lijken de klinische gevolgen per individu beperkt. Desalniettemin wordt op populatie niveau 
een verhoogde kans op een beroerte en meningitis worden aangetoond. Er zijn therapeutische 
mogelijkheden voor deze ziekten, zoals vaccinaties en medicatie, en zullen interessante 
onderwerpen vormen voor toekomstige onderzoeksinitiatieven. Daarnaast worden ook milde 
neuropsychologische stoornissen beschreven, maar deze lijken relatief  mild vergeleken met 
de gevreesde HIV-dementie. Andere factoren dan HIV spelen ook een rol in het optreden 
van neurocognitieve stoornissen; dit is dan ook zeker een onderzoeksveld in ontwikkeling. 
In Hoofdstuk 3 bespreken we de TREVI studie. We onderzoeken het optreden van 
neurocognitieve stoornissen en de invloed van ziekte gerelateerde factoren in HIV geïnfecteerde 
mensen in het Erasmus MC. We constateren dat de huidige geadviseerde screening beperkingen 
oplevert. Een belangrijke bevinding is dat er relatief  veel patiënten cognitieve klachten ervaren 
(33%). Uit deze groep blijkt echter maar 57% daadwerkelijk neurocognitief  beperkt te zijn als 
een uitgebreid onderzoek wordt ingezet. Hoewel de internationale ‘HIV dementia scale’ een 
internationaal gevalideerd instrument is om cognitieve beperkingen op te sporen, blijkt deze 
niet effectief  genoeg om de behandelaar te helpen in de keuze om patiënten te selecteren die 
gebaat zijn bij verder onderzoek. Overigens blijkt het CD4 nadir (een maat die aangeeft hoe 
diep iemand immuungecompromitteerd is geweest) geassocieerd met de aanwezigheid van een 
neurocognitieve stoornis. Dit komt overeen met eerdere grote studies uit de Verenigde Staten. 
Derhalve lijkt het voorkomen van immuundeficientie zinvol. Ook vonden we bij mensen met 
een cognitieve stoornis vaker een bijkomende ziekte (co-morbiditeit), maar er waren te weinig 
participanten binnen deze studie zodat statistische significantie uitbleef. Cognitieve stoornissen 
kunnen een grote beperking opleveren voor patiënten. Sociale contacten en arbeidsparticipatie 
kunnen hierdoor negatief  beïnvloed worden. In Hoofdstuk 4 onderzoeken we de arbeid 
gerelateerde en socio-economische karakteristieken van ons cohort. De invloed van de diagnose 
HIV op het hebben van een baan en het functioneren op de werkvloer staan hierin centraal. De 
arbeidsparticipatie binnen ons cohort is over het geheel genomen vergelijkbaar met de algehele 
Nederlandse populatie, maar jonge mannen lijken vergeleken met controle data vaker werkloos. 
Daarnaast valt op dat 15% van ons cohort aangeeft een aanpassing nodig te hebben in het aantal 
arbeidsuren of  functie. Derhalve kan geconcludeerd worden dat HIV wel degelijk invloed heeft 
op de arbeidsparticipatie. Deze bevindingen kunnen als hulpmiddel dienen voor werkgevers 
zodat werknemers met HIV beter begeleid kunnen worden.
Zoals aangegeven in Hoofdstuk 3 en 4 is de behandeling van HIV een ‘team effort’. Zowel de 
patiënt als de behandelaar spelen hierin een grote rol. Adequate behandeling van HIV heeft 
als effect dat er minder complicaties optreden, met name neurologische en neurocognitieve 
aandoeningen. Desalniettemin is de prevalentie van niet-AIDS gerelateerde ziekten (zoals hart- 
en vaatziekten, bepaalde vormen van kanker) hoger bij patiënten met HIV vergeleken met 
ongeïnfecteerde leeftijdsgenoten. Er zijn enkele theorieën over het ontstaan van dit fenomeen. 
Sommige factoren staan onder invloed van het gedrag (zoals roken), anderen lijken (in)direct 
onder invloed te staan van het virus (zoals pyroptosis en microbiële translocatie). Een veel 
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genoemde overkoepelende theorie is ‘chronische immuun activatie’, hetgeen inhoud dat er 
binnen het lichaam een constant pro-inflammatoir milieu bestaat. In het volgende deel van 
dit manuscript onderzoeken we mechanismen achter deze theorie. We gebruikten biologische 
materialen van patiënten uit ons cohort om basaal wetenschappelijke experimenten te 
verrichten. In Hoofdstuk 5 bespreken we de effecten van langdurige therapie op het ontstaan 
van inflammatoire kenmerken. De meeste studies in de huidige literatuur kijken naar immuun 
activatie tijdens het eerste jaar van therapie. In onze studie includeerden we patiënten die op 
dat moment wel tot wel 10 jaar op antiretrovirale therapie stonden. De patiënten uit ons cohort 
waren relatief  vrij van co-morbiditeiten. Biomarkers in het bloedplasma en op de oppervlakte 
van bepaalde bloedcellen (PBMC’s) werden hiervoor gemeten bij patiënten die 0, 1, 3, 5 of  
10 jaar op therapie zaten. De kracht van de studie zit in de diversiteit en uitgebreidheid van 
de onderzochte markers. Sommige markers bleken verhoogd, zoals IP-10 en HLA-DR, maar 
over het algemeen constateren we dat er relatief  weinig tekenen van inflammatie bestaan bij 
chronische HIV infectie. Dit staat in contrast met eerder gepubliceerde studies. In Hoofdstuk 
6 bekijken we de prevalentie van het metabool syndroom bij patiënten met HIV en wat de 
relatie is met cortisol. Het metabool syndroom wordt gekenmerkt door dyslipidemie, insuline 
resistentie en hypertensie en is geassocieerd met een hoog cortisol. Cortisol wordt vaak het ‘stress 
hormoon’ genoemd en kan sinds kort worden gemeten in haren. Aangezien chronische immuun 
activatie geïnterpreteerd kan worden als een vorm van chronische stress, veronderstelden we dat 
cortisol verhoogd zou zijn bij patiënten met HIV. Het gemiddelde cortisol in 91 patiënten met 
HIV vergeleken met gezonde controles bleek echter gelijk. De correlatie van cortisol met het 
metabool syndroom bleek echter omgekeerd evenredig bij patiënten met HIV. Bij niet HIV-
geïnfecteerde mensen is de kans op het metabool syndroom hoger indien het cortisol verhoogd 
is. In onze studie bleek dat HIV patienten met een laag cortisol een hogere kans hadden op 
het metabool syndroom. Deze observatie kan verklaard worden door de aanwezigheid van een 
overgevoelig glucocorticoid receptor (GR), mogelijk door het virus veroorzaakt. Om deze theorie 
te toetsen werd het effect van steroïden op PBMC’s van dezelfde HIV geïnfecteerde patiënten 
gemeten. We gebruikten hiervoor markers die stijgen (GILZ) of  dalen (IL-2) na blootstelling 
met dexamethason. We vonden een toegenomen stijging in GILZ expressie en daling in IL-2 
expressie bij patiënten met een laag haar cortisol na blootstelling met dexamethason, zelfs bij 
lage concentraties. Hoewel deze bevinding onze theorie van GR hypersensitiviteit bevestigd, 
is nog meer validatie nodig om tot een definitieve conclusie te komen. Een ander interessant 
onderzoeksgebied is de relatie tussen inflammatie en stolling. Een bekende theorie binnen de 
HIV onderzoekswereld is het ontwikkelen van immuun activatie door microbiële translocatie. 
Als gevolg van HIV infectie kan het aantal CD4 T cellen in de darm drastisch verminderen. Dit 
resulteert in een verminderde barrière functie van de darm en leidt tot translocatie van bacteriële 
producten. Een voorbeeld van deze producten is lipopolysaccharide (LPS). LPS is een krachtige 
stimulus voor stollingsactivatie. Aangezien er een toegenomen kans is op het ontwikkelen van 
vasculaire complicaties bij HIV onderzochten we de relatie van LPS met von Willebrand 
factor, een bekend pro-coagulante stollingsfactor, in Hoofdstuk 7. We bevestigden de hogere 
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prevalentie van stollingscomplicaties in meer dan 14.000 patientjaren door retrospectieve analyse. 
Daarnaast onderzochten we de relatie tussen trombose en een toegenomen hoeveelheid vWF 
en LPS. Derhalve evalueerden we of  hoogte van vWF door middel van een case-control studie. 
Het vWF bleek verhoogd in het plasma van HIV geïnfecteerde patiënten die in het verleden een 
veneuze of  arteriële trombose hadden doorgemaakt, met name bij patiënten met een recidief. 
In onze experimenten konden we geen relatie aantonen tussen LPS of  daaraan gerelateerde 
factoren (zoals LPS Binding Protein en soluble CD14) en het optreden van trombose. Het vWF 
wordt geproduceerd in het endotheel, een celtype dat de binnenkant van alle bloedvaten bedekt. 
Een toegenomen productie zou kunnen duiden op een activatie van dit celtype. Samengevat 
toont deze studie aan dat er een toegenomen stollingsactiviteit bestaat bij HIV, alhoewel het 
mechanisme nog onduidelijk blijft. In Hoofdstuk 8 kijken we naar het optreden van vasculaire 
schade door HIV. We onderzochten de rol van circulerende endotheelcellen (CECs). Het lichaam 
is in staat nieuwe bloedvaten te formeren, hetgeen belangrijk is voor een toevoer van zuurstof  en 
nutriënten. Binnen de oncologie wordt reeds uitgebreid onderzoek verricht naar mogelijkheden 
om neovascularisatie te remmen, aangezien dit ook tumorgroei verminderd. CECs kunnen 
beschouwd worden als verouderde endotheelcellen die afgegeven worden aan de bloedcirculatie. 
In de context van HIV is neovascularisatie niet een uitgesproken onderwerp, maar CECs zouden 
wellicht meer inzicht kunnen geven waarom vasculaire complicaties vaker optreden bij HIV. We 
onderzochten de hoogte van CECs in HIV geïnfecteerde kinderen, omdat deze populatie relatief  
vrij is van traditionele risicofactoren als roken. We constateerden dat de concentratie CECs 
toegenomen was in kinderen met HIV ten opzichte van ongeïnfecteerde volwassenen, maar 
niet ten opzichte van ongeïnfecteerde die een geplande operatie ondergingen. Deze observatie 
bevestigd het gegeven dat er een verstoring van de homeostase is van endotheelcellen bij HIV, 
maar in welke mate blijft onduidelijk. Meer studies zijn nodig om deze gegevens in context te 
plaatsen. 
Het onderzoek dat vooraf  ging aan dit manuscript was initieel gericht op neurocognitieve 
complicaties bij patiënten met HIV binnen de TREVI studie. Gedurende het onderzoek kwamen 
verscheidene onderzoeksvragen en mogelijkheden naar de oppervlakte. Door de inzet van vele 
onderzoekers en clinici werd het mogelijk deze vraagstukken te behandelen. Mede hierdoor 
ontwikkelde zich een manuscript dat een variëteit aan relevante onderwerpen behandeld, zoals 
stolling, immuun activatie en metabole stoornissen. Al deze onderwerpen zijn reeds eerder 
onderzocht, maar niet in de vorm zoals het nu gepresenteerd wordt. We pasten nieuwe en 
innovatieve technieken toe op zeer representatieve groepen patiënten.
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Oral presentations
2015  4th CCAS HIV/AIDS International Workshop, St. Kitts
2015  HIV in the context of  occupational medicine (invited speaker), Amsterdam  
  (AMC), the Netherlands.
2015  HIV and Immune Activation (invited speaker), Paramaribo, Suriname.
2015  34th meeting of  the Dutch Society of  HIV treating physicians (NVHB). 
 
Poster presentations
2015  6th International Meeting on NeuroHIV, Matera, Italy.
2015  9th Dutch Conference on HIV Pathogenesis, Epidemiology, Prevention and  
  Treatment (NCHIV).
2014  17th Annual meeting of  the European Society for Clinical Virology, Prague,  
  Czech republic.
2014  8th Dutch Conference on HIV Pathogenesis, Epidemiology, Prevention and  
  Treatment (NCHIV).
Attended Conferences and symposia
2015  22nd Conference on Retroviruses and Opportunistic Infections, Seatle, MA,  
  USA.
2014  HIV Drug Therapy Meeting, Glasgow, United Kingdom.
2013  North European Workschop on HIV infection in the CNS (HANSA), Berlin,  
  Germany.
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2013  59th Conference of  the International Society on Thrombosis and   
  Haemostasis, Amsterdam, the Netherlands. 
2013  14th European AIDS Conference, Brussels, Belgium.
2013  European Congress of  Virology, Lyon, France.
2013  5th International Meeting on NeuroHIV, Palermo, Italy
Extracurricular activities
2011 – 2016 Teacher at annual international education project ‘Viruskenner’
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Chapter 13 Dankwoord
“If  I have seen further it is by standing on the shoulders of  giants.” Een uitspraak die bekendheid 
heeft gekregen door Isaac Newton. Hij refereert hier naar de mogelijkheid om tot grotere 
hoogte gebracht te worden met behulp van de kennis van anderen die jou voorgingen. Ik heb 
tijdens mijn promotie inderdaad mijn horizon verbreed. Ik leerde een scala aan eigenschappen 
aan die ik mijn leven meeneem. In de eerste plaats wil ik mijn dankwoord richten aan de 
leescommissie: professor Boucher, professor Verbon, professor Meijers, dr. Nouwen, professor 
Robertson, professor Van Agtmael en professor Koopmans. Jullie hebben in de kostbare tijd die 
jullie bezitten de moeite genomen om mijn werk met kritisch oog te beoordelen, waarvoor mijn 
dank. Besides critically appraising my manuscript, some of  you have travelled a great distance 
just to be at my defense, for which even more gratitude is in order. Dit werk was alleen nooit 
af  geweest zonder de begeleiding van professor van Gorp. Beste Eric, jouw vertrouwen in mij 
is bemoedigend. Ik heb af  en toe met de handen in het haar gezeten en telkens wist je op een 
immer kalme intonatie de hoofdzaken te benoemen. Je bent de manager van mijn promotie 
traject geweest. Jij hield het overzicht als ik (te) geconcentreerd was op een specifiek onderwerp. 
Je gaf  me de ruimte om te proberen, om te falen en gelukkig ook succesvol te zijn. Daarvoor ben 
ik je erg dankbaar. Dit proefschrift zal een waardevol aandenken zijn van mijn promotietijd. Ook 
mijn co-promotor Kirsten wil ik hartelijk bedanken. Je bent grondig door mijn papers gegaan 
en hebt me geholpen om het overzicht te houden. Daarnaast ben je een heel toegankelijke en 
fijne collega. Dat je in alle drukte nog tijd wist vrij te maken om mij te begeleiden waardeer 
ik enorm. Beste Annemarie, professor van Rossum inmiddels, jou wil ik ook danken voor 
het vertrouwen dat je in me had. Rondom de afronding van mijn promotie neigde ik door alle 
drukte soms de binnenbocht te pakken, maar zoals je me leerde is het belangrijk om secuur te 
werk te blijven gaan. Als ik een opzet voor een artikel of  poster naar je opstuurde  kreeg ik die 
volledig rood terug. Met veel zorgvuldigheid bracht je belangrijke opmerkingen in mijn teksten 
aan. Dank voor je kritische blik; de lessen die ik van je heb geleerd zullen mijn carrière verrijken. 
Marco, jij bent tijdens en na mijn promotie een wereldvent gebleken. Je hebt een verfrissende 
en aanstekelijke invloed op mij gehad. ‘Work hard, play hard’ is jouw motto. De ritjes in jouw 
oude auto met Flora van Amsterdam naar Rotterdam waren legendarisch (en altijd met een 
homemade koffie erbij). Auto op de Kralingse zoom (gratis parkeren), metrootje naar de 
sportschool voor een Gladiator work out, proteïnshake erin en alsnog als eerste op het Erasmus 
MC. Je werkethos zou gepatenteerd moeten worden, de productie gaat dan gegarandeerd 200% 
omhoog. Samen legden we heel wat afstanden af; bijvoorbeeld naar buitenlandse congressen, 
tientallen kilometers rennen door de bagger tijdens een mudrace en natuurlijk de Marathon van 
Athene. Ik hoop jou en Odette (en natuurlijk Liz) nog vaker te zien in de toekomst. Marco en ik 
werkten in de ‘kelder’ van Viroscience op de 16e verdieping. Daar kwamen snel anderen op af. 
Aan het einde van de dag was er gelukkig vaak genoeg animo om te borrelen. Daar was dr. Dave 
vd Fever altijd wel bij. Samen met dr. Brooke kon je steevast rekenen op een diepgaande discussie 
over kosten-effectiviteit, de tour de France, integratiecursus of  andere zaken waar ik eerlijk 
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gezegd weinig kaas van had gegeten. Hartelijk dank ook voor het geduld waarmee jullie mij de 
fijne kneepjes van de statistiek hebben bijgebracht. Te midden van deze hectiek deed Carola haar 
intrede. Carola, je staat altijd klaar om me te helpen als ik iets geregeld moet krijgen. Je bent een 
fijn persoon met een gezond gevoel voor humor en ik vermoed dat zonder jou vele agenda’s de 
soep in zouden lopen. In de loop van de tijd raakten we Flora kwijt aan de charmes van Pieter 
Fraaij. Inmiddels ben je gepromoveerd en begrijp ik dat je de muren van een ander ziekenhuis 
nu roze aan het verven bent. Succes! Gelukkig krijgen we een vervanger die ook graag (zalm)roze 
draagt: Wesley de Jong. Je bent altijd door een ringetje te halen en gebalanceerd van mening 
in elk gesprek. Dit gecombineerd met je Rotterdamse gevoel voor humor maakt je de ideale 
arts naar mijn mening. Wat betreft je humor: tijdens borrels kon jij ‘pleidooien’ houden waar je 
gezelschap nog weken van kon nagenieten. Ik kijk met veel plezier uit naar jouw promotie. Tot 
die tijd moet je de borrels doorbrengen met Thomas en Jurre. Thomas, je bent als student gaan 
meehelpen in de TREVI studie. Je hebt een heel cool project van de grond af  opgebouwd en 
we hebben samen de Cortisol paper geschreven. Je PhD carrière begon je op de eerste hulp na 
een onvrijwillige automutilatie met een kapot glas. Je bent de eerste PhD student die ik ken die 
moest zuchten toen hij hoorde dat hij wéér naar Suriname moest. Man, man, man, wat heb je 
het zwaar. Gelukkig hebben we Jurre die de boel luchtig opgeklopt houdt. Hij staat altijd voor 
je klaar (met een camera) en geeft graag ongevraagd advies. Zonder dollen: je bent een gouden 
kerel en enorm gastvrij. Als er iets te vieren valt ben jij de eerste die zijn best doet om erbij te 
zijn of  stuur je op zijn minst een uitgebreide PowerPoint presentatie ter vervanging. Dat zijn 
eigenschappen die ertoe doen. Laura, wat mij betreft ben je één van de boys! Je oergezellige 
karakter met bijpassende zachte ‘G’ maakt elk feestje geslaagd!” Wetenschappelijk gezien is er 
geen grotere doorzetter dan Bas Mourik. Bassie, als ik één ding geleerd heb van jou dan is het 
dat er niks onmogelijk is. Je energie lijkt wel oneindig. Van het leger naar uitsmijter naar chirurg 
en self  made promovendus. Zelfs de financiële bronnen regelde je zelf. Je huwelijk met Genelva 
was onvergetelijk, alhoewel ik sommige dingen van jouw bachelor in Edinburgh liever zou 
vergeten. 
Als ik vertel over mijn tijd bij Viroscience kan ik natuurlijk niet de ‘Exotics’ vergeten. Aan het 
hoofd dr. Byron Martina, een sparringpartner als geen ander. Je weet de essentie van elke 
onderzoeksvraag onder de loep te nemen. Er bestaan geen aannames voor jou. De gesprekken in 
de late uurtjes zijn mij het beste bijgebleven… alsmede je flexibiliteit als de Salsa muziek aangaat. 
Penelope, your high heels will be remembered and if  I ever encounter a silver haired bat I will 
think of  you (and Rabies)! Steffie, dr. Lim, ik ben blij dat we elkaar blijven zien na ons vertrek 
bij het Erasmus MC. Het jaar 2017, waarin je je maatje hebt verloren, was een oneerlijke start 
voor jou. Ik hoop dat de zon weer gaat schijnen voor je. Fasa, what can I say about you. I’m 
not convinced you’re completely fond of  me, but I’m sure you don’t dislike me. Maybe it’s the 
involuntary Bro-Love we Dutch people like so much. I will give you the biggest hug when you get 
your PhD! Involuntary of  course… Petra, je hebt een ijzersterke mening en altijd bereid me te 
helpen als ik een concentratie moest berekenen. Uiteraard kan ik Jeroen niet vergeten. Culinaire 
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hoogstandjes, gouden pipetduimpjes en een scala aan schuine moppen. 
Buiten de Exotics en de 16e verdieping zijn er nog een hele hoop anderen die ik graag wil 
bedanken van Viroscience. Ik ga nu ongetwijfeld nog een hoop vergeten. Ik hoop dat die persoon 
zich dan realiseert dat er geen moment opzet in het spel is geweest. In de eerste plaats wil ik Ab 
Osterhaus bedanken dat hij mij überhaupt wilde aannemen. De sollicitatieprocedure bleek 
(zoals anderen vooraf  al voorspelden) legendarisch; ik verliet je kantoor met hartkloppingen 
en een bezweet voorhoofd. Je kritische opmerkingen tijdens research meetings hield iedereen 
op de afdeling scherp. Dat je humor hebt liet je ook doorschemeren tijdens borrels en uitjes. 
Bij een Exotics uitje in Antwerpen ontving je ons zelfs in huis, met bizar lekkere oesters erbij. 
Rob (Gruters), ik kijk op naar de hoeveelheid kennis die je bezit en je brede interesse binnen 
de wetenschap. Je trots voor je muzikale familie steek je niet onder stoelen of  banken. Je lijkt 
je prioriteiten goed op een rij te hebben. Ik wacht nog het moment af  tot we jouw HIV vaccin 
in de kliniek gaan toepassen. Dank je voor je begeleiding bij mijn experimenten en ik hoop tot 
ziens. Lineke, super gezellig om jou ook nog te hebben meegemaakt. Do, I’m sure you’ll make 
it in research! Bri, it has been a pleasure during our research master! Sander, wat doe je met 
je carrière; je zou de beste show-host ooit kunnen zijn en toch kies je voor Nature, Science en 
aanlokkelijke beurzen. Rory, Caroline, Miranda, Arwen, Eefje, Oanh en al die anderen 
zonder wie Sinterkerst of  al die andere borrels niet geslaagd zouden zijn: bedankt! 
Naast de afdeling Viroscience heb ik ook nog op andere afdelingen mogen meekijken. Op de 
6e verdieping (Biochemistry) heb ik de fijne kneepjes van het pipetteren mogen leren van dr. 
Tokameh Mahmoudi. Thank you for you patience in teaching me how to handle experiments. 
Sometimes my monocytes would illuminate spontaneously when they shouldn’t, at other times it 
remained dark under the microscope when I expected a discotheque. Your insight in HIV latency 
and how to reverse it is the truly impressive. Elisa, you have helped me deal with complex PCR 
protocols and arranging bicycle racing trips in Italy, grazie mille! Michael, ik heb je te weinig 
gezien door alle drukte rondom het einde van mijn promotie, maar je snoeiharde (en soms platte) 
Amsterdamse grappen zal ik voor altijd bij me dragen, I’m positive about that. Tsung-Wai, 
Robert Jan, Mateusz and Khalid, good luck with finding a cure for HIV! Van de research 
toren naar de klinische toren van het Erasmus. De groep van Georgina op 10e verdieping 
verzorgde een aanzienlijke bijdrage aan mijn onderzoek. Hartelijk dank voor jullie geduld als er 
wéér een patiënt op de niet afgesproken tijd langskwam en er wéér PBMC’s geïsoleerd moesten 
worden. Jullie hebben aan de basis gestaan van mijn experimenten. De laatste personen van deze 
verdieping zijn eigenlijk per toeval op mijn pad gekomen (en gelukkig maar!). André, ons idee 
om PBMC’s te gebruiken en er immuun activatie op te meten ontstond in Seattle bij een congres. 
Na een glas whiskey met Mark ging het idee rollen en na veel werk hebben we dit gave artikel 
gepubliceerd. Anthonie, je deed overkomen alsof  de meest ingewikkelde FACS kleuringen 
kinderspel waren, bedankt voor de praktische lessen! Casper, je bent halverwege mijn promotie 
op onze afdeling gekomen. Je hebt keihard gewerkt en dat resulteerde in een promotie, huwelijk 
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en kort daarop een kind. Lekker bezig ouwe! Simone, je bent de stille motor achter de 
vaccinatiepoli! Op de afdeling kindergeneeskunde lopen 2 experts rond die ik niet ongenoemd 
wil laten. Linda en Eline, jullie besteden bewonderenswaardig veel aandacht aan jullie 
patiënten. Dat jullie breed georiënteerd zijn blijkt wel uit het feit dat jullie naast patiëntenzorg 
ook zonder problemen meedenken aan research initiatieven. Buiten het Erasmus om zijn er ook 
nog enkele ‘buitenbeentjes’ die hebben bijgedragen aan dit boekje. Stephanie, we zullen elkaar 
ongetwijfeld nog blijven spreken in de afronding van de TREVI-kinder studie. Laten we er een 
mooi artikel van maken! Marlies, het includeren van patiënten tijdens de TREVI studie was een 
hele klus. Met veel geduld hebben we er uiteindelijk 400 kunnen includeren. Een hele prestatie 
en wat mij betreft gaan we nog een keer naar St. Kitts om dat te vieren. Ik heb het als een 
toptijd ervaren! Ook bedankt Harald en Pepijn, ik zal jullie ongetwijfeld nog vaker ontmoeten. 
Job (van Exel), ook met jou was het fijn samenwerken! Ik wil ook extra aandacht besteden aan 
iemand die mij buiten mijn promotie heeft geïnspireerd. Frank van Vliet staat altijd (in werk 
en privé) voor iedereen klaar. Je kan je kwaad maken als iemand zich niet aan de afspraak houdt, 
of  dat nou een student of  een internationaal gerenommeerde professor is. Ook als ik dan moest 
rennen van de poli naar mijn les en ik kwam enkele minuten te laat dan wisten alle professoren 
van het Erasmus dat. Samen met Dr. Nouwen heb je een inspirerende master opgebouwd. Dank 
jullie beide voor de kans om hier aan mee te mogen doen. 
Ik mag me gelukkig prijzen met bovenstaande collega’s. Ik ben ook gezegend met de rijkdom 
van een warme familie die met mij de vierdagen viert en zo nodig met me mee leeft als het even 
niet zo lekker gaat. In de eerste plaats zijn dit mijn ouders. Pap, mam, ik ben trots dat jullie 
mijn ouders zijn. In vele opzichten zijn jullie mijn voorbeeld. Alle boeken in de wereld zouden 
me niet kunnen leren wat jullie me hebben bijgebracht. Dan nog mijn grote zus Frenske (die 
eigenlijk alles wel kan waar ze haar zinnen op zet), mijn minder grote maar zachtaardige zus 
Hanna (meer zen kom je ze niet tegen) en mijn ronduit brutale broer Siger met humor en een 
hart van goud (veel meer hoeft daar niet aan toegevoegd te worden). Fijn dat jullie er zijn, ik kan 
geen betere familie wensen. Ook Robert, Ronald en Saskia, jullie zijn mij inmiddels net zo 
vertrouwd als familie. Hetzelfde geldt voor mijn waarde schoonbroer Fokke. We leren elkaar 
steeds beter kennen en dat bevalt me prima! Mike, ik heb het vermoeden dat we nog vaak 
samen in de kroeg zullen staan! In deze omvangrijke familie is iedereen nét even anders, en dat 
maakt het zo leuk en interessant. 
Wat mij betreft voeg ik nog twee mensen toe aan deze familie. Twee die ik al zo lang ken dat ik ze 
niet weg kan denken uit mijn natuurlijke habitat. In de eerste plaats Cor Paul. Corrie. CP. Knor. 
Je bent de oceaan overgevlogen om mijn promotie mee te maken. Toevallig ga je hierna snel 
trouwen, maar we weten allebei wat je échte motivatie was. Top dat je er bent. Ik ken je al sinds 
je nog maar 1 meter 90 was. Ook Jan hoort in dit rijtje thuis. Een vriend waar ik op kan bouwen. 
We zijn allemaal gegroeid, de één woont in Canada, de ander om de hoek. We kiezen allemaal 
een ander pad, maar als die samenkomt is het weer als vanouds. 
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Traditiegetrouw wil ik afsluiten met het dierbaarste wat er in mijn leven bestaat. Je bent mijn 
grootste fan en meest kritische publiek. Je nam de tijd om te luisteren naar mijn promotie 
perikelen, je las mijn artikelen en accepteerde de soms vreemde werktijden. Ik probeerde 
regelmatig muisstil naast je te kruipen na een geslaagde afdelingsborrel. Je ging mee naar Praag 
en trotseerde orkanen samen met Eric, Marlies en mij in St. Kitts. Als ik tijdens mijn promotie 
met een dilemma zat, probeerde je altijd de essentiële vraagstukken te vinden door me uit te 
dagen. Ik ben fan van onze gesprekken aan de keukentafel met een goed glas wijn. Inmiddels 
weten we elkaar met steeds minder woorden aan te voelen. Ik had het jou en mezelf  gegund dat 
je ouders bij mijn promotie hadden kunnen zijn. Lieve Tjitske, je bent het mooiste hoofdstuk 
van mijn leven, ik ben gelukkig met je. Dank je wel.
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